PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30911094-2 2019 Here, we attempt to explore choroidal and retinal vascular compliance in patients with AMD by evaluating dynamic vascular changes using live ocular imaging following treatment with oral sildenafil citrate, a phosphodiesterase type 5 (PDE5) inhibitor and potent vasodilator. Sildenafil Citrate 186-204 phosphodiesterase 5A Homo sapiens 208-232 30911094-2 2019 Here, we attempt to explore choroidal and retinal vascular compliance in patients with AMD by evaluating dynamic vascular changes using live ocular imaging following treatment with oral sildenafil citrate, a phosphodiesterase type 5 (PDE5) inhibitor and potent vasodilator. Sildenafil Citrate 186-204 phosphodiesterase 5A Homo sapiens 234-238 30705876-7 2018 The data demonstrated that sildenafil or vardenafil (two structure-related PDE5 inhibitors) but not tadalafil (structure-unrelated to sildenafil) sensitized doxorubicin-induced apoptosis in CRPC cells with deteriorating the down-regulation of anti-apoptotic Bcl-2 family members, including Bcl-xL and Mcl-1, and amplifying caspase activation. Sildenafil Citrate 27-37 phosphodiesterase 5A Homo sapiens 75-79 30705876-11 2018 In conclusion, the data suggest that sildenafil and vardenafil induce PDE5-independent apoptotic sensitization to doxorubicin (or other topoisomerase II inhibitors) through impairment of both HR and NHEJ repair systems that are evident by a decrease of nuclear Rad51 levels and their foci formation in the nucleus, and an inhibition of Ku80 DNA end-binding capability. Sildenafil Citrate 37-47 phosphodiesterase 5A Homo sapiens 70-74 30747070-3 2019 Currently, PDE5 inhibitors (ex; Sildenafil, Tadalafil) available in the market are not only being used for the treatment of erectile dysfunction but at the same time, they are also in clinical trials being investigated as anticancer agents. Sildenafil Citrate 32-42 phosphodiesterase 5A Homo sapiens 11-15 30548639-6 2018 Tadalafil is more selective to PDE5 against PDE6 whereas sildenafil, another commercially available PDE5 inhibitor shows similar potencies to inhibit PDE5 and PDE6. Sildenafil Citrate 57-67 phosphodiesterase 5A Homo sapiens 100-104 30548639-6 2018 Tadalafil is more selective to PDE5 against PDE6 whereas sildenafil, another commercially available PDE5 inhibitor shows similar potencies to inhibit PDE5 and PDE6. Sildenafil Citrate 57-67 phosphodiesterase 5A Homo sapiens 100-104 29667180-0 2018 PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery. Sildenafil Citrate 72-82 phosphodiesterase 5A Homo sapiens 0-4 30292404-1 2018 BACKGROUND: Sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, is known to increase the intracellular level of cyclic guanosine monophosphate (cGMP), which causes vasodilation. Sildenafil Citrate 12-22 phosphodiesterase 5A Homo sapiens 26-45 30292404-1 2018 BACKGROUND: Sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, is known to increase the intracellular level of cyclic guanosine monophosphate (cGMP), which causes vasodilation. Sildenafil Citrate 12-22 phosphodiesterase 5A Homo sapiens 47-51 30352768-5 2018 Effects of NO is augmented by inhibiting degradation of the second messenger cyclic guanosine monophosphate (cGMP) using sildenafil and tadalafil, both of which inhibit the enzyme phosphodiesterase 5 (PDE5). Sildenafil Citrate 121-131 phosphodiesterase 5A Homo sapiens 180-199 30352768-5 2018 Effects of NO is augmented by inhibiting degradation of the second messenger cyclic guanosine monophosphate (cGMP) using sildenafil and tadalafil, both of which inhibit the enzyme phosphodiesterase 5 (PDE5). Sildenafil Citrate 121-131 phosphodiesterase 5A Homo sapiens 201-205 30381311-2 2018 Sildenafil, a selective phosphodiesterase 5 (PDE5) inhibitor, has been reported to potentially play a therapeutic role in FGR, but this has not been established. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 24-43 30381311-2 2018 Sildenafil, a selective phosphodiesterase 5 (PDE5) inhibitor, has been reported to potentially play a therapeutic role in FGR, but this has not been established. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 45-49 30148362-4 2018 Further, different binding patterns from sildenafil were revealed in cocrystal structures, which provide structural templates for discovery of highly potent PDE5 inhibitors. Sildenafil Citrate 41-51 phosphodiesterase 5A Homo sapiens 157-161 29667180-2 2018 Since the discovery and introduction of sildenafil, inhibitors of PDE5 have been the first-line therapy for erectile dysfunction (ED). Sildenafil Citrate 40-50 phosphodiesterase 5A Homo sapiens 66-70 29667180-3 2018 The success of sildenafil in the treatment of ED stimulated research in the field of PDE5 inhibition and led to many new applications, such as treatment of lower urinary symptoms, and pulmonary arterial hypertension, which are now approved indications. Sildenafil Citrate 15-25 phosphodiesterase 5A Homo sapiens 85-89 29901310-1 2018 Sildenafil is the first phosphodiesterase type 5 inhibitor (PDE-5), used in the management of erectile dysfunction (ED). Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 60-65 29735634-3 2018 A potential treatment associated with placental vasoconstriction is the class of PDE5 (phosphodiesterase type 5) inhibitors such as sildenafil, which is known to cross the placenta. Sildenafil Citrate 132-142 phosphodiesterase 5A Homo sapiens 87-111 29735634-8 2018 PDE5 and endothelial nitric oxide synthase activity were altered with sildenafil but not tadalafil. Sildenafil Citrate 70-80 phosphodiesterase 5A Homo sapiens 0-4 30023062-1 2018 Sildenafil induces relaxation of smooth muscle cells by blocking PDE5. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 65-69 29735634-3 2018 A potential treatment associated with placental vasoconstriction is the class of PDE5 (phosphodiesterase type 5) inhibitors such as sildenafil, which is known to cross the placenta. Sildenafil Citrate 132-142 phosphodiesterase 5A Homo sapiens 81-85 28964803-1 2017 Sildenafil and tadalafil are widely-used phosphodiesterase 5 (PDE5) inhibitors for which no clear dose-response relationship could be established. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 62-66 29089445-10 2018 We directly visualized that the PDE5 inhibitors sildenafil and tadalafil act by reducing spontaneous contractility of the glands, thereby reducing the muscle tone of the organ. Sildenafil Citrate 48-58 phosphodiesterase 5A Homo sapiens 32-36 29467656-0 2018 Sublingual Administration of Sildenafil Oro-dispersible Film: New Profiles of Drug Tolerability and Pharmacokinetics for PDE5 Inhibitors. Sildenafil Citrate 29-39 phosphodiesterase 5A Homo sapiens 121-125 29511676-3 2018 The objective was to evaluate the therapeutic efficacy and antiremodeling potential of the phosphodiesterase type 5 (PDE5) inhibitor sildenafil and the soluble guanylate cyclase stimulator riociguat in a model of pressure overload RV hypertrophy induced by pulmonary artery banding (PAB). Sildenafil Citrate 133-143 phosphodiesterase 5A Homo sapiens 91-115 29511676-3 2018 The objective was to evaluate the therapeutic efficacy and antiremodeling potential of the phosphodiesterase type 5 (PDE5) inhibitor sildenafil and the soluble guanylate cyclase stimulator riociguat in a model of pressure overload RV hypertrophy induced by pulmonary artery banding (PAB). Sildenafil Citrate 133-143 phosphodiesterase 5A Homo sapiens 117-121 29694963-1 2018 OBJECTIVE: To evaluate PDE5/6 inhibition with sildenafil to reduce choroidal ischemia and treat age-related macular degeneration. Sildenafil Citrate 46-56 phosphodiesterase 5A Homo sapiens 23-27 28798156-9 2017 The PDE5 inhibitors sildenafil and tadalafil ameliorated functional muscle ischemia in boys with DMD, and sildenafil reversed cardiac dysfunction in the mdx mouse. Sildenafil Citrate 20-30 phosphodiesterase 5A Homo sapiens 4-8 29141888-7 2017 The PDE5 inhibitor sildenafil largely suppressed PH in the LLC1 model. Sildenafil Citrate 19-29 phosphodiesterase 5A Homo sapiens 4-8 28150511-4 2017 Due to the amino acid sequence and the secondary structural similarity of PDE6 and PDE11 with the catalytic domain of PDE5, first-generation PDE5 inhibitors (i.e. sildenafil and vardenafil) are also competitive inhibitors of PDE6 and PDE11. Sildenafil Citrate 163-173 phosphodiesterase 5A Homo sapiens 118-122 28150511-4 2017 Due to the amino acid sequence and the secondary structural similarity of PDE6 and PDE11 with the catalytic domain of PDE5, first-generation PDE5 inhibitors (i.e. sildenafil and vardenafil) are also competitive inhibitors of PDE6 and PDE11. Sildenafil Citrate 163-173 phosphodiesterase 5A Homo sapiens 141-145 28964803-2 2017 Using isolated and/or recombinant PDE5, it has been demonstrated that cGMP can increase the affinity of this enzyme for sildenafil and tadalafil. Sildenafil Citrate 120-130 phosphodiesterase 5A Homo sapiens 34-38 28964803-3 2017 We thus hypothesized that in cells expressing the nitric oxide - soluble guanylyl cyclase - cyclic guanosine monophosphate - PDE5 (NO-sGC-cGMP-PDE5) pathway such as platelets, the presence of NO increases the intracellular cGMP content and thus promotes the intracellular accumulation of sildenafil or tadalafil. Sildenafil Citrate 288-298 phosphodiesterase 5A Homo sapiens 125-129 28964803-3 2017 We thus hypothesized that in cells expressing the nitric oxide - soluble guanylyl cyclase - cyclic guanosine monophosphate - PDE5 (NO-sGC-cGMP-PDE5) pathway such as platelets, the presence of NO increases the intracellular cGMP content and thus promotes the intracellular accumulation of sildenafil or tadalafil. Sildenafil Citrate 288-298 phosphodiesterase 5A Homo sapiens 131-147 27581752-0 2017 In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors. Sildenafil Citrate 39-49 phosphodiesterase 5A Homo sapiens 55-59 29151951-4 2017 Methods: Theophylline as Methylxanthines, Roflumilast as phosphodiesterase type 4 (PDE4) inhibitor and Sildenafil as phosphodiesterase type 5 (PDE5) inhibitor are the drugs that we combined with the chemotherapeutic agents (Docetaxel, Cisplatin and Carboplatin) in vitro. Sildenafil Citrate 103-113 phosphodiesterase 5A Homo sapiens 117-141 27338710-4 2017 The great success of synthetic phosphodiesterase type-5 (PDE-5) inhibitory drugs like sildenafil, vardenafil and tadalafil, used for the treatment of erectile dysfunction has made them, as well as their unapproved analogues, popular as adulterants in herbal dietary supplements. Sildenafil Citrate 86-96 phosphodiesterase 5A Homo sapiens 31-55 27338710-4 2017 The great success of synthetic phosphodiesterase type-5 (PDE-5) inhibitory drugs like sildenafil, vardenafil and tadalafil, used for the treatment of erectile dysfunction has made them, as well as their unapproved analogues, popular as adulterants in herbal dietary supplements. Sildenafil Citrate 86-96 phosphodiesterase 5A Homo sapiens 57-62 27581752-4 2017 Patch clamp experiments showed that the IC50 values of the human ether-a-go-go-related gene (hERG1) potassium (K) ion channel blocking affinity of PDE5 inhibitors sildenafil, vardenafil, and tadalafil as 33, 12, and 100 muM, respectively. Sildenafil Citrate 163-173 phosphodiesterase 5A Homo sapiens 147-151 28587325-2 2017 Regressions of lymphatic malformations combined with pulmonary hypertension was first reported in 2012 after three children received treatment with oral sildenafil, which serves as an antagonist of phosphodiesterase isoform-5 (PDE-5). Sildenafil Citrate 153-163 phosphodiesterase 5A Homo sapiens 198-225 28860509-6 2017 alpha1-adrenoreceptor antagonists (Tamsulosin) and PDE5 inhibitors (Sildenafil) both significantly reduced myogenic contractile parameters, including frequency, with notable interpatient variability. Sildenafil Citrate 68-78 phosphodiesterase 5A Homo sapiens 51-55 27101805-2 2017 Recent study results indicate that men with ED in China who were naive to phosphodiesterase inhibitor type 5 (PDE5) therapy prefer tadalafil 20-mg (on-demand) versus sildenafil 100-mg (on-demand). Sildenafil Citrate 166-176 phosphodiesterase 5A Homo sapiens 74-108 27101805-2 2017 Recent study results indicate that men with ED in China who were naive to phosphodiesterase inhibitor type 5 (PDE5) therapy prefer tadalafil 20-mg (on-demand) versus sildenafil 100-mg (on-demand). Sildenafil Citrate 166-176 phosphodiesterase 5A Homo sapiens 110-114 28751142-6 2017 Notably, compound 12 presented potent activities against PDE5A with IC50 values about 50muM (sildenafil IC50 12.59muM), and some of these compounds showed low cell toxicity to A549 cells in vitro. Sildenafil Citrate 93-103 phosphodiesterase 5A Homo sapiens 57-62 29245915-1 2017 The present studies focused on the ability of the phosphodiesterase 5 (PDE5) inhibitor sildenafil to enhance the anti-cancer properties of clinically relevant concentrations of the dietary diarylheptanoid curcumin. Sildenafil Citrate 87-97 phosphodiesterase 5A Homo sapiens 50-69 29245915-1 2017 The present studies focused on the ability of the phosphodiesterase 5 (PDE5) inhibitor sildenafil to enhance the anti-cancer properties of clinically relevant concentrations of the dietary diarylheptanoid curcumin. Sildenafil Citrate 87-97 phosphodiesterase 5A Homo sapiens 71-75 28956417-6 2017 In the pursuit to deliver chemotherapeutic agents to the brain, several studies demonstrated that phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil, may increase the permeability of the BBB enabling successful delivery of chemotherapeutic agents to the brain. Sildenafil Citrate 150-160 phosphodiesterase 5A Homo sapiens 98-122 28956417-6 2017 In the pursuit to deliver chemotherapeutic agents to the brain, several studies demonstrated that phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil, may increase the permeability of the BBB enabling successful delivery of chemotherapeutic agents to the brain. Sildenafil Citrate 150-160 phosphodiesterase 5A Homo sapiens 124-128 28587325-2 2017 Regressions of lymphatic malformations combined with pulmonary hypertension was first reported in 2012 after three children received treatment with oral sildenafil, which serves as an antagonist of phosphodiesterase isoform-5 (PDE-5). Sildenafil Citrate 153-163 phosphodiesterase 5A Homo sapiens 227-232 28587325-4 2017 Therefore, the present study hypothesized that the antagonist of PDE-5, sildenafil, may lead to the regression of hemangiomas. Sildenafil Citrate 72-82 phosphodiesterase 5A Homo sapiens 65-70 28496549-1 2017 BACKGROUND: Several studies have compared the use of phosphodiesterase-5 (PDE5) inhibitors sildenafil or udenafil with the placebo in patients suffering from pulmonary hypertension (PH) due to left chronic heart failure (CHF), corresponding to group 2 (PH due to left heart disease) of the PH classification (according to 2015 ESC/ERS guidelines for the diagnosis and treatment of PH). Sildenafil Citrate 91-101 phosphodiesterase 5A Homo sapiens 53-72 28496549-1 2017 BACKGROUND: Several studies have compared the use of phosphodiesterase-5 (PDE5) inhibitors sildenafil or udenafil with the placebo in patients suffering from pulmonary hypertension (PH) due to left chronic heart failure (CHF), corresponding to group 2 (PH due to left heart disease) of the PH classification (according to 2015 ESC/ERS guidelines for the diagnosis and treatment of PH). Sildenafil Citrate 91-101 phosphodiesterase 5A Homo sapiens 74-78 28211580-2 2017 METHODS: Sildenafil analogues were identified by virtual ligand screening (VLS) and screened for their ability to inhibit adenosine cyclic monophosphate (cAMP) hydrolysis by PDE1A1, PDE1B1, PDE2A1, PDE3A, PDE10A1 and PDE10A2, and cGMP hydrolysis by PDE5A, PDE6C, PDE9A2 for a low (1 nm) and high concentration (10 mum). Sildenafil Citrate 9-19 phosphodiesterase 5A Homo sapiens 249-254 28211580-10 2017 CONCLUSIONS: Sildenafil analogues that inhibit cellular cGMP efflux are potent inhibitors of PDE5A and PDE6C. Sildenafil Citrate 13-23 phosphodiesterase 5A Homo sapiens 93-98 28139291-0 2017 Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction: Pharmacology and Clinical Impact of the Sildenafil Citrate Orodispersible Tablet Formulation. Sildenafil Citrate 119-137 phosphodiesterase 5A Homo sapiens 0-24 28597769-10 2017 Currently, the only evidence in support of transitioning between oral PDE5 inhibitors is from sildenafil to tadalafil. Sildenafil Citrate 94-104 phosphodiesterase 5A Homo sapiens 70-74 28533270-1 2017 Inhibitors of phosphodiesterase 5 (PDE5) - sildenafil citrate (Viagra; Pfizer) and vardenafil hydrochloride (Levitra; Bayer/GlaxoSmithKline) - approved for the treatment of erectile dysfunction and pulmonary arterial hypertension also rescue the loss of cystic fibrosis (CF) chloride channel function and the mislocalization of F508del-CFTR in affected tissues in CF. Sildenafil Citrate 43-61 phosphodiesterase 5A Homo sapiens 14-33 28533270-1 2017 Inhibitors of phosphodiesterase 5 (PDE5) - sildenafil citrate (Viagra; Pfizer) and vardenafil hydrochloride (Levitra; Bayer/GlaxoSmithKline) - approved for the treatment of erectile dysfunction and pulmonary arterial hypertension also rescue the loss of cystic fibrosis (CF) chloride channel function and the mislocalization of F508del-CFTR in affected tissues in CF. Sildenafil Citrate 43-61 phosphodiesterase 5A Homo sapiens 35-39 28394532-2 2017 The most studied PDE-5 inhibitor is sildenafil. Sildenafil Citrate 36-46 phosphodiesterase 5A Homo sapiens 17-22 28013386-4 2017 We hypothesized exercise hyperemia would be augmented by sildenafil citrate (SDF, PDE-5 inhibitor). Sildenafil Citrate 57-75 phosphodiesterase 5A Homo sapiens 82-87 28139291-1 2017 PURPOSE: The purpose of this review is to provide an overview of the pharmacology, tolerability, and efficacy of the different phosphodiesterase type 5 (PDE5) inhibitors available for the treatment of erectile dysfunction (ED), with a special focus on the sildenafil orodispersible tablet (ODT) formulation. Sildenafil Citrate 256-266 phosphodiesterase 5A Homo sapiens 153-157 29256125-5 2017 The specific PDE5 inhibitors, particularly sildenafil and tadalafil, are prescribed for erectile dysfunction, as well as pulmonary hypertension, lower urinary tract symptoms, and premature ejaculation. Sildenafil Citrate 43-53 phosphodiesterase 5A Homo sapiens 13-17 27979766-1 2017 Phosphodiesterase type 5 (PDE-5) inhibitors - among which sildenafil citrate (SC) - play a primary role in the treatment of pulmonary hypertension (PH). Sildenafil Citrate 58-76 phosphodiesterase 5A Homo sapiens 0-24 27979766-1 2017 Phosphodiesterase type 5 (PDE-5) inhibitors - among which sildenafil citrate (SC) - play a primary role in the treatment of pulmonary hypertension (PH). Sildenafil Citrate 58-76 phosphodiesterase 5A Homo sapiens 26-31 28123846-4 2017 Sildenafil, a specific PDE-5 inhibitor, was used to treat AOM/DSS-induced and AOM-induced colonic tumorigenesis model and DSS-induced colitis model. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 23-28 28123846-8 2017 More importantly, PDE-5 inhibitor Sildenafil inhibited colonic tumorigenesis dependent on inflammation and suppressed DSS-induced colitis. Sildenafil Citrate 34-44 phosphodiesterase 5A Homo sapiens 18-23 28243607-2 2017 In this study, we aimed to demonstrate the role of sildenafil (an antagonist of phosphodiesterase type 5 (PDE-5)) and donepezil (a specific and reversible inhibitor of acetylcholinesterase (Ach)) in increasing ischemia-induced angiogenesis. Sildenafil Citrate 51-61 phosphodiesterase 5A Homo sapiens 80-104 28243607-2 2017 In this study, we aimed to demonstrate the role of sildenafil (an antagonist of phosphodiesterase type 5 (PDE-5)) and donepezil (a specific and reversible inhibitor of acetylcholinesterase (Ach)) in increasing ischemia-induced angiogenesis. Sildenafil Citrate 51-61 phosphodiesterase 5A Homo sapiens 106-111 27466020-2 2016 Sildenafil is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor, which induces cyclic GMP accumulation. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 58-63 27979549-0 2017 Re: PDE5A Polymorphisms Influence on Sildenafil Treatment Success. Sildenafil Citrate 37-47 phosphodiesterase 5A Homo sapiens 4-9 28316997-1 2017 Sildenafil, a type 5 phosphodiesterase inhibitor (PDE5-I), is primarily used for treating erectile dysfunction. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 50-54 28316997-2 2017 Sildenafil inhibits the degradation of cyclic guanosine monophosphate (cGMP) by competing with cGMP for binding site of PDE5. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 120-124 27246899-1 2016 The authors previously demonstrated that acute administration of sildenafil-a phosphodiesterase 5 (PDE5) inhibitor-improves hemodynamic parameters in patients with resistant hypertensive (RH), but its effect on ambulatory blood pressure monitoring (ABPM) is unknown. Sildenafil Citrate 65-75 phosphodiesterase 5A Homo sapiens 99-103 27466020-2 2016 Sildenafil is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor, which induces cyclic GMP accumulation. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 37-56 27326921-1 2016 Sildenafil, a selective phosphodiesterase type 5 (PDE5) inhibitor, commonly used in the oral treatment for erectile dysfunction, relaxes smooth muscle of human bladder through the activation of hydrogen sulfide (H2S) signaling. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 24-48 27326921-1 2016 Sildenafil, a selective phosphodiesterase type 5 (PDE5) inhibitor, commonly used in the oral treatment for erectile dysfunction, relaxes smooth muscle of human bladder through the activation of hydrogen sulfide (H2S) signaling. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 50-54 27235284-0 2016 PDE5A Polymorphisms Influence on Sildenafil Treatment Success. Sildenafil Citrate 33-43 phosphodiesterase 5A Homo sapiens 0-5 27310564-1 2016 Sildenafil is a phosphodiesterase-5 inhibitor (PDE-5) for the treatment of erectile dysfunction. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 47-52 27235284-5 2016 AIM: The aim of this study is to analyze the relationship between PDE5A polymorphisms, diabetes, and the efficacy of sildenafil treatment. Sildenafil Citrate 117-127 phosphodiesterase 5A Homo sapiens 66-71 27235284-16 2016 CONCLUSION: The response to sildenafil treatment depends on polymorphisms in the PDE5A gene and the glycemic status of the patients. Sildenafil Citrate 28-38 phosphodiesterase 5A Homo sapiens 81-86 27871960-2 2016 Oral PDE-5 inhibitors such as sildenafil, vardenafil, tadalafil, and avanafil have provided noninvasive, effective, well-tolerated treatment for erectile dysfunction (ED) patients and, at the same time, stimulated both academic and clinical interests. Sildenafil Citrate 30-40 phosphodiesterase 5A Homo sapiens 5-10 29057299-1 2017 Use of the phosphodiesterase 5 (PDE5) blocker sildenafil (Viagra) has been linked to an increased risk of melanoma. Sildenafil Citrate 46-56 phosphodiesterase 5A Homo sapiens 11-30 29057299-4 2017 Inhibition of PDE5 releases this brake, providing a mechanism for the promelanoma effects of sildenafil. Sildenafil Citrate 93-103 phosphodiesterase 5A Homo sapiens 14-18 29057299-1 2017 Use of the phosphodiesterase 5 (PDE5) blocker sildenafil (Viagra) has been linked to an increased risk of melanoma. Sildenafil Citrate 46-56 phosphodiesterase 5A Homo sapiens 32-36 29057299-1 2017 Use of the phosphodiesterase 5 (PDE5) blocker sildenafil (Viagra) has been linked to an increased risk of melanoma. Sildenafil Citrate 58-64 phosphodiesterase 5A Homo sapiens 11-30 29057299-1 2017 Use of the phosphodiesterase 5 (PDE5) blocker sildenafil (Viagra) has been linked to an increased risk of melanoma. Sildenafil Citrate 58-64 phosphodiesterase 5A Homo sapiens 32-36 26816265-10 2016 However, because cGMP is quickly degraded by phosphodiesterases (PDEs), the selective PDE5 inhibitor sildenafil was added to inhibit its degradation. Sildenafil Citrate 101-111 phosphodiesterase 5A Homo sapiens 86-90 26802314-9 2016 Relaxations to sildenafil, a PDE5 inhibitor, and sodium nitroprusside (SNP), an nitric oxide donor, were reduced by blocking Kv 7 channels with linopirdine in penile arteries and corpus cavernosum. Sildenafil Citrate 15-25 phosphodiesterase 5A Homo sapiens 29-33 26553865-1 2015 INTRODUCTION: Sildenafil (Viagra ) is a selective phosphodiesterase type 5 (PDE5) inhibitor that block the breakdown of cyclic guanyl monophosphate (cGMP) leading to relaxation of the smooth muscles of the corpus cavernous and an increase in blood flow resulting in penile erection. Sildenafil Citrate 14-24 phosphodiesterase 5A Homo sapiens 50-74 26108184-5 2016 Moreover, we observed that the nuclear factor-kappaB (NF-kappaB) transcriptionally upregulated PDE5 expression, which was inhibited by sildenafil and yonkenafil in LPS-stimulated N9 microglia. Sildenafil Citrate 135-145 phosphodiesterase 5A Homo sapiens 95-99 26108184-6 2016 Therefore, sildenafil and yonkenafil may exert their inhibitory effects on microglial activation by reducing the expression of PDE5. Sildenafil Citrate 11-21 phosphodiesterase 5A Homo sapiens 127-131 26108184-7 2016 Furthermore, sildenafil and yonkenafil increased the cyclic guanosine monophosphate (cGMP) level in N9 microglia, and 8-Br-cGMP, an analogue of cGMP, downregulates extracellular signal-regulated kinases 1 and 2 (ERK1/2)/the NF-kappaB pathway, suggesting that sildenafil and yonkenafil inhibit microglial activation by decreasing PDE5 expression and increasing the cGMP level. Sildenafil Citrate 13-23 phosphodiesterase 5A Homo sapiens 329-333 26043796-7 2016 All four studies utilized the PDE5 inhibitor sildenafil with various doses for up to 3 months. Sildenafil Citrate 45-55 phosphodiesterase 5A Homo sapiens 30-34 25263347-5 2016 Nineteen PDE-5 inhibitors and their analogues were detected, with tadalafil group compounds being the most frequently observed (53.0%), followed by the sildenafil group (42.5%). Sildenafil Citrate 152-162 phosphodiesterase 5A Homo sapiens 9-14 26432842-4 2015 A group of young (23 +- 1 yr) and a group of older (72 +- 1 yr) male subjects performed knee-extensor exercise in a control setting and following intake of the highly selective PDE5 inhibitor sildenafil. Sildenafil Citrate 192-202 phosphodiesterase 5A Homo sapiens 177-181 26108184-1 2016 Our previous studies showed that the phosphodiesterase-5 (PDE5) inhibitor sildenafil inhibited the microglial activation induced by lipopolysaccharide (LPS). Sildenafil Citrate 74-84 phosphodiesterase 5A Homo sapiens 37-56 26108184-1 2016 Our previous studies showed that the phosphodiesterase-5 (PDE5) inhibitor sildenafil inhibited the microglial activation induced by lipopolysaccharide (LPS). Sildenafil Citrate 74-84 phosphodiesterase 5A Homo sapiens 58-62 27121186-1 2016 BACKGROUND: Phosphodiesterase 5 inhibitors (PDE5-Is) sildenafil, vardenafil, tadalafil and the recently approved avanafil represent the first-line choice for both on-demand and chronic treatment of erectile dysfunction (ED). Sildenafil Citrate 53-63 phosphodiesterase 5A Homo sapiens 44-48 27121186-8 2016 CONCLUSION: Sildenafil, vardenafil, tadalafil and the other chemical entities considered PDE5-Is showed overall positive results and significant improvements in the studied disease, thus some discordant results, in particular when comparing pre-clinical and clinical data, have to be pointed out, suggesting that further insights are needed especially to assess the exact molecular pathway underlying. Sildenafil Citrate 12-22 phosphodiesterase 5A Homo sapiens 89-93 26387628-5 2015 The phosphodiesterase (PDE) 5 inhibitor sildenafil increased the intracellular cGMP levels in skin fibroblasts in a dose-dependent manner. Sildenafil Citrate 40-50 phosphodiesterase 5A Homo sapiens 23-29 26553865-1 2015 INTRODUCTION: Sildenafil (Viagra ) is a selective phosphodiesterase type 5 (PDE5) inhibitor that block the breakdown of cyclic guanyl monophosphate (cGMP) leading to relaxation of the smooth muscles of the corpus cavernous and an increase in blood flow resulting in penile erection. Sildenafil Citrate 14-24 phosphodiesterase 5A Homo sapiens 76-80 26553865-1 2015 INTRODUCTION: Sildenafil (Viagra ) is a selective phosphodiesterase type 5 (PDE5) inhibitor that block the breakdown of cyclic guanyl monophosphate (cGMP) leading to relaxation of the smooth muscles of the corpus cavernous and an increase in blood flow resulting in penile erection. Sildenafil Citrate 26-32 phosphodiesterase 5A Homo sapiens 50-74 26553865-1 2015 INTRODUCTION: Sildenafil (Viagra ) is a selective phosphodiesterase type 5 (PDE5) inhibitor that block the breakdown of cyclic guanyl monophosphate (cGMP) leading to relaxation of the smooth muscles of the corpus cavernous and an increase in blood flow resulting in penile erection. Sildenafil Citrate 26-32 phosphodiesterase 5A Homo sapiens 76-80 26072210-11 2015 Among the 26 samples of dietary supplements and herbal remedies bulk marketed for erectile dysfunctions, three samples were found to be contaminated with both registered and unregistered synthetic PDE-5 inhibitors, i.e. yohimbine, sildenafil, dimethylsildenafil and thiodimethylsildenafil or thiomethisosildenafil. Sildenafil Citrate 231-241 phosphodiesterase 5A Homo sapiens 197-202 26807313-2 2015 In the present study, we investigated that the anticancer effect of sildenafil on human colorectal cancer in vitro and in vivo, which is a potent and selective inhibitor of PDE5 for the treatment of erectile dysfunction and pulmonary arterial hypertension in the clinic. Sildenafil Citrate 68-78 phosphodiesterase 5A Homo sapiens 173-177 25704960-1 2015 We determined whether the multi-kinase inhibitor sorafenib or its derivative regorafenib interacted with phosphodiesterase 5 (PDE5) inhibitors such as Viagra (sildenafil) to kill tumor cells. Sildenafil Citrate 151-157 phosphodiesterase 5A Homo sapiens 126-130 25704960-1 2015 We determined whether the multi-kinase inhibitor sorafenib or its derivative regorafenib interacted with phosphodiesterase 5 (PDE5) inhibitors such as Viagra (sildenafil) to kill tumor cells. Sildenafil Citrate 159-169 phosphodiesterase 5A Homo sapiens 105-124 25704960-1 2015 We determined whether the multi-kinase inhibitor sorafenib or its derivative regorafenib interacted with phosphodiesterase 5 (PDE5) inhibitors such as Viagra (sildenafil) to kill tumor cells. Sildenafil Citrate 159-169 phosphodiesterase 5A Homo sapiens 126-130 26272735-6 2015 A group of young (23 +- 1 years) and a group of older (72 +- 2 years) male human subjects performed submaximal knee-extensor exercise in a control setting and following intake of the highly selective PDE5 inhibitor sildenafil. Sildenafil Citrate 215-225 phosphodiesterase 5A Homo sapiens 200-204 26962606-7 2015 Phosphodiesterase type 5 (PDE-5) inhibitors (sildenafil, tadalafil). Sildenafil Citrate 45-55 phosphodiesterase 5A Homo sapiens 0-24 26962606-7 2015 Phosphodiesterase type 5 (PDE-5) inhibitors (sildenafil, tadalafil). Sildenafil Citrate 45-55 phosphodiesterase 5A Homo sapiens 26-31 26328208-4 2015 Today, the American Urological Association recommends the use of three PDE5 inhibitors (sildenafil, tadalafil, and vardenafil) as a first-line therapy for the treatment of ED. Sildenafil Citrate 88-98 phosphodiesterase 5A Homo sapiens 71-75 25801159-2 2015 Sildenafil, vardenafil, tadalafil and avanafil are FDA approved drugs in market as PDE5 inhibitors for treating erectile dysfunction. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 83-87 26188003-4 2015 Patients were randomized to the PDE-5 inhibitor sildenafil, titrated to 60 mg three times a day, or placebo for 12 weeks. Sildenafil Citrate 48-58 phosphodiesterase 5A Homo sapiens 32-37 26303758-4 2015 Sildenafil inhibits phosphodiesterase Type-5 (PDE5). Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 20-44 26303758-4 2015 Sildenafil inhibits phosphodiesterase Type-5 (PDE5). Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 46-50 26060141-1 2015 UNLABELLED: The purpose of this descriptive study was to assess frequency of phosphodiesterase type (PDE-5) inhibitor use (sildenafil, tadalafil, ardenafil) in community settings. Sildenafil Citrate 123-133 phosphodiesterase 5A Homo sapiens 101-106 26047999-6 2015 Sildenafil, tadalafil and vardenafil are 3 specific PDE-5 inhibitors in current clinical use, which share similar mechanisms of action but present some significant differences regarding potency, selectivity for PDE-5 and pharmacokinetic properties. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 52-57 26047999-6 2015 Sildenafil, tadalafil and vardenafil are 3 specific PDE-5 inhibitors in current clinical use, which share similar mechanisms of action but present some significant differences regarding potency, selectivity for PDE-5 and pharmacokinetic properties. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 211-216 26103029-5 2015 EXPOSURES: Number of filled prescriptions for the PDE5 inhibitors sildenafil and vardenafil or tadalafil. Sildenafil Citrate 66-76 phosphodiesterase 5A Homo sapiens 50-54 25444755-1 2015 The phosphodiesterase 5 (PDE5) inhibitors, including sildenafil (Viagra ), vardenafil (Levitra ), and tadalafil (Cialis ) have been developed for treatment of erectile dysfunction. Sildenafil Citrate 53-63 phosphodiesterase 5A Homo sapiens 4-23 25793988-2 2015 This study aims to demonstrate the immediate impact of Sildenafil, a PDE5 inhibitor, on RV function, measured by cardiovascular magnetic resonance (CMR), in patients with heart failure (HF). Sildenafil Citrate 55-65 phosphodiesterase 5A Homo sapiens 69-73 25444755-1 2015 The phosphodiesterase 5 (PDE5) inhibitors, including sildenafil (Viagra ), vardenafil (Levitra ), and tadalafil (Cialis ) have been developed for treatment of erectile dysfunction. Sildenafil Citrate 53-63 phosphodiesterase 5A Homo sapiens 25-29 25444755-1 2015 The phosphodiesterase 5 (PDE5) inhibitors, including sildenafil (Viagra ), vardenafil (Levitra ), and tadalafil (Cialis ) have been developed for treatment of erectile dysfunction. Sildenafil Citrate 65-71 phosphodiesterase 5A Homo sapiens 4-23 25444755-1 2015 The phosphodiesterase 5 (PDE5) inhibitors, including sildenafil (Viagra ), vardenafil (Levitra ), and tadalafil (Cialis ) have been developed for treatment of erectile dysfunction. Sildenafil Citrate 65-71 phosphodiesterase 5A Homo sapiens 25-29 25444755-3 2015 Since our first report showing the cardioprotective effect of sildenafil in 2002, there has been tremendous growth of preclinical and clinical studies on the use of PDE5 inhibitors for cardiovascular diseases and cancer. Sildenafil Citrate 62-72 phosphodiesterase 5A Homo sapiens 165-169 25352458-3 2015 This review gathers data from studies evaluating the effects of phosphodiesterase-5 (PDE-5) inhibitors (administration of acute sildenafil and short-term tadalafil) on diastolic function, biochemical and hemodynamic parameters in patients with RHTN. Sildenafil Citrate 128-138 phosphodiesterase 5A Homo sapiens 64-83 25352458-4 2015 Acute study with sildenafil treatment found that inhibition of PDE-5 improved hemodynamic parameters and diastolic relaxation. Sildenafil Citrate 17-27 phosphodiesterase 5A Homo sapiens 63-68 25318865-1 2015 INTRODUCTION: Two phosphodiesterase-type 5 (PDE-5) inhibitors, sildenafil and tadalafil, are approved for treatment of pulmonary arterial hypertension (PAH). Sildenafil Citrate 63-73 phosphodiesterase 5A Homo sapiens 18-42 25318865-1 2015 INTRODUCTION: Two phosphodiesterase-type 5 (PDE-5) inhibitors, sildenafil and tadalafil, are approved for treatment of pulmonary arterial hypertension (PAH). Sildenafil Citrate 63-73 phosphodiesterase 5A Homo sapiens 44-49 25352458-3 2015 This review gathers data from studies evaluating the effects of phosphodiesterase-5 (PDE-5) inhibitors (administration of acute sildenafil and short-term tadalafil) on diastolic function, biochemical and hemodynamic parameters in patients with RHTN. Sildenafil Citrate 128-138 phosphodiesterase 5A Homo sapiens 85-90 25744459-1 2015 The aim of this study was to characterize the kinetics of metabolite formation of the phosphodiesterase type-5 (PDE5) inhibitors sildenafil and tadalafil by CYP3A4, CYP3A5, and CYP3A7 isoforms. Sildenafil Citrate 129-139 phosphodiesterase 5A Homo sapiens 86-110 25744459-1 2015 The aim of this study was to characterize the kinetics of metabolite formation of the phosphodiesterase type-5 (PDE5) inhibitors sildenafil and tadalafil by CYP3A4, CYP3A5, and CYP3A7 isoforms. Sildenafil Citrate 129-139 phosphodiesterase 5A Homo sapiens 112-116 26004378-1 2015 Type 2 diabetic men commonly experience erectile dysfunction for which phosphodiesterase-5 (PDE5) inhibitors like sildenafil (Viagra) are often recommended. Sildenafil Citrate 114-124 phosphodiesterase 5A Homo sapiens 71-90 26179419-1 2015 Two groups of isomeric phosphodiestrase-type 5 inhibitors (PDE-5), consisting of four sildenafil- and three thiosildenafil-like analogues, have been successfully differentiated using high-resolution MS/MS. Sildenafil Citrate 86-96 phosphodiesterase 5A Homo sapiens 59-64 26162831-9 2015 In addition the bladder relaxant effect of the PDE-5 inhibitor sildenafil involves H2S as mediator. Sildenafil Citrate 63-73 phosphodiesterase 5A Homo sapiens 47-52 26004378-1 2015 Type 2 diabetic men commonly experience erectile dysfunction for which phosphodiesterase-5 (PDE5) inhibitors like sildenafil (Viagra) are often recommended. Sildenafil Citrate 114-124 phosphodiesterase 5A Homo sapiens 92-96 26004378-1 2015 Type 2 diabetic men commonly experience erectile dysfunction for which phosphodiesterase-5 (PDE5) inhibitors like sildenafil (Viagra) are often recommended. Sildenafil Citrate 126-132 phosphodiesterase 5A Homo sapiens 71-90 26004378-1 2015 Type 2 diabetic men commonly experience erectile dysfunction for which phosphodiesterase-5 (PDE5) inhibitors like sildenafil (Viagra) are often recommended. Sildenafil Citrate 126-132 phosphodiesterase 5A Homo sapiens 92-96 25163536-5 2014 RESULTS: The phosphodiesterase 5 (PDE5) inhibitor sildenafil inhibited human platelet aggregation in vitro. Sildenafil Citrate 50-60 phosphodiesterase 5A Homo sapiens 13-32 26583228-2 2014 The most successful examples are PDE5 inhibitors (i.e., sildenafil and tadalafil), which have been approved for the treatment of male erectile dysfunction and pulmonary hypertension. Sildenafil Citrate 56-66 phosphodiesterase 5A Homo sapiens 33-37 25163536-5 2014 RESULTS: The phosphodiesterase 5 (PDE5) inhibitor sildenafil inhibited human platelet aggregation in vitro. Sildenafil Citrate 50-60 phosphodiesterase 5A Homo sapiens 34-38 24996004-0 2014 Qualitative and quantitative analysis of PDE-5 inhibitors in counterfeit medicines and dietary supplements by HPLC-UV using sildenafil as a sole reference. Sildenafil Citrate 124-134 phosphodiesterase 5A Homo sapiens 41-46 25042693-4 2014 To determine whether the PDE5-inhibitor sildenafil benefits human dystrophinopathy, we conducted a randomized, double-blind, placebo-controlled trial (ClinicalTrials.gov, number NCT01168908). Sildenafil Citrate 40-50 phosphodiesterase 5A Homo sapiens 25-29 24808022-6 2014 Second, PDE5 inhibition with standard clinical doses of either tadalafil or sildenafil alleviates this ischemia in a dose-dependent manner. Sildenafil Citrate 76-86 phosphodiesterase 5A Homo sapiens 8-12 25202677-2 2014 Sildenafil citrate (PDE -5 inhibitor) as a vasodilator increases utero-placental blood flow and potentiates fetal growth. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 20-26 24899690-4 2014 PDE5 inhibitors (eg, sildenafil) are licensed for PH, but a role for PDE2 in lung physiology and disease has yet to be established. Sildenafil Citrate 21-31 phosphodiesterase 5A Homo sapiens 0-4 25202655-3 2014 Augmenting the effect of NO in the renal medulla by the use of selective inhibitors of cyclic guanosine monophosphate (cGMP)-specific phosphadiesterase type 5 (PDE 5) such as sildenafil (Viagra ), vardenafil (Levitra ) or tadalafil (Cialis ) could reduce the severity of the hypoxic insult induced by the contrast medium and reduce the risk of CIN. Sildenafil Citrate 175-185 phosphodiesterase 5A Homo sapiens 160-165 25202655-3 2014 Augmenting the effect of NO in the renal medulla by the use of selective inhibitors of cyclic guanosine monophosphate (cGMP)-specific phosphadiesterase type 5 (PDE 5) such as sildenafil (Viagra ), vardenafil (Levitra ) or tadalafil (Cialis ) could reduce the severity of the hypoxic insult induced by the contrast medium and reduce the risk of CIN. Sildenafil Citrate 187-193 phosphodiesterase 5A Homo sapiens 160-165 24322481-2 2014 Sildenafil, a specific inhibitor of phosphodiesterase 5 (PDE5), induces migraine-like headache in a human headache model without concomitant artery dilation. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 36-55 24651037-4 2014 Expression of dominant negative caspase 9 did not significantly inhibit chemotherapy lethality but did significantly reduce enhanced killing in combination with the PDE5 inhibitor sildenafil. Sildenafil Citrate 180-190 phosphodiesterase 5A Homo sapiens 165-169 24322481-2 2014 Sildenafil, a specific inhibitor of phosphodiesterase 5 (PDE5), induces migraine-like headache in a human headache model without concomitant artery dilation. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 57-61 24710960-3 2014 Recent studies have shown that BRAF activation down-regulates PDE5A levels, and low PDE5A expression by BRAF activation or sildenafil use increases the invasiveness of melanoma cells, which raises the possible adverse effect of sildenafil use on melanoma risk. Sildenafil Citrate 123-133 phosphodiesterase 5A Homo sapiens 84-89 24786017-1 2014 BACKGROUND: A sildenafil tablet formulation as a PDE-5 inhibitor is widely used for the treatment of erectile dysfunction. Sildenafil Citrate 14-24 phosphodiesterase 5A Homo sapiens 49-54 24710960-3 2014 Recent studies have shown that BRAF activation down-regulates PDE5A levels, and low PDE5A expression by BRAF activation or sildenafil use increases the invasiveness of melanoma cells, which raises the possible adverse effect of sildenafil use on melanoma risk. Sildenafil Citrate 228-238 phosphodiesterase 5A Homo sapiens 84-89 25175135-3 2014 In the present report, we herein describe a PLCH patient with severe PH in whom sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, substantially improved the pulmonary hemodynamics before lung transplantation. Sildenafil Citrate 80-90 phosphodiesterase 5A Homo sapiens 94-113 24940471-1 2014 About 25% of patients who are prescribed sildenafil, the phosphodiesterase type 5 (PDE-5) inhibitor, for erectile dysfunction (ED) experience headaches. Sildenafil Citrate 41-51 phosphodiesterase 5A Homo sapiens 57-81 24940471-1 2014 About 25% of patients who are prescribed sildenafil, the phosphodiesterase type 5 (PDE-5) inhibitor, for erectile dysfunction (ED) experience headaches. Sildenafil Citrate 41-51 phosphodiesterase 5A Homo sapiens 83-88 24796952-2 2014 A multi-residual ultra-performance liquid chromatography-time of flight mass spectrometry (UPLC-TOF/MS) method was developed to screen for the presence of the phosphodiesterase-5 (PDE-5) inhibitors sildenafil, tadalafil, and vardenafil and their analogues thioaildenafil and thiohomosildenafil in powders and pharmaceutical dosage forms. Sildenafil Citrate 198-208 phosphodiesterase 5A Homo sapiens 180-185 24796952-5 2014 In two of the eleven specimens under investigation, high-resolution mass spectrometry (HR-MS) allowed the identification of the PDE-5 inhibitors sildenafil and tadalafil, while another specimen proved to contain a unapproved dimethylated thioderivative of sildenafil, thioaildenafil or thiodimethylsildenafil, identified for the first time in Italy as adulterant in food supplements. Sildenafil Citrate 145-155 phosphodiesterase 5A Homo sapiens 128-133 24673534-9 2014 All of these studies used sildenafil as the PDE-5 inhibitor. Sildenafil Citrate 26-36 phosphodiesterase 5A Homo sapiens 44-49 24534379-0 2014 PDE5 inhibitor sildenafil in the treatment of heart failure: a meta-analysis of randomized controlled trials. Sildenafil Citrate 15-25 phosphodiesterase 5A Homo sapiens 0-4 24618671-12 2014 The subgroup analysis could find a trend that longer treatment duration, higher dosage, on-demand dosing, sildenafil and mild ED are associated with more responsiveness to PDE5-Is. Sildenafil Citrate 106-116 phosphodiesterase 5A Homo sapiens 172-176 24251665-2 2014 Preliminary clinical trials show that continuous treatment with PDE5 inhibitor sildenafil unassociated with sexual activity decreases priapic activity in patients with SCD. Sildenafil Citrate 79-89 phosphodiesterase 5A Homo sapiens 64-68 24211383-3 2014 Using myelin oligodendrocyte glycoprotein peptide 35-55 (MOG)-induced experimental autoimmune encephalomyelitis (EAE) as a model of MS, we recently showed that daily treatment with the phosphodiesterase 5 (PDE5) inhibitor sildenafil at peak disease rapidly ameliorates clinical symptoms and neuropathology (Pifarre et al., 2011). Sildenafil Citrate 222-232 phosphodiesterase 5A Homo sapiens 185-204 25175135-3 2014 In the present report, we herein describe a PLCH patient with severe PH in whom sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, substantially improved the pulmonary hemodynamics before lung transplantation. Sildenafil Citrate 80-90 phosphodiesterase 5A Homo sapiens 115-119 24180640-2 2013 However, sildenafil causes side effects on visual functions since it shows similar potencies to inhibit PDE5 and PDE6, whereas tadalafil gives a high selectivity of 1020-fold against PDE6. Sildenafil Citrate 9-19 phosphodiesterase 5A Homo sapiens 104-108 23721687-2 2014 PDE-5 inhibitors, namely sildenafil, tadalafil and vardenafil, and their unapproved designer analogues are being increasingly used as adulterants in the herbal products and health supplements marketed for sexual performance enhancement. Sildenafil Citrate 25-35 phosphodiesterase 5A Homo sapiens 0-5 24341639-2 2014 Polymorphisms in the PDE5A gene that may predict response to therapy with sildenafil and nitric oxide, be linked to disease progression, and aid in risk assessment have been identified in human beings. Sildenafil Citrate 74-84 phosphodiesterase 5A Homo sapiens 21-26 24550991-6 2014 Cell proliferation induced by PDE5 inhibitors was dependent on the activation of the mitogen-activated protein kinase (MAPK) and was abolished by inhibitors of MAPK signaling, soluble guanylyl cyclase, and protein kinase G. Moreover, sildenafil neither activated ERK1/2 nor altered p27(Kip1) levels, suggesting the involvement of pathways different from those activated by T0156 or zaprinast. Sildenafil Citrate 234-244 phosphodiesterase 5A Homo sapiens 30-34 24180640-1 2013 Great attention has been paid to the clinical significance of phosphodiesterase 5 (PDE5) inhibitors, such as sildenafil, tadalafil, and vardenafil widely used for erectile dysfunction. Sildenafil Citrate 109-119 phosphodiesterase 5A Homo sapiens 62-81 24180640-1 2013 Great attention has been paid to the clinical significance of phosphodiesterase 5 (PDE5) inhibitors, such as sildenafil, tadalafil, and vardenafil widely used for erectile dysfunction. Sildenafil Citrate 109-119 phosphodiesterase 5A Homo sapiens 83-87 24180640-8 2013 These findings have shed light on the continuous puzzle of why sildenafil (IC50 = 74 and 6 nM toward PDE6 and PDE5, respectively) causes visual disorders because of its poor selectivity but tadalafil does not. Sildenafil Citrate 63-73 phosphodiesterase 5A Homo sapiens 110-114 23925396-4 2013 Sildenafil citrate inhibits type 5-specific phosphodiesterase (PDE5), thus preventing the degradation of cyclic guanosine monophosphate (cGMP) in the muscle and augmenting the vasodilatory effects of NO. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 63-67 23823195-7 2013 MAIN RESULTS: Maximum sildenafil concentrations ranged from 92 to 775 ng/mL and were above the in vitro threshold needed for 77% phosphodiesterase type 5 (PDE-5) inhibition in 80% of subjects and 90% inhibition in 80% of subjects with doses >=0.35 mg/kg. Sildenafil Citrate 22-32 phosphodiesterase 5A Homo sapiens 129-153 23917809-4 2013 This hypothesis led to the development of PDE 5 inhibitors with the first being sildenafil citrate. Sildenafil Citrate 80-98 phosphodiesterase 5A Homo sapiens 42-47 22806713-1 2013 New evidence of increased phosphodiesterase-5 (PDE-5) in hypertrophied human myocardium suggests that sildenafil, a selective PDE-5 inhibitor, may improve muscle contraction and therefore improve ventricular function. Sildenafil Citrate 102-112 phosphodiesterase 5A Homo sapiens 26-45 22806713-1 2013 New evidence of increased phosphodiesterase-5 (PDE-5) in hypertrophied human myocardium suggests that sildenafil, a selective PDE-5 inhibitor, may improve muscle contraction and therefore improve ventricular function. Sildenafil Citrate 102-112 phosphodiesterase 5A Homo sapiens 47-52 22806713-1 2013 New evidence of increased phosphodiesterase-5 (PDE-5) in hypertrophied human myocardium suggests that sildenafil, a selective PDE-5 inhibitor, may improve muscle contraction and therefore improve ventricular function. Sildenafil Citrate 102-112 phosphodiesterase 5A Homo sapiens 126-131 26558086-2 2013 Currently, three PDE5 inhibitors are widely available clinically, i.e., sildenafil, vardenafil and tadalafil. Sildenafil Citrate 72-82 phosphodiesterase 5A Homo sapiens 17-21 23804703-5 2013 Knockdown of the cGMP-specific PDE5 isozyme by siRNA and PDE5-specific inhibitors tadalafil and sildenafil also selectively inhibited the growth of colon tumor cells that expressed high levels of PDE5 compared with colonocytes. Sildenafil Citrate 96-106 phosphodiesterase 5A Homo sapiens 31-35 23804703-5 2013 Knockdown of the cGMP-specific PDE5 isozyme by siRNA and PDE5-specific inhibitors tadalafil and sildenafil also selectively inhibited the growth of colon tumor cells that expressed high levels of PDE5 compared with colonocytes. Sildenafil Citrate 96-106 phosphodiesterase 5A Homo sapiens 57-61 23804703-5 2013 Knockdown of the cGMP-specific PDE5 isozyme by siRNA and PDE5-specific inhibitors tadalafil and sildenafil also selectively inhibited the growth of colon tumor cells that expressed high levels of PDE5 compared with colonocytes. Sildenafil Citrate 96-106 phosphodiesterase 5A Homo sapiens 57-61 24448333-0 2013 VICTORY project: a study of counterfeit PDE5 inhibitor (sildenafil) in Indonesia. Sildenafil Citrate 56-66 phosphodiesterase 5A Homo sapiens 40-44 23058346-1 2013 BACKGROUND: The goal was to examine the hemodynamic and clinical effects of long-term therapy with PDE5 inhibitor sildenafil (SILD) in patients with advanced, pre-transplant heart failure (HF) and severe pulmonary hypertension (PH), in comparison to a similar control group (CON). Sildenafil Citrate 114-124 phosphodiesterase 5A Homo sapiens 99-103 23758451-1 2013 Sildenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE-5). Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 112-117 23823195-7 2013 MAIN RESULTS: Maximum sildenafil concentrations ranged from 92 to 775 ng/mL and were above the in vitro threshold needed for 77% phosphodiesterase type 5 (PDE-5) inhibition in 80% of subjects and 90% inhibition in 80% of subjects with doses >=0.35 mg/kg. Sildenafil Citrate 22-32 phosphodiesterase 5A Homo sapiens 155-160 23382484-8 2013 CONCLUSIONS: PDE5 inhibition with sildenafil did not improve exercise capacity in hypertensive men. Sildenafil Citrate 34-44 phosphodiesterase 5A Homo sapiens 13-17 23443723-1 2013 BACKGROUND: Sildenafil, a selective phosphodiesterase-type-5 (PDE-5) inhibitor, produces vasodilation that improves erectile dysfunction and pulmonary hypertension. Sildenafil Citrate 12-22 phosphodiesterase 5A Homo sapiens 36-60 23443723-1 2013 BACKGROUND: Sildenafil, a selective phosphodiesterase-type-5 (PDE-5) inhibitor, produces vasodilation that improves erectile dysfunction and pulmonary hypertension. Sildenafil Citrate 12-22 phosphodiesterase 5A Homo sapiens 62-67 23347555-1 2013 INTRODUCTION: Sildenafil was the first oral phosphodiesterase type 5 (PDE5) inhibitor introduced as primary therapy for erectile dysfunction (ED). Sildenafil Citrate 14-24 phosphodiesterase 5A Homo sapiens 44-68 23347555-1 2013 INTRODUCTION: Sildenafil was the first oral phosphodiesterase type 5 (PDE5) inhibitor introduced as primary therapy for erectile dysfunction (ED). Sildenafil Citrate 14-24 phosphodiesterase 5A Homo sapiens 70-74 23441682-5 2013 KEY RESULTS: Concentration-dependent vasodilation to the PDE5 inhibitor, sildenafil, in HPRA was sensitive to endothelium removal, NO/cGMP pathway inhibition and KCa blockade. Sildenafil Citrate 73-83 phosphodiesterase 5A Homo sapiens 57-61 23656343-3 2013 PDE inhibitors, in particular the PDE5 (cyclic GMP PDE) inhibitors avanafil, lodenafil, sildenafil, tadalafil, udenafil and vardenafil, are regarded as efficacious, having a fast onset of drug action and an improved effect-to-adverse event ratio, combining a high response rate with the advantage of an on-demand intake. Sildenafil Citrate 77-86 phosphodiesterase 5A Homo sapiens 34-38 23656343-3 2013 PDE inhibitors, in particular the PDE5 (cyclic GMP PDE) inhibitors avanafil, lodenafil, sildenafil, tadalafil, udenafil and vardenafil, are regarded as efficacious, having a fast onset of drug action and an improved effect-to-adverse event ratio, combining a high response rate with the advantage of an on-demand intake. Sildenafil Citrate 88-98 phosphodiesterase 5A Homo sapiens 34-38 23372609-1 2013 Orally active, selective inhibitors of phosphodiesterase type 5 (PDE 5, cyclic GMP PDE), such as sildenafil, tadalafil and vardenafil, are currently the first-choice treatment options for the clinical management of erectile dysfunction (ED) of various etiologies and severities. Sildenafil Citrate 97-107 phosphodiesterase 5A Homo sapiens 39-63 23369145-5 2013 On the other hand, growing evidence suggests that PDE 5 inhibitors (vardenafil, tadalafil and sildenafil) seem to better satisfy the needs of NYHA HF I- II class men suffering from ED. Sildenafil Citrate 94-104 phosphodiesterase 5A Homo sapiens 50-55 23386068-9 2013 The available PDE-5 inhibitors (sildenafil, tadalafil, and vardenafil) have shown efficacy in the treatment of LUTS in several randomized controlled trials in men with and without concomitant ED. Sildenafil Citrate 32-42 phosphodiesterase 5A Homo sapiens 14-19 22095394-3 2013 Sildenafil (Viagra(R)) and the other phosphodiesterase type 5 (PDE5) inhibitors are the first-line options for the treatment of erectile dysfunction, but transient visual symptoms and serious ocular side effects have been reported in PDE5 inhibitor users. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 234-238 23417046-1 2013 Phosphodiesterase-5 (PDE5) inhibitors, such as sildenafil, tadalafil and vardenafil are first line treatment for erectile dysfunction (ED). Sildenafil Citrate 47-57 phosphodiesterase 5A Homo sapiens 0-19 23417046-1 2013 Phosphodiesterase-5 (PDE5) inhibitors, such as sildenafil, tadalafil and vardenafil are first line treatment for erectile dysfunction (ED). Sildenafil Citrate 47-57 phosphodiesterase 5A Homo sapiens 21-25 23372609-1 2013 Orally active, selective inhibitors of phosphodiesterase type 5 (PDE 5, cyclic GMP PDE), such as sildenafil, tadalafil and vardenafil, are currently the first-choice treatment options for the clinical management of erectile dysfunction (ED) of various etiologies and severities. Sildenafil Citrate 97-107 phosphodiesterase 5A Homo sapiens 65-70 24261938-2 2013 The aim of this study was to determine whether herbal food supplements on the Dutch market indeed contain APIs that inhibit phosphodiesterase type 5 (PDE-5) inhibitors, such as sildenafil and analogous PDE-5 inhibitors. Sildenafil Citrate 177-187 phosphodiesterase 5A Homo sapiens 124-148 24261938-2 2013 The aim of this study was to determine whether herbal food supplements on the Dutch market indeed contain APIs that inhibit phosphodiesterase type 5 (PDE-5) inhibitors, such as sildenafil and analogous PDE-5 inhibitors. Sildenafil Citrate 177-187 phosphodiesterase 5A Homo sapiens 150-155 23088905-4 2013 Sildenafil, a selective inhibitor of phosphodiesterase type 5 (PDE5), was administered in case of erectile dysfunction for two months. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 37-61 23088905-4 2013 Sildenafil, a selective inhibitor of phosphodiesterase type 5 (PDE5), was administered in case of erectile dysfunction for two months. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 63-67 23086989-5 2012 The effect of melatonin on SNP-induced relaxation was abolished in the presence of the PDE5 inhibitors zaprinast and sildenafil. Sildenafil Citrate 117-127 phosphodiesterase 5A Homo sapiens 87-91 23353150-6 2013 Pretreatment of the cells with Cyclosporine blocked the effects of ET-1, and PDE5 inhibition by sildenafil pretreatment also abolished ET-1-induced reduction of cGMP level in the cells. Sildenafil Citrate 96-106 phosphodiesterase 5A Homo sapiens 77-81 22492839-3 2012 The aim of this study was to evaluate the acute effects of sildenafil, a PDE5 inhibitor, on uroflowmetry parameters. Sildenafil Citrate 60-70 phosphodiesterase 5A Homo sapiens 74-78 22947364-4 2012 This hypothesis led to the development of PDE-5 inhibitors, the first being sildenafil citrate. Sildenafil Citrate 76-94 phosphodiesterase 5A Homo sapiens 42-47 22840979-1 2012 Two new phosphodiesterase-5 inhibitors (PDE-5) which consist of one sildenafil analogue and one thiosildenafil analogue have been found in heath supplements. Sildenafil Citrate 68-78 phosphodiesterase 5A Homo sapiens 40-45 24027721-4 2012 Sildenafil is a phosphodiesterase inhibitor type 5 (PDE5) that has been shown to selectively reduce pulmonary vascular resistance in both animal models and adult humans. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 16-50 24027721-4 2012 Sildenafil is a phosphodiesterase inhibitor type 5 (PDE5) that has been shown to selectively reduce pulmonary vascular resistance in both animal models and adult humans. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 52-56 22901823-9 2012 Pre-exposure of the tissue to a threshold concentration (0.05 muM) of forskolin (adenlyl cyclase activator) increased the reversion of tension induced by rolipram and RP 73401 and the PDE5 inhibitor sildenafil. Sildenafil Citrate 199-209 phosphodiesterase 5A Homo sapiens 184-188 22260245-11 2012 The PDE5 inhibitor sildenafil (10(-4) M) reduced the increase in tension by 69%, while a combination of sildenafil and ROCK inhibitor, fasudil, inhibited tension by 81%. Sildenafil Citrate 19-29 phosphodiesterase 5A Homo sapiens 4-8 22260245-16 2012 The Rho-kinase (ROCK) inhibitor fasudil, L-type Ca(2+) channel antagonist isradipine, and PDE5 inhibitor sildenafil, as well as a NO-independent stimulator of sGC, had similar inhibitory effects, suggesting parallel mechanisms in the HCC. Sildenafil Citrate 105-115 phosphodiesterase 5A Homo sapiens 90-94 22285803-12 2012 Phosphodiestaerase-5 (PDE-5 inhibitor) sildenafil augmented ANP-mediated effects on hnRNPA1 phosphorylation, translocation to nucleus and nuclear cGK activity. Sildenafil Citrate 39-49 phosphodiesterase 5A Homo sapiens 22-27 22775210-0 2012 Characterization of efflux transport of the PDE5 inhibitors, vardenafil and sildenafil. Sildenafil Citrate 76-86 phosphodiesterase 5A Homo sapiens 44-48 22925748-4 2012 METHOD: Ten articles, which used the IIEF to study satisfaction and/or efficacy of PDE5is sildenafil, tadalafil, and vardenafil in the treatment of ED were reviewed and analyzed. Sildenafil Citrate 91-101 phosphodiesterase 5A Homo sapiens 84-88 22563707-4 2012 Surprisingly, the phosphodiesterase 5 (PDE5) inhibitor sildenafil was found to possess submicromolar affinity for AA2AR. Sildenafil Citrate 55-65 phosphodiesterase 5A Homo sapiens 18-37 22563707-4 2012 Surprisingly, the phosphodiesterase 5 (PDE5) inhibitor sildenafil was found to possess submicromolar affinity for AA2AR. Sildenafil Citrate 55-65 phosphodiesterase 5A Homo sapiens 39-43 22453196-3 2012 We tested the effect of the phosphodiesterase 5 (PDE5) inhibitor sildenafil, which potentiates the effect of NO, on skin blood flow. Sildenafil Citrate 65-75 phosphodiesterase 5A Homo sapiens 28-47 22453196-3 2012 We tested the effect of the phosphodiesterase 5 (PDE5) inhibitor sildenafil, which potentiates the effect of NO, on skin blood flow. Sildenafil Citrate 65-75 phosphodiesterase 5A Homo sapiens 49-53 22707162-1 2012 Recent publications on pharmaceutical monitoring are increasingly covering the field of illicit drugs and lately the forensic evaluation of designing illegal analogs of lifestyle drugs like the phosphodiesterase type 5 (PDE-5) inhibitors Viagra (sildenafil), Levitra (vardenafil) and Cialis (tadalafil). Sildenafil Citrate 238-244 phosphodiesterase 5A Homo sapiens 194-218 22707162-1 2012 Recent publications on pharmaceutical monitoring are increasingly covering the field of illicit drugs and lately the forensic evaluation of designing illegal analogs of lifestyle drugs like the phosphodiesterase type 5 (PDE-5) inhibitors Viagra (sildenafil), Levitra (vardenafil) and Cialis (tadalafil). Sildenafil Citrate 238-244 phosphodiesterase 5A Homo sapiens 220-225 22707162-1 2012 Recent publications on pharmaceutical monitoring are increasingly covering the field of illicit drugs and lately the forensic evaluation of designing illegal analogs of lifestyle drugs like the phosphodiesterase type 5 (PDE-5) inhibitors Viagra (sildenafil), Levitra (vardenafil) and Cialis (tadalafil). Sildenafil Citrate 246-256 phosphodiesterase 5A Homo sapiens 194-218 22707162-1 2012 Recent publications on pharmaceutical monitoring are increasingly covering the field of illicit drugs and lately the forensic evaluation of designing illegal analogs of lifestyle drugs like the phosphodiesterase type 5 (PDE-5) inhibitors Viagra (sildenafil), Levitra (vardenafil) and Cialis (tadalafil). Sildenafil Citrate 246-256 phosphodiesterase 5A Homo sapiens 220-225 22444253-2 2012 METHODS: We compared the effects of SAR407899, the Rho-kinase inhibitor Y-27632 and the PDE5 inhibitor sildenafil for their ability to relax corpus cavernosum strips contracted with phenylephrine in healthy and diabetic animals. Sildenafil Citrate 103-113 phosphodiesterase 5A Homo sapiens 88-92 22304626-3 2012 AIM: An up-to-date review on oral phosphodiesterase 5 inhibitors (PDE5): sildenafil, tadalafil, and vardenafil for individuals with CND and ED. Sildenafil Citrate 75-85 phosphodiesterase 5A Homo sapiens 68-72 22370268-6 2012 We outline the synthesis and biological evaluation of analogs of sildenafil (1), a human PDE5 inhibitor, for activities against trypanosomal PDEB1 (TbrPDEB1). Sildenafil Citrate 65-75 phosphodiesterase 5A Homo sapiens 89-93 21996373-3 2012 Sildenafil inhibits the cGMP-hydrolyzing PDE5 and thereby promotes relaxation of smooth muscle cells. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 41-45 21996373-9 2012 Data demonstrate that PDE5 is an important member of cGMP signaling pathways regulating the finely orchestrated process of epididymal duct contractility and suggest, however, that in the epididymis side effects of therapeutically used sildenafil are unlikely. Sildenafil Citrate 235-245 phosphodiesterase 5A Homo sapiens 22-26 22067410-0 2012 Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study. Sildenafil Citrate 36-46 phosphodiesterase 5A Homo sapiens 0-19 22785374-7 2012 Several clinical trials are ongoing or planned to test the efficacy of PDE5 inhibitors in human heart disease, including a large multicenter clinical trial (RELAX) led by the NIH evaluating sildenafil efficacy in heart failure with preserved ejection fraction. Sildenafil Citrate 190-200 phosphodiesterase 5A Homo sapiens 71-75 22564297-6 2012 PDE 5 is particularly prevalent in vascular smooth muscle (VSM) and PDE 5 inhibitors, such as sildenafil, have been used in clinical practice. Sildenafil Citrate 94-104 phosphodiesterase 5A Homo sapiens 0-5 22564297-6 2012 PDE 5 is particularly prevalent in vascular smooth muscle (VSM) and PDE 5 inhibitors, such as sildenafil, have been used in clinical practice. Sildenafil Citrate 94-104 phosphodiesterase 5A Homo sapiens 68-73 22256833-3 2012 Animal studies of cerebral stroke suggest potential regenerative benefits following treatment with sildenafil citrate, a PDE5 inhibitor. Sildenafil Citrate 99-117 phosphodiesterase 5A Homo sapiens 121-125 21924956-4 2011 ED in diabetics is more refractory to acute treatment with phosphodiesterase-5 (PDE5) inhibitors (Viagra, Cialis, Levitra, Zydena) than in non-diabetics, but recent studies indicate that chronic administration of these drugs improves endothelial function, preserves vascular smooth muscle and decreases fibrotic changes. Sildenafil Citrate 98-104 phosphodiesterase 5A Homo sapiens 59-78 21924956-4 2011 ED in diabetics is more refractory to acute treatment with phosphodiesterase-5 (PDE5) inhibitors (Viagra, Cialis, Levitra, Zydena) than in non-diabetics, but recent studies indicate that chronic administration of these drugs improves endothelial function, preserves vascular smooth muscle and decreases fibrotic changes. Sildenafil Citrate 98-104 phosphodiesterase 5A Homo sapiens 80-84 21987443-7 2011 Treatment of L-1236 with PDE5A-inhibitor sildenafil or with siRNA directed against PDE5A and concomitant stimulation with cyclic guanosine monophosphate (cGMP) resulted in enhanced apoptosis, indicating PDE5A as an oncogene. Sildenafil Citrate 41-51 phosphodiesterase 5A Homo sapiens 25-30 21620965-4 2011 Band 2 PDE5 was converted almost entirely to Band 3 PDE5 by overnight incubation with sildenafil at 30 C. This time-dependent conversion was accompanied by a 7-fold increase in allosteric cGMP-binding activity, suggesting that Band 3 PDE5 is a much more active form than Band 2 PDE5 for allosteric cGMP binding. Sildenafil Citrate 86-96 phosphodiesterase 5A Homo sapiens 7-11 21995676-4 2011 Sildenafil, tadalafil, and vardenafil are the most widely used and studied PDE5 inhibitors. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 75-79 21851826-1 2011 AIMS: To examine whether calcineurin/NFAT signaling pathway leads to proliferation of pulmonary artery smooth muscle cells (PASMCs) by regulating cell cycle proteins and whether the phosphodiesterase-5 (PDE5) inhibitor sildenafil affects calcineurin/NFAT-induced cell proliferation. Sildenafil Citrate 219-229 phosphodiesterase 5A Homo sapiens 182-201 21851826-1 2011 AIMS: To examine whether calcineurin/NFAT signaling pathway leads to proliferation of pulmonary artery smooth muscle cells (PASMCs) by regulating cell cycle proteins and whether the phosphodiesterase-5 (PDE5) inhibitor sildenafil affects calcineurin/NFAT-induced cell proliferation. Sildenafil Citrate 219-229 phosphodiesterase 5A Homo sapiens 203-207 21620965-0 2011 Conformational conversion of PDE5 by incubation with sildenafil or metal ion is accompanied by stimulation of allosteric cGMP binding. Sildenafil Citrate 53-63 phosphodiesterase 5A Homo sapiens 29-33 21620965-3 2011 A preparation comprised mainly of Band 2 PDE5 was partially converted to Band 3 PDE5 by 1h incubation with cGMP or the PDE5-specific inhibitors sildenafil, vardenafil, or tadalafil, but not with cAMP, milrinone (PDE3-specific), or rolipram (PDE4-specific). Sildenafil Citrate 144-154 phosphodiesterase 5A Homo sapiens 41-45 21620965-3 2011 A preparation comprised mainly of Band 2 PDE5 was partially converted to Band 3 PDE5 by 1h incubation with cGMP or the PDE5-specific inhibitors sildenafil, vardenafil, or tadalafil, but not with cAMP, milrinone (PDE3-specific), or rolipram (PDE4-specific). Sildenafil Citrate 144-154 phosphodiesterase 5A Homo sapiens 80-84 21620965-3 2011 A preparation comprised mainly of Band 2 PDE5 was partially converted to Band 3 PDE5 by 1h incubation with cGMP or the PDE5-specific inhibitors sildenafil, vardenafil, or tadalafil, but not with cAMP, milrinone (PDE3-specific), or rolipram (PDE4-specific). Sildenafil Citrate 144-154 phosphodiesterase 5A Homo sapiens 80-84 21620965-4 2011 Band 2 PDE5 was converted almost entirely to Band 3 PDE5 by overnight incubation with sildenafil at 30 C. This time-dependent conversion was accompanied by a 7-fold increase in allosteric cGMP-binding activity, suggesting that Band 3 PDE5 is a much more active form than Band 2 PDE5 for allosteric cGMP binding. Sildenafil Citrate 86-96 phosphodiesterase 5A Homo sapiens 52-56 21620965-4 2011 Band 2 PDE5 was converted almost entirely to Band 3 PDE5 by overnight incubation with sildenafil at 30 C. This time-dependent conversion was accompanied by a 7-fold increase in allosteric cGMP-binding activity, suggesting that Band 3 PDE5 is a much more active form than Band 2 PDE5 for allosteric cGMP binding. Sildenafil Citrate 86-96 phosphodiesterase 5A Homo sapiens 52-56 21620965-4 2011 Band 2 PDE5 was converted almost entirely to Band 3 PDE5 by overnight incubation with sildenafil at 30 C. This time-dependent conversion was accompanied by a 7-fold increase in allosteric cGMP-binding activity, suggesting that Band 3 PDE5 is a much more active form than Band 2 PDE5 for allosteric cGMP binding. Sildenafil Citrate 86-96 phosphodiesterase 5A Homo sapiens 52-56 21620965-5 2011 Conversion of Band 2 PDE5 to Band 3 PDE5 occurred faster by pre-incubation with cGMP, which binds to both the allosteric and catalytic sites of PDE5, than with catalytic site-specific sildenafil. Sildenafil Citrate 184-194 phosphodiesterase 5A Homo sapiens 21-25 21620965-5 2011 Conversion of Band 2 PDE5 to Band 3 PDE5 occurred faster by pre-incubation with cGMP, which binds to both the allosteric and catalytic sites of PDE5, than with catalytic site-specific sildenafil. Sildenafil Citrate 184-194 phosphodiesterase 5A Homo sapiens 36-40 21620965-5 2011 Conversion of Band 2 PDE5 to Band 3 PDE5 occurred faster by pre-incubation with cGMP, which binds to both the allosteric and catalytic sites of PDE5, than with catalytic site-specific sildenafil. Sildenafil Citrate 184-194 phosphodiesterase 5A Homo sapiens 36-40 25961263-5 2011 Our previous study has indicated that sildenafil has a protective effect on human mammary epithelial cells as a consequence of XO inhibition and of the resulting decrease of free oxygen radicals that can impair the expression of NADPH oxidase and type 5 phosphodiesterase (PDE-5). Sildenafil Citrate 38-48 phosphodiesterase 5A Homo sapiens 273-278 21771280-3 2011 Sildenafil (Viagra(R)), tadalafil (Cialis(R)), and vardenafil (Levitra(R)) are from the same class of drugs that inhibit PDE5. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 121-125 21460862-7 2011 We found reports on five kinds of PDE-5 inhibitors for the management of ED: sildenafil, vardenafil, tadalafil, udenafil and mirodenafil. Sildenafil Citrate 77-87 phosphodiesterase 5A Homo sapiens 34-39 23391833-2 2011 We investigated the effect of sildenafil, a phosphodiesterase 5 (PDE5) inhibitor that inhibits the breakdown of cyclic guanosine monophosphate (cGMP) resulting in vasodilatation, on the elasticity of HbSS erythrocyte. Sildenafil Citrate 30-40 phosphodiesterase 5A Homo sapiens 44-63 23391833-2 2011 We investigated the effect of sildenafil, a phosphodiesterase 5 (PDE5) inhibitor that inhibits the breakdown of cyclic guanosine monophosphate (cGMP) resulting in vasodilatation, on the elasticity of HbSS erythrocyte. Sildenafil Citrate 30-40 phosphodiesterase 5A Homo sapiens 65-69 21651908-1 2011 Anecdotal reports have suggested that the vasodilator, sildenafil citrate, which evokes its effect via a select inhibition of PDE5, has the potential to increase intraocular pressure (IOP) in some individuals. Sildenafil Citrate 55-73 phosphodiesterase 5A Homo sapiens 126-130 21651908-14 2011 Our results suggest that sildenafil can elicit a transient IOP increase that may be of importance to patients chronically treated with PDE5 inhibitors for various vascular diseases (e.g., pulmonary hypertension). Sildenafil Citrate 25-35 phosphodiesterase 5A Homo sapiens 135-139 25961263-6 2011 In the present study, we report that the dual inhibitory effect exerted by sildenafil on both XO and PDE-5 is a consequence of a structural modification induced by O2 -, also consisting of the release of a piperazine group that could in turn inhibit the XO enzyme. Sildenafil Citrate 75-85 phosphodiesterase 5A Homo sapiens 101-106 21735661-1 2011 Phosphodiesterase type 5 (PDE5) inhibitors, sildenafil, tadalafil and vardenafil, are the first-line drugs for the treatment of erectile dysfunction (ED). Sildenafil Citrate 44-54 phosphodiesterase 5A Homo sapiens 26-30 21220057-2 2011 The present study showed that sildenafil, a PDE5 inhibitor, significantly suppressed NO, interleukin 1beta (IL-1beta) and tumor necrosis factor alpha (TNF-alpha) production induced by LPS in microglial cells through decreasing the protein and/or mRNA expressions of inducible NO synthase (iNOS), IL-1beta and TNF-alpha in a concentration-dependent manner. Sildenafil Citrate 30-40 phosphodiesterase 5A Homo sapiens 44-48 21187142-0 2011 Metal ion stimulators of PDE5 cause similar conformational changes in the enzyme as does cGMP or sildenafil. Sildenafil Citrate 97-107 phosphodiesterase 5A Homo sapiens 25-29 21187142-2 2011 Treatment of recombinant or native PDE5 with either cGMP or a substrate analog such as sildenafil, each of which is known to produce stimulatory effects on enzyme functions, caused a similar native PAGE band-shift to the lower mobility form (shift of Band 2 to Band 3). Sildenafil Citrate 87-97 phosphodiesterase 5A Homo sapiens 35-39 21187142-3 2011 Incubation of PDE5 with Mg(++) or Mn(++), which is known to stimulate activity, caused a similar shift of the enzyme from Band 2 to Band 3 as did cGMP or sildenafil, but incubation with EDTA caused a time- and concentration-dependent shift to higher mobility (shift of Bands 2 and 3 to Band 1). Sildenafil Citrate 154-164 phosphodiesterase 5A Homo sapiens 14-18 21537000-7 2011 Antenatal sildenafil administered to the pregnant rat from embryonic day 11.5 to embryonic day 20.5 crossed the placenta, increased fetal lung cyclic GMP and decreased active PDE5 expression. Sildenafil Citrate 10-20 phosphodiesterase 5A Homo sapiens 175-179 21416414-11 2011 To search for new analogues of PDE-5 inhibitors, a precursor ion scan of an expected ion m/z 283, which was one of the mass fragments from the analogues of sildenafil or vardenafil, was performed and fragmentation of the precursor ion, by combining a precursor ion scan with automatic confirmation using EPI spectra, was acquired. Sildenafil Citrate 156-166 phosphodiesterase 5A Homo sapiens 31-36 22131856-2 2011 Three selective inhibitors of PDE-5 - sildenafil, vardenafil and tadalafil - have been successfully used by millions of men worldwide for the treatment of erectile dysfunction. Sildenafil Citrate 38-48 phosphodiesterase 5A Homo sapiens 30-35 21591526-1 2011 OBJECTIVE: Sildenafil, an orally administered phosphodiesterase type 5 (PDE-5) inhibitor, was known for enhancing the downstream effects of NO. Sildenafil Citrate 11-21 phosphodiesterase 5A Homo sapiens 46-70 21591526-1 2011 OBJECTIVE: Sildenafil, an orally administered phosphodiesterase type 5 (PDE-5) inhibitor, was known for enhancing the downstream effects of NO. Sildenafil Citrate 11-21 phosphodiesterase 5A Homo sapiens 72-77 21585174-2 2011 To date, three PDE5 inhibitors are on the market: sildenafil, vardenafil and tadalafil. Sildenafil Citrate 50-60 phosphodiesterase 5A Homo sapiens 15-19 21297971-2 2011 Recent evidences suggest that therapy with PDE5 inhibitors, i.e. sildenafil, may increase the expression of nitric oxide synthase (NOS) proteins in the heart and cardiomyocytes. Sildenafil Citrate 65-75 phosphodiesterase 5A Homo sapiens 43-47 22178885-9 2011 Our study shows that the effect of UGN on pH(i) is GC-C/cGMP-mediated and enhanced by sildenafil, thus involving PDE5 enzyme. Sildenafil Citrate 86-96 phosphodiesterase 5A Homo sapiens 113-117 21036891-0 2011 PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Sildenafil Citrate 21-31 phosphodiesterase 5A Homo sapiens 0-4 21036891-3 2011 In a cohort of systolic HF patients, we tested the effects of PDE5 inhibition (sildenafil) on LV ejection fraction, diastolic function, cardiac geometry, and clinical status. Sildenafil Citrate 79-89 phosphodiesterase 5A Homo sapiens 62-66 21036891-9 2011 CONCLUSIONS: Findings confirm that in HF, sildenafil improves functional capacity and clinical status and provide the first human evidence that LV diastolic function and cardiac geometry are additional targets of benefits related to chronic PDE5 inhibition. Sildenafil Citrate 42-52 phosphodiesterase 5A Homo sapiens 241-245 20859794-5 2011 Several of these inhibitors are highly selective for particular PDEs; potent and largely selective PDE5 inhibitors are used clinically for treatment of erectile dysfunction [sildenafil (Viagra ), tadalafil (Cialis ) and vardenafil (Levitra )] and pulmonary hypertension [sildenafil (Revatio ) and tadalafil (Adenocirca)]. Sildenafil Citrate 174-184 phosphodiesterase 5A Homo sapiens 99-103 20859794-5 2011 Several of these inhibitors are highly selective for particular PDEs; potent and largely selective PDE5 inhibitors are used clinically for treatment of erectile dysfunction [sildenafil (Viagra ), tadalafil (Cialis ) and vardenafil (Levitra )] and pulmonary hypertension [sildenafil (Revatio ) and tadalafil (Adenocirca)]. Sildenafil Citrate 186-192 phosphodiesterase 5A Homo sapiens 99-103 20859794-5 2011 Several of these inhibitors are highly selective for particular PDEs; potent and largely selective PDE5 inhibitors are used clinically for treatment of erectile dysfunction [sildenafil (Viagra ), tadalafil (Cialis ) and vardenafil (Levitra )] and pulmonary hypertension [sildenafil (Revatio ) and tadalafil (Adenocirca)]. Sildenafil Citrate 271-281 phosphodiesterase 5A Homo sapiens 99-103 21695645-5 2011 PDE5 inhibitors such as sildenafil are clinically approved to treat different forms of PAH and lower mPAP, increase functional capacity, and decrease right ventricular hypertrophy, without decreasing systemic arterial pressure. Sildenafil Citrate 24-34 phosphodiesterase 5A Homo sapiens 0-4 21193396-0 2011 Distinct allostery induced in the cyclic GMP-binding, cyclic GMP-specific phosphodiesterase (PDE5) by cyclic GMP, sildenafil, and metal ions. Sildenafil Citrate 114-124 phosphodiesterase 5A Homo sapiens 93-97 21193396-4 2011 PDE5 is the target for catalytic site inhibitors, such as sildenafil, that are used for the treatment of erectile dysfunction and pulmonary hypertension. Sildenafil Citrate 58-68 phosphodiesterase 5A Homo sapiens 0-4 21193396-7 2011 Employing intramolecular bioluminescence resonance energy transfer, which can monitor conformational changes both in vitro and in intact cells, we show that binding of cGMP and sildenafil to PDE5 results in distinct conformations of the protein. Sildenafil Citrate 177-187 phosphodiesterase 5A Homo sapiens 191-195 19945540-1 2010 Sildenafil, a selective and potent inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase (PDE)5, has a relaxant effect on the smooth muscle cells of the arterioles supplying the human corpus cavernosum acting via nitric oxide (NO)-dependent mechanism. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 114-119 20970280-2 2010 BACKGROUND: PDE5 expression is up-regulated in human hypertrophied and failing hearts, and its inhibition (e.g., by sildenafil) stimulates protein kinase G activity, suppressing and reversing maladaptive hypertrophy, fibrosis, and contractile dysfunction. Sildenafil Citrate 116-126 phosphodiesterase 5A Homo sapiens 12-16 20942592-2 2010 Recent studies on the effects of sildenafil on different organs have shown that PDE-5 inhibitors may offer new horizons in therapeutic treatment of pulmonary hypertension, multiple sclerosis, neuropathic pain, and age-related memory impairment. Sildenafil Citrate 33-43 phosphodiesterase 5A Homo sapiens 80-85 20919747-2 2010 Phosphodiesterase-5 (PDE-5) inhibitors, sildenafil, vardenafil and tadalafil, are well known oral treatment for males with erectile dysfunction. Sildenafil Citrate 40-50 phosphodiesterase 5A Homo sapiens 21-26 20884855-1 2010 We have shown that the potent phosphodiesterase-5 (PDE-5) inhibitor sildenafil (Viagra) induces a powerful effect on reduction of infarct size following ischemia/reperfusion injury and improvement of left ventricular dysfunction in the failing heart after myocardial infarction or doxorubicin (DOX) treatment. Sildenafil Citrate 68-78 phosphodiesterase 5A Homo sapiens 30-49 20884855-1 2010 We have shown that the potent phosphodiesterase-5 (PDE-5) inhibitor sildenafil (Viagra) induces a powerful effect on reduction of infarct size following ischemia/reperfusion injury and improvement of left ventricular dysfunction in the failing heart after myocardial infarction or doxorubicin (DOX) treatment. Sildenafil Citrate 68-78 phosphodiesterase 5A Homo sapiens 51-56 20884855-1 2010 We have shown that the potent phosphodiesterase-5 (PDE-5) inhibitor sildenafil (Viagra) induces a powerful effect on reduction of infarct size following ischemia/reperfusion injury and improvement of left ventricular dysfunction in the failing heart after myocardial infarction or doxorubicin (DOX) treatment. Sildenafil Citrate 80-86 phosphodiesterase 5A Homo sapiens 30-49 20884855-1 2010 We have shown that the potent phosphodiesterase-5 (PDE-5) inhibitor sildenafil (Viagra) induces a powerful effect on reduction of infarct size following ischemia/reperfusion injury and improvement of left ventricular dysfunction in the failing heart after myocardial infarction or doxorubicin (DOX) treatment. Sildenafil Citrate 80-86 phosphodiesterase 5A Homo sapiens 51-56 21045254-6 2010 Three of these drugs (namely sildenafil, tadalafil and vardenafil) are inhibitors of the enzyme phosphodiesterase type 5 (PDE5)and work peripherally within the penis to potentiate the smooth muscle relaxation that is needed for a penile erection. Sildenafil Citrate 29-39 phosphodiesterase 5A Homo sapiens 122-126 19540696-3 2010 Therefore, the objective of the present study was to explore the presence of synthetic PDE-5 inhibitors (sildenafil, tadalafil and/or vardenafil) in ayurvedic/herbal healthcare products sold in Indian market for aphrodisiac/related uses. Sildenafil Citrate 105-115 phosphodiesterase 5A Homo sapiens 87-92 20394470-7 2010 When co-possessed prescriptions were defined by overlapping exposure periods, the proportion of PDE5-I patients with co-possessed nitrates ranged from 1.44% (tadalafil) to 1.72% (vardenafil) and 2.13% (sildenafil). Sildenafil Citrate 202-212 phosphodiesterase 5A Homo sapiens 96-100 20394470-8 2010 Co-possession percentages of PDE5-I prescriptions were 0.83% for tadalafil and 1.07% for sildenafil and vardenafil. Sildenafil Citrate 89-99 phosphodiesterase 5A Homo sapiens 29-33 20939743-2 2010 Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil and vardenafil) are currently the first-line treatment option presented to patients with ED. Sildenafil Citrate 44-54 phosphodiesterase 5A Homo sapiens 0-24 20939743-2 2010 Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil and vardenafil) are currently the first-line treatment option presented to patients with ED. Sildenafil Citrate 44-54 phosphodiesterase 5A Homo sapiens 26-30 19171388-2 2010 Sildenafil is a phosphodiesterase-5 (PDE-5) inhibitor used in the treatment of iPAH. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 16-35 19171388-2 2010 Sildenafil is a phosphodiesterase-5 (PDE-5) inhibitor used in the treatment of iPAH. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 37-42 20713918-5 2010 Phosphodiesterase 5A inhibition with sildenafil (1 mumol/L) did not affect basal intracellular pH; yet, it did decrease proton efflux (J(H); in millimoles per liter per minute) after the acidic load (proton efflux: 6.97+-0.43 in control versus 3.31+-0.58 with sildenafil; P<0.05). Sildenafil Citrate 37-47 phosphodiesterase 5A Homo sapiens 0-20 20713918-5 2010 Phosphodiesterase 5A inhibition with sildenafil (1 mumol/L) did not affect basal intracellular pH; yet, it did decrease proton efflux (J(H); in millimoles per liter per minute) after the acidic load (proton efflux: 6.97+-0.43 in control versus 3.31+-0.58 with sildenafil; P<0.05). Sildenafil Citrate 260-270 phosphodiesterase 5A Homo sapiens 0-20 20590606-1 2010 BACKGROUND AND PURPOSE: Sildenafil, a specific inhibitor of phosphodiesterase 5A (PDE5A), is currently tested as a treatment for severe Raynaud"s phenomenon. Sildenafil Citrate 24-34 phosphodiesterase 5A Homo sapiens 60-80 20590606-1 2010 BACKGROUND AND PURPOSE: Sildenafil, a specific inhibitor of phosphodiesterase 5A (PDE5A), is currently tested as a treatment for severe Raynaud"s phenomenon. Sildenafil Citrate 24-34 phosphodiesterase 5A Homo sapiens 82-87 20590607-3 2010 Thus, we assessed the ability of a PDE5 inhibitor, sildenafil, to relax such tissue, and identified the signalling pathways involved in this relaxation. Sildenafil Citrate 51-61 phosphodiesterase 5A Homo sapiens 35-39 20590607-10 2010 The effect of this sildenafil-induced relaxation on the clinical benefit of PDE5 inhibitors on urinary storage symptoms in men deserves further investigation. Sildenafil Citrate 19-29 phosphodiesterase 5A Homo sapiens 76-80 20093183-7 2010 Furthermore, CSE-induced pg91(phox) and PDE5 mRNA overexpression were suppressed by both sildenafil and DPI. Sildenafil Citrate 89-99 phosphodiesterase 5A Homo sapiens 40-44 20308615-9 2010 In addition, administration of sildenafil to inhibit PDE5 attenuated TAC-induced myocardial oxidative stress, PDE5 expression, and CHF. Sildenafil Citrate 31-41 phosphodiesterase 5A Homo sapiens 53-57 20308615-9 2010 In addition, administration of sildenafil to inhibit PDE5 attenuated TAC-induced myocardial oxidative stress, PDE5 expression, and CHF. Sildenafil Citrate 31-41 phosphodiesterase 5A Homo sapiens 110-114 19961855-1 2010 Increased cyclic GMP from enhanced synthesis or suppressed catabolism (e.g. PDE5 inhibition by sildenafil, SIL) activates protein kinase G (PKG) and blunts cardiac pathological hypertrophy. Sildenafil Citrate 95-105 phosphodiesterase 5A Homo sapiens 76-80 20402554-1 2010 IMPORTANCE TO THE FIELD: Since sildenafil was introduced 10 years ago, highly selective phosphodiesterase type 5 inhibitors (PDE5i) have changed the medical management of erectile dysfunction (ED). Sildenafil Citrate 31-41 phosphodiesterase 5A Homo sapiens 88-112 20086037-3 2010 We showed previously that PDE5 could be converted from a low-activity (nonactivated) state to a high-activity state upon cGMP binding to the GAF-A domain with higher sensitivities toward sildenafil (EMBO J 22:469-478, 2003). Sildenafil Citrate 187-197 phosphodiesterase 5A Homo sapiens 26-30 20086037-4 2010 Here we investigated whether sildenafil sensitivity of PDE5 could be modified by cGMP-independent mechanisms. Sildenafil Citrate 29-39 phosphodiesterase 5A Homo sapiens 55-59 20086037-5 2010 Individually expressed recombinant GAF-A and GAF-B proteins were tested for their ability to modulate full-length recombinant PDE5 affinity to sildenafil. Sildenafil Citrate 143-153 phosphodiesterase 5A Homo sapiens 126-130 20086037-6 2010 The GAF-A domain protein had the most dramatic effect on the affinity of the nonactivated recombinant PDE5 for sildenafil, revealing much higher sensitivity to sildenafil inhibition. Sildenafil Citrate 111-121 phosphodiesterase 5A Homo sapiens 102-106 20086037-6 2010 The GAF-A domain protein had the most dramatic effect on the affinity of the nonactivated recombinant PDE5 for sildenafil, revealing much higher sensitivity to sildenafil inhibition. Sildenafil Citrate 160-170 phosphodiesterase 5A Homo sapiens 102-106 20086037-7 2010 The apparent affinity for sildenafil increased from the nanomolar range to the picomolar range, providing evidence for the presence of a "super-high" sensitivity state of PDE5 for sildenafil inhibition. Sildenafil Citrate 26-36 phosphodiesterase 5A Homo sapiens 171-175 20086037-7 2010 The apparent affinity for sildenafil increased from the nanomolar range to the picomolar range, providing evidence for the presence of a "super-high" sensitivity state of PDE5 for sildenafil inhibition. Sildenafil Citrate 180-190 phosphodiesterase 5A Homo sapiens 171-175 20086037-8 2010 In human platelet, higher sensitivity of PDE5 for sildenafil inhibition has been detected after blocking cGMP-binding sites of the GAF-A domain. Sildenafil Citrate 50-60 phosphodiesterase 5A Homo sapiens 41-45 20086037-9 2010 Thus, our data demonstrate that high sensitivity of PDE5 for sildenafil can be obtained not only through cGMP-induced activation of PDE, but also through cGMP-independent modulation of PDE5 in the nonactivated state, possibly through protein-protein interaction. Sildenafil Citrate 61-71 phosphodiesterase 5A Homo sapiens 52-56 20086037-9 2010 Thus, our data demonstrate that high sensitivity of PDE5 for sildenafil can be obtained not only through cGMP-induced activation of PDE, but also through cGMP-independent modulation of PDE5 in the nonactivated state, possibly through protein-protein interaction. Sildenafil Citrate 61-71 phosphodiesterase 5A Homo sapiens 185-189 20086037-10 2010 Furthermore, data suggest that nonactivated PDE5 with "super-high" affinities for sildenafil inhibition may be responsible for therapeutic effects of long-term treatments with low doses of PDE5 inhibitors. Sildenafil Citrate 82-92 phosphodiesterase 5A Homo sapiens 44-48 20086037-10 2010 Furthermore, data suggest that nonactivated PDE5 with "super-high" affinities for sildenafil inhibition may be responsible for therapeutic effects of long-term treatments with low doses of PDE5 inhibitors. Sildenafil Citrate 82-92 phosphodiesterase 5A Homo sapiens 189-193 21537421-1 2010 Phosphodiesterase type-5 inhibitor (PDE5-i) drugs were first marketed in 1998 (sildenafil) for "ondemand" treatment of male erectile dysfunction (ED) of any origin. Sildenafil Citrate 79-89 phosphodiesterase 5A Homo sapiens 36-40 20518197-7 2010 Hypogonadism, when present, should be treated regardless of age; furthermore, synergistic effects have been found during testosterone replacement therapy when using an oral therapy with a PDE-5 inhibitor (sildenafil, vardenafil or tadalafil). Sildenafil Citrate 205-215 phosphodiesterase 5A Homo sapiens 188-193 19185976-1 2010 BACKGROUND: Sildenafil, vardenafil, and tadalafil are phosphodiesterase type 5 inhibitors (PDE5-Is) usually used in the treatment of erectile dysfunction (ED). Sildenafil Citrate 12-22 phosphodiesterase 5A Homo sapiens 91-95 19793106-6 2010 The effects of the selective PDE5 inhibitor sildenafil and subsequent protein kinase G-specific inhibitor Rp-8Br-cGMPs on MMP-2 production and RhoA activation were further exmamined. Sildenafil Citrate 44-54 phosphodiesterase 5A Homo sapiens 29-33 19793106-12 2010 The selective PDE5 inhibitor sildenafil (0.1-1 micromol/L) concentration-dependently reduced the increased MMP-2 production induced by 100 nmol/L ET-1. Sildenafil Citrate 29-39 phosphodiesterase 5A Homo sapiens 14-18 19968586-7 2010 Overall, the data suggest that the protective effect of sildenafil on epithelial cells is a consequence of the inhibition of the XO and of the resulting decrease of free oxygen radical production that may influence the expression of NADPH oxidase and PDE-5. Sildenafil Citrate 56-66 phosphodiesterase 5A Homo sapiens 251-256 19929916-1 2010 INTRODUCTION: Phosphodiesterase type 5 inhibitors (PDE5), such as sildenafil, tadalafil, and vardenafil, have revolutionized the treatment of erectile dysfunction. Sildenafil Citrate 66-76 phosphodiesterase 5A Homo sapiens 51-55 21499570-3 2010 Phosphodiesterase-5 (PDE-5) inhibitors or erectile dysfunction drugs including sildenafil, have been shown to have powerful cardioprotective effect against injuries under a variety of experimental situations including ischemia/reperfusion injury, myocardial infarction and DOX-induced cardiomyopathy. Sildenafil Citrate 79-89 phosphodiesterase 5A Homo sapiens 0-19 20030615-4 2010 Among them, PDE3, PDE4 and PDE5 were viewed as therapeutic targets and therefore, due to the successful development of Viagra (sildenafil, potent selective PDE5 inhibitor), the knowledge in PDE field burst out with the help of academic/pharmaceutical collaborations. Sildenafil Citrate 119-125 phosphodiesterase 5A Homo sapiens 27-31 20030615-4 2010 Among them, PDE3, PDE4 and PDE5 were viewed as therapeutic targets and therefore, due to the successful development of Viagra (sildenafil, potent selective PDE5 inhibitor), the knowledge in PDE field burst out with the help of academic/pharmaceutical collaborations. Sildenafil Citrate 119-125 phosphodiesterase 5A Homo sapiens 156-160 20030615-4 2010 Among them, PDE3, PDE4 and PDE5 were viewed as therapeutic targets and therefore, due to the successful development of Viagra (sildenafil, potent selective PDE5 inhibitor), the knowledge in PDE field burst out with the help of academic/pharmaceutical collaborations. Sildenafil Citrate 127-137 phosphodiesterase 5A Homo sapiens 27-31 20030615-4 2010 Among them, PDE3, PDE4 and PDE5 were viewed as therapeutic targets and therefore, due to the successful development of Viagra (sildenafil, potent selective PDE5 inhibitor), the knowledge in PDE field burst out with the help of academic/pharmaceutical collaborations. Sildenafil Citrate 127-137 phosphodiesterase 5A Homo sapiens 156-160 19887943-3 2010 PDE5 inhibitors (sildenafil, tadalafil, vardenafil, etc.) Sildenafil Citrate 17-27 phosphodiesterase 5A Homo sapiens 0-4 21499570-3 2010 Phosphodiesterase-5 (PDE-5) inhibitors or erectile dysfunction drugs including sildenafil, have been shown to have powerful cardioprotective effect against injuries under a variety of experimental situations including ischemia/reperfusion injury, myocardial infarction and DOX-induced cardiomyopathy. Sildenafil Citrate 79-89 phosphodiesterase 5A Homo sapiens 21-26 19665054-8 2009 Incubation of PDE5 with non-hydrolyzable, catalytic site-specific, substrate analogs such as the inhibitors sildenafil and tadalafil, followed by dilution, did not produce activation of catalytic activity like that obtained with cGMP, although both inhibitors produced a similar gel shift to the upper band as that obtained with cGMP. Sildenafil Citrate 108-118 phosphodiesterase 5A Homo sapiens 14-18 20003325-1 2009 BACKGROUND: Sildenafil, a potent phosphodiesterase type 5 (PDE5) inhibitor, has been proposed as a treatment for pulmonary arterial hypertension (PAH). Sildenafil Citrate 12-22 phosphodiesterase 5A Homo sapiens 33-57 20003325-1 2009 BACKGROUND: Sildenafil, a potent phosphodiesterase type 5 (PDE5) inhibitor, has been proposed as a treatment for pulmonary arterial hypertension (PAH). Sildenafil Citrate 12-22 phosphodiesterase 5A Homo sapiens 59-63 20030481-1 2010 The phosphodiesterase type 5 (PDE-5) inhibitors-sildenafil, vardenafil, and tadalafil-are used primarily in erectile dysfunction, but sildenafil is also indicated for pulmonary hypertension. Sildenafil Citrate 48-58 phosphodiesterase 5A Homo sapiens 4-28 20030481-1 2010 The phosphodiesterase type 5 (PDE-5) inhibitors-sildenafil, vardenafil, and tadalafil-are used primarily in erectile dysfunction, but sildenafil is also indicated for pulmonary hypertension. Sildenafil Citrate 48-58 phosphodiesterase 5A Homo sapiens 30-35 20030481-1 2010 The phosphodiesterase type 5 (PDE-5) inhibitors-sildenafil, vardenafil, and tadalafil-are used primarily in erectile dysfunction, but sildenafil is also indicated for pulmonary hypertension. Sildenafil Citrate 134-144 phosphodiesterase 5A Homo sapiens 4-28 20030481-1 2010 The phosphodiesterase type 5 (PDE-5) inhibitors-sildenafil, vardenafil, and tadalafil-are used primarily in erectile dysfunction, but sildenafil is also indicated for pulmonary hypertension. Sildenafil Citrate 134-144 phosphodiesterase 5A Homo sapiens 30-35 19570039-1 2009 INTRODUCTION: The three effective, commercially available drugs for the treatment of erectile dysfunction-sildenafil, vardenafil, and tadalafil-inhibit the same substrate, the erectolytic enzyme phosphodiesterase type 5 (PDE5). Sildenafil Citrate 106-116 phosphodiesterase 5A Homo sapiens 195-219 19936151-4 2009 The availability of three (sildenafil citrate, tadalafil, and vardenafil) well tolerated and effective oral PDE5 inhibitors gives treatment options for men with ED. Sildenafil Citrate 27-45 phosphodiesterase 5A Homo sapiens 108-112 19936152-4 2009 Currently, three PDE5 inhibitors - sildenafil, tadalafil and vardenafil - are approved to be taken as needed in anticipation of sexual activity, but only one of these, tadalafil, has been approved to be taken once daily. Sildenafil Citrate 35-45 phosphodiesterase 5A Homo sapiens 17-21 19427155-2 2009 Currently, three PDE-5 inhibitors have been approved by the U.S. Food and Drug Administration (FDA) for use in the United States: sildenafil citrate, tadalafil, and vardenafil hydrochloride trihydrate. Sildenafil Citrate 130-148 phosphodiesterase 5A Homo sapiens 17-22 19884625-2 2009 Current pharmacologic therapies include phosphodiesterase-5 (PDE-5) inhibitors, such as sildenafil, vardenafil, tadalafil, mirodenafil, and udenafil, and hormonal treatment. Sildenafil Citrate 88-98 phosphodiesterase 5A Homo sapiens 61-66 19884626-10 2009 The PDE-5 inhibitors were associated with increased risk for any adverse events compared with placebo (for example, relative risk with sildenafil, 1.72 [95% CI, 1.53 to 1.93]). Sildenafil Citrate 135-145 phosphodiesterase 5A Homo sapiens 4-9 19737280-1 2009 Sildenafil citrate is a selective phosphodiesterase 5 (PDE-5) inhibitor and partial phosphodiesterase 6 inhibitor prescribed for erectile dysfunction. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 34-53 19737280-1 2009 Sildenafil citrate is a selective phosphodiesterase 5 (PDE-5) inhibitor and partial phosphodiesterase 6 inhibitor prescribed for erectile dysfunction. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 55-60 19768639-6 2009 Three oral PDE-5 inhibitors are available (sildenafil, tadalafil, and vardenafil) and are the recommended first-line treatment for erectile dysfunction. Sildenafil Citrate 43-53 phosphodiesterase 5A Homo sapiens 11-16 19768639-8 2009 Randomized clinical trials in monotherapy or combination therapy have been conducted in PAH with sildenafil and tadalafil, which are therefore currently the approved PDE-5 inhibitors in PAH treatment. Sildenafil Citrate 97-107 phosphodiesterase 5A Homo sapiens 166-171 19570039-1 2009 INTRODUCTION: The three effective, commercially available drugs for the treatment of erectile dysfunction-sildenafil, vardenafil, and tadalafil-inhibit the same substrate, the erectolytic enzyme phosphodiesterase type 5 (PDE5). Sildenafil Citrate 106-116 phosphodiesterase 5A Homo sapiens 221-225 19416631-8 2009 Meanwhile, these two pathways are also separately modulated by enhanced cGMP-PKG signalling derived from inhibition of PDE5 with sildenafil to confer the overall roles of sildenafil against pulmonary hypertension. Sildenafil Citrate 171-181 phosphodiesterase 5A Homo sapiens 119-123 18667251-3 2009 The purpose of the present study was to determine if chronic phosphodiesterase 5 (PDE5) inhibition with Sildenafil, previously shown to improve arterial stiffness, favorably impacts HRR in patients with HF. Sildenafil Citrate 104-114 phosphodiesterase 5A Homo sapiens 61-80 18667251-3 2009 The purpose of the present study was to determine if chronic phosphodiesterase 5 (PDE5) inhibition with Sildenafil, previously shown to improve arterial stiffness, favorably impacts HRR in patients with HF. Sildenafil Citrate 104-114 phosphodiesterase 5A Homo sapiens 82-86 19635671-1 2009 Sildenafil citrate, a phosphodiesterase-5 (PDE5) inhibitor widely used for the treatment of erectile dysfunction was investigated for its interaction with the zinc-enzyme carbonic anhydrase (CA, EC 4.2.1.1), as it has in its molecule a piperazine moiety also found in some CA activators (CAAs). Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 22-41 19635671-1 2009 Sildenafil citrate, a phosphodiesterase-5 (PDE5) inhibitor widely used for the treatment of erectile dysfunction was investigated for its interaction with the zinc-enzyme carbonic anhydrase (CA, EC 4.2.1.1), as it has in its molecule a piperazine moiety also found in some CA activators (CAAs). Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 43-47 19624790-3 2009 Phosphodiesterase-type 5 (PDE5) inhibitors have revolutionised treatment for ED and three such drugs are currently available: sildenafil citrate, tadalafil and vardenafil HCl. Sildenafil Citrate 126-144 phosphodiesterase 5A Homo sapiens 0-24 19624790-3 2009 Phosphodiesterase-type 5 (PDE5) inhibitors have revolutionised treatment for ED and three such drugs are currently available: sildenafil citrate, tadalafil and vardenafil HCl. Sildenafil Citrate 126-144 phosphodiesterase 5A Homo sapiens 26-30 19374906-7 2009 The PDE5 inhibitor Sildenafil was several-fold more powerful in relaxing the HF/LF MA1s, and pre-treatment with Sildenafil uncovered an increased responsiveness of HF/LF MA1s to the NO donor DEA/NO. Sildenafil Citrate 19-29 phosphodiesterase 5A Homo sapiens 4-8 19638092-1 2009 BACKGROUND AND AIM: Sildenafil, a selective and potent inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase (PDE)5, has a relaxant effect on the smooth muscle cells of the arterioles supplying the human corpus cavernosum acting via nitric oxide (NO)-dependent mechanism. Sildenafil Citrate 20-30 phosphodiesterase 5A Homo sapiens 134-139 19131365-4 2009 PDE5 inhibition using oral sildenafil (50 mg/kg/day in drinking water) or placebo was initiated 14 days after monocrotaline treatment and continued for 14 days until final examination. Sildenafil Citrate 27-37 phosphodiesterase 5A Homo sapiens 0-4 19215288-2 2009 L-arginine, an NO precursor, and the phosphodiesterase (PDE) 5 inhibitor sildenafil, which potentiates cGMP, were studied in adults with sickle cell disease (SCD) who were stably on HU. Sildenafil Citrate 73-83 phosphodiesterase 5A Homo sapiens 37-62 18716761-2 2009 The PDE5 inhibitor sildenafil has been shown to enhance memory in animal models. Sildenafil Citrate 19-29 phosphodiesterase 5A Homo sapiens 4-8 19182409-4 2009 Recently, a large number of phosphodiesterase-5 (PDE-5) inhibitors, including their analogues, have been isolated from dietary supplements, while cyclopentynafil and N-octylnortadalafil are the first compounds reported to be new sildenafil and tadalafil analogues, respectively. Sildenafil Citrate 229-239 phosphodiesterase 5A Homo sapiens 49-54 18823318-0 2009 The PDE5 inhibitor sildenafil increases circulating endothelial progenitor cells and CXCR4 expression. Sildenafil Citrate 19-29 phosphodiesterase 5A Homo sapiens 4-8 19040619-1 2009 INTRODUCTION: It has been suggested that the capability of the phosphodiesterase 5 (PDE5) inhibitor sildenafil citrate (VIAGRA) to retard the ejaculatory response may include modulation of the contraction of seminal vesicle (SV) smooth muscle. Sildenafil Citrate 100-118 phosphodiesterase 5A Homo sapiens 63-82 19040619-1 2009 INTRODUCTION: It has been suggested that the capability of the phosphodiesterase 5 (PDE5) inhibitor sildenafil citrate (VIAGRA) to retard the ejaculatory response may include modulation of the contraction of seminal vesicle (SV) smooth muscle. Sildenafil Citrate 100-118 phosphodiesterase 5A Homo sapiens 84-88 19040619-1 2009 INTRODUCTION: It has been suggested that the capability of the phosphodiesterase 5 (PDE5) inhibitor sildenafil citrate (VIAGRA) to retard the ejaculatory response may include modulation of the contraction of seminal vesicle (SV) smooth muscle. Sildenafil Citrate 120-126 phosphodiesterase 5A Homo sapiens 63-82 19040619-1 2009 INTRODUCTION: It has been suggested that the capability of the phosphodiesterase 5 (PDE5) inhibitor sildenafil citrate (VIAGRA) to retard the ejaculatory response may include modulation of the contraction of seminal vesicle (SV) smooth muscle. Sildenafil Citrate 120-126 phosphodiesterase 5A Homo sapiens 84-88 19143907-1 2009 INTRODUCTION: Phosphodiesterase 5 inhibitors (PDE5) such as sildenafil are first-line treatment for erectile dysfunction (ED). Sildenafil Citrate 60-70 phosphodiesterase 5A Homo sapiens 46-50 19057210-3 2009 RECENT FINDINGS: All three commonly used PDE-5 inhibitors (sildenafil, vardenafil and tadalafil) appear to improve LUTS as measured by the International Prostate Symptom Score. Sildenafil Citrate 59-69 phosphodiesterase 5A Homo sapiens 41-46 19860692-2 2009 Three PDE5 inhibitors--sildenafil (Viagra), vardenafil (Levitra) and tadalafil (Cialis)--are currently approved by the FDA and the EMEA for use in ED, whereas sildenafil is also marketed under a different proprietary name (Revatio) for the treatment of pulmonary arterial hypertension (PAH). Sildenafil Citrate 23-33 phosphodiesterase 5A Homo sapiens 6-10 19860692-2 2009 Three PDE5 inhibitors--sildenafil (Viagra), vardenafil (Levitra) and tadalafil (Cialis)--are currently approved by the FDA and the EMEA for use in ED, whereas sildenafil is also marketed under a different proprietary name (Revatio) for the treatment of pulmonary arterial hypertension (PAH). Sildenafil Citrate 35-41 phosphodiesterase 5A Homo sapiens 6-10 19860693-2 2009 Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil) are currently the first choice treatment option for ED by most physicians and patients due to their high efficacy rates and favourable safety profiles. Sildenafil Citrate 44-54 phosphodiesterase 5A Homo sapiens 0-24 19860693-2 2009 Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil) are currently the first choice treatment option for ED by most physicians and patients due to their high efficacy rates and favourable safety profiles. Sildenafil Citrate 44-54 phosphodiesterase 5A Homo sapiens 26-30 19132801-1 2009 Phosphodiesterase type 5 (PDE-5) inhibitors (sildenafil, vardenafil and tadalafil) have been in widespread use for the safe and effective treatment of erectile dysfunction (ED) for nearly a decade. Sildenafil Citrate 45-55 phosphodiesterase 5A Homo sapiens 0-24 19132801-1 2009 Phosphodiesterase type 5 (PDE-5) inhibitors (sildenafil, vardenafil and tadalafil) have been in widespread use for the safe and effective treatment of erectile dysfunction (ED) for nearly a decade. Sildenafil Citrate 45-55 phosphodiesterase 5A Homo sapiens 26-31 19288739-2 2009 Sildenafil citrate, the first oral PDE-5 inhibitor in the world, has established its efficacy and safety credit in both doctors and ED patients. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 35-40 19432232-1 2009 Currently available three highly selective and effective PDE-5 inhibitors (sildenafil, tadalafil and wardenafil) are comparable by PDE-5 inhibition and selectivity of action on PDE-5 but their differences in activity, interaction with food and alcohol, biological half-life and other characteristics make their use individual for certain clinical situations. Sildenafil Citrate 75-85 phosphodiesterase 5A Homo sapiens 57-62 19432232-1 2009 Currently available three highly selective and effective PDE-5 inhibitors (sildenafil, tadalafil and wardenafil) are comparable by PDE-5 inhibition and selectivity of action on PDE-5 but their differences in activity, interaction with food and alcohol, biological half-life and other characteristics make their use individual for certain clinical situations. Sildenafil Citrate 75-85 phosphodiesterase 5A Homo sapiens 131-136 19432232-1 2009 Currently available three highly selective and effective PDE-5 inhibitors (sildenafil, tadalafil and wardenafil) are comparable by PDE-5 inhibition and selectivity of action on PDE-5 but their differences in activity, interaction with food and alcohol, biological half-life and other characteristics make their use individual for certain clinical situations. Sildenafil Citrate 75-85 phosphodiesterase 5A Homo sapiens 131-136 18854967-3 2008 In this review the current knowledge of association studies of single nucleotide polymorphisms and erectile dysfunction and the response to the PDE-5 inhibitor sildenafil is described. Sildenafil Citrate 160-170 phosphodiesterase 5A Homo sapiens 144-149 18951784-1 2008 A series of potent chiral PDE5 inhibitors are described that are based on the sildenafil architecture but exhibit much greater selectivity over PDE6. Sildenafil Citrate 78-88 phosphodiesterase 5A Homo sapiens 26-30 18951784-3 2008 This PDE5 specificity translated to levels of selectivity over PDE6 that were hitherto unprecedented in the sildenafil scaffold. Sildenafil Citrate 108-118 phosphodiesterase 5A Homo sapiens 5-9 18631254-4 2008 METHODS: Sildenafil, a specific PDE-5 inhibitor, was administrated orally to cirrhotic patients (n = 7) to see the hemodynamic changes. Sildenafil Citrate 9-19 phosphodiesterase 5A Homo sapiens 32-37 18607596-4 2008 The hypothesis that an impaired NO/cGMP-signaling may contribute to the pathophysiology of benign prostatic hyperplasia (BPH) is supported by the results from randomized, placebo-controlled clinical studies, indicating that NO donor drugs and PDE5-inhibitors sildenafil, tadalafil and vardenafil may be useful to treat storage and voiding dysfunctions resulting from LUTS in men. Sildenafil Citrate 259-269 phosphodiesterase 5A Homo sapiens 243-247 18790048-1 2008 Cyclic GMP-selective phosphodiesterase type 5 (PDE5) has been traditionally thought to play a little role in cardiac myocytes, yet recent studies using selective inhibitors such as sildenafil suggest it can potently modulate acute and chronic cardiac stress responses. Sildenafil Citrate 181-191 phosphodiesterase 5A Homo sapiens 47-51 18790048-8 2008 These data confirm PDE5 expression, activity, and targeted inhibition by sildenafil in cardiomyocytes, as well as the role of this PDE in cardiomyocyte hypertrophy modulation. Sildenafil Citrate 73-83 phosphodiesterase 5A Homo sapiens 19-23 18854969-2 2008 The development of the PDE5 inhibitors Sildenafil (Viagra), Vardenafil (Levitra), and Tadalafil (Cialis), combining a high response rate and the advantage of on-demand intake, is the result of the scientific characterization of the physiology of penile erectile smooth muscle.The introduction of these compounds as safe and well-tolerated orally active drugs for the treatment of erectile dysfunction has not only become a worldwide clinical success, but it provided the basis for the development and introduction of several new therapeutic modalities into the management of male and female sexual dysfunction. Sildenafil Citrate 39-49 phosphodiesterase 5A Homo sapiens 23-27 18656371-0 2008 In silico prediction of novel phosphodiesterase type-5 inhibitors derived from Sildenafil, Vardenafil and Tadalafil. Sildenafil Citrate 79-89 phosphodiesterase 5A Homo sapiens 30-54 18729002-2 2008 Pharmacotherapy for PAH is currently dominated by three endothelin receptor antagonists, bosentan, ambrisentan and sitaxentan (which is not yet approved in the US), and the PDE5 inhibitor sildenafil. Sildenafil Citrate 188-198 phosphodiesterase 5A Homo sapiens 173-177 19051742-5 2008 Recently, phosphodiesterase (PDE) 5 inhibitor (sildenafil, Viagra) and endothelin receptor antagonist (bosentan, Tracleer) in addition to prostacyclin used as a combination therapy can be used for this age population. Sildenafil Citrate 47-57 phosphodiesterase 5A Homo sapiens 29-35 19051742-5 2008 Recently, phosphodiesterase (PDE) 5 inhibitor (sildenafil, Viagra) and endothelin receptor antagonist (bosentan, Tracleer) in addition to prostacyclin used as a combination therapy can be used for this age population. Sildenafil Citrate 59-65 phosphodiesterase 5A Homo sapiens 29-35 18689467-1 2008 RATIONALE: Phosphodiesterase 5 (PDE5) inhibitors (e.g., sildenafil) are selective pulmonary vasodilators in patients with pulmonary arterial hypertension. Sildenafil Citrate 56-66 phosphodiesterase 5A Homo sapiens 11-30 18689467-1 2008 RATIONALE: Phosphodiesterase 5 (PDE5) inhibitors (e.g., sildenafil) are selective pulmonary vasodilators in patients with pulmonary arterial hypertension. Sildenafil Citrate 56-66 phosphodiesterase 5A Homo sapiens 32-36 18593576-2 2008 Phosphodiesterase 5 (PDE5) inhibitors, such as sildenafil, prolong the NO effects by inhibiting cGMP breakdown. Sildenafil Citrate 47-57 phosphodiesterase 5A Homo sapiens 0-19 18593576-2 2008 Phosphodiesterase 5 (PDE5) inhibitors, such as sildenafil, prolong the NO effects by inhibiting cGMP breakdown. Sildenafil Citrate 47-57 phosphodiesterase 5A Homo sapiens 21-25 18593576-3 2008 Here, we report a novel PDE5 inhibitor, lodenafil carbonate, (Bis-(2-{4-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-benzenesulfonyl]piperazin-1-yl}-ethyl)carbonate) that is a dimer of lodenafil. Sildenafil Citrate 40-49 phosphodiesterase 5A Homo sapiens 24-28 18591337-5 2008 One PDE5 inhibitor, sildenafil, has been shown to improve pulmonary haemodynamics and exercise capacity in patients with PAH and is now an approved treatment. Sildenafil Citrate 20-30 phosphodiesterase 5A Homo sapiens 4-8 18614424-3 2008 Sildenafil citrate (Viagra) is a potent inhibitor of the electrolytic enzyme type V phosphodiesterase (PDE5), in the corpus cavernosum and therefore increases the penile response to sexual stimulation. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 103-107 18418391-3 2008 Sildenafil (Viagra), vardenafil (Levitra) and tadalafil (Cialis), treatments for erectile dysfunction, inhibit PDE5 action. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 111-115 18418391-3 2008 Sildenafil (Viagra), vardenafil (Levitra) and tadalafil (Cialis), treatments for erectile dysfunction, inhibit PDE5 action. Sildenafil Citrate 12-18 phosphodiesterase 5A Homo sapiens 111-115 18614424-3 2008 Sildenafil citrate (Viagra) is a potent inhibitor of the electrolytic enzyme type V phosphodiesterase (PDE5), in the corpus cavernosum and therefore increases the penile response to sexual stimulation. Sildenafil Citrate 20-26 phosphodiesterase 5A Homo sapiens 103-107 18953278-4 2008 The US Food and Drug Administration has approved 3 phosphodiesterase-5 (PDE-5) inhibitors for treatment of male sexual dysfunction: sildenafil, tadalafil, and vardenafil. Sildenafil Citrate 132-142 phosphodiesterase 5A Homo sapiens 51-70 18953278-4 2008 The US Food and Drug Administration has approved 3 phosphodiesterase-5 (PDE-5) inhibitors for treatment of male sexual dysfunction: sildenafil, tadalafil, and vardenafil. Sildenafil Citrate 132-142 phosphodiesterase 5A Homo sapiens 72-77 18953278-8 2008 PDE-5 inhibition with sildenafil improves cardiac output by balancing pulmonary and systemic vasodilation, and augments and prolongs the hemodynamic effects of inhaled nitric oxide in patients with chronic congestive heart failure and pulmonary hypertension. Sildenafil Citrate 22-32 phosphodiesterase 5A Homo sapiens 0-5 18587266-7 2008 When SW982 cells were pretreated with sildenafil citrate (Viagra), a PDE5 specific inhibitor, sildenafil citrate significantly inhibited IL-1beta-induced NO synthesis and iNOS expressions. Sildenafil Citrate 38-56 phosphodiesterase 5A Homo sapiens 69-73 18587266-7 2008 When SW982 cells were pretreated with sildenafil citrate (Viagra), a PDE5 specific inhibitor, sildenafil citrate significantly inhibited IL-1beta-induced NO synthesis and iNOS expressions. Sildenafil Citrate 58-64 phosphodiesterase 5A Homo sapiens 69-73 18587266-7 2008 When SW982 cells were pretreated with sildenafil citrate (Viagra), a PDE5 specific inhibitor, sildenafil citrate significantly inhibited IL-1beta-induced NO synthesis and iNOS expressions. Sildenafil Citrate 94-112 phosphodiesterase 5A Homo sapiens 69-73 17991881-5 2008 We demonstrate that inhibition of PDE5 activity with sildenafil partially rescues cGMP responsiveness to exogenous NO. Sildenafil Citrate 53-63 phosphodiesterase 5A Homo sapiens 34-38 18346713-3 2008 Here we report the synthesis of a new class of the sildenafil derivatives and a crystal structure of the PDE5 catalytic domain in complex with 5-(2-ethoxy-5-(sulfamoyl)-3-thienyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (12). Sildenafil Citrate 51-61 phosphodiesterase 5A Homo sapiens 105-109 18058160-1 2008 It is shown that phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil can modulate pulmonary arterial hypertension (PAH) via increasing the level of guanosine-3,5-cyclic monophosphate (cGMP) and decreases pulmonary artery pressure (PAP). Sildenafil Citrate 68-78 phosphodiesterase 5A Homo sapiens 17-41 18058160-1 2008 It is shown that phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil can modulate pulmonary arterial hypertension (PAH) via increasing the level of guanosine-3,5-cyclic monophosphate (cGMP) and decreases pulmonary artery pressure (PAP). Sildenafil Citrate 68-78 phosphodiesterase 5A Homo sapiens 43-47 18728748-4 2008 In particular, sildenafil, an inhibitor of PDE5, has been mainly used in the treatment of erectile dysfunction but is now also utilized against pulmonary hypertension. Sildenafil Citrate 15-25 phosphodiesterase 5A Homo sapiens 43-47 18369062-1 2008 Sildenafil is a potent phosphodiesterase (PDE) 5 inhibitor that is used for patients with erectile dysfunction. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 42-48 18293931-8 2008 PDE5 is the target for the anti-impotence drug sildenafil citrate; therefore, this GAF-BRET (2) sensor could be used for the identification of novel compounds that inhibit cGMP binding to the GAF domain, thereby regulating PDE5 catalytic activity. Sildenafil Citrate 47-65 phosphodiesterase 5A Homo sapiens 0-4 18293931-8 2008 PDE5 is the target for the anti-impotence drug sildenafil citrate; therefore, this GAF-BRET (2) sensor could be used for the identification of novel compounds that inhibit cGMP binding to the GAF domain, thereby regulating PDE5 catalytic activity. Sildenafil Citrate 47-65 phosphodiesterase 5A Homo sapiens 223-227 18300861-2 2008 Sildenafil citrate is a phosphodiesterase type 5 (PDE5) inhibitor used clinically for the treatment of male erectile dysfunction. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 24-48 18300861-2 2008 Sildenafil citrate is a phosphodiesterase type 5 (PDE5) inhibitor used clinically for the treatment of male erectile dysfunction. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 50-54 17823768-1 2008 The phosphodiesterase (PDE) 5 inhibitor sildenafil has been shown to display psychotropic actions in humans and animals, and has been used for the treatment of antidepressant-associated erectile dysfunction. Sildenafil Citrate 40-50 phosphodiesterase 5A Homo sapiens 23-29 18165313-8 2008 In contrast, ANP elicited sustained submembrane elevations in [cGMP](i), which were converted to global cGMP elevations by inhibition of PDE-5 by sildenafil. Sildenafil Citrate 146-156 phosphodiesterase 5A Homo sapiens 137-142 17585311-1 2008 OBJECTIVE: We tested the effect of two phosphodiesterase type-5 (PDE5) inhibitors, sildenafil and tadalafil, on ophthalmic artery (OA) blood flow velocity and investigated the presence of the PDE5 enzyme on human retinal tissue in comparison with the PDE6 enzyme localization. Sildenafil Citrate 83-93 phosphodiesterase 5A Homo sapiens 65-69 18235020-1 2008 PURPOSE: Sildenafil (Viagra; Pfizer, New York, NY), a selective phosphodiesterase type-5 (PDE5) inhibitor, is widely used to treat impotence by improving penile blood flow via elevation of cGMP. Sildenafil Citrate 9-19 phosphodiesterase 5A Homo sapiens 64-88 18235020-1 2008 PURPOSE: Sildenafil (Viagra; Pfizer, New York, NY), a selective phosphodiesterase type-5 (PDE5) inhibitor, is widely used to treat impotence by improving penile blood flow via elevation of cGMP. Sildenafil Citrate 9-19 phosphodiesterase 5A Homo sapiens 90-94 18235020-1 2008 PURPOSE: Sildenafil (Viagra; Pfizer, New York, NY), a selective phosphodiesterase type-5 (PDE5) inhibitor, is widely used to treat impotence by improving penile blood flow via elevation of cGMP. Sildenafil Citrate 21-27 phosphodiesterase 5A Homo sapiens 64-88 18235020-1 2008 PURPOSE: Sildenafil (Viagra; Pfizer, New York, NY), a selective phosphodiesterase type-5 (PDE5) inhibitor, is widely used to treat impotence by improving penile blood flow via elevation of cGMP. Sildenafil Citrate 21-27 phosphodiesterase 5A Homo sapiens 90-94 18235020-12 2008 Moreover, the elevated cGMP, from endogenous or exogenous NO, plays a permissive role for sildenafil to exert vasodilation through inhibition of the PDE5 pathway independent of ERK signaling. Sildenafil Citrate 90-100 phosphodiesterase 5A Homo sapiens 149-153 18197727-4 2008 Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil) are currently the first-choice treatment option for ED by most physicians and patients. Sildenafil Citrate 44-54 phosphodiesterase 5A Homo sapiens 0-24 18197727-4 2008 Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil) are currently the first-choice treatment option for ED by most physicians and patients. Sildenafil Citrate 44-54 phosphodiesterase 5A Homo sapiens 26-30 18257613-1 2008 Sildenafil citrate (Revatio), an inhibitor of phosphodiesterase type 5 (PDE5), is approved for use in the US, Europe and other countries for the treatment of pulmonary arterial hypertension (PAH). Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 46-70 18257613-1 2008 Sildenafil citrate (Revatio), an inhibitor of phosphodiesterase type 5 (PDE5), is approved for use in the US, Europe and other countries for the treatment of pulmonary arterial hypertension (PAH). Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 72-76 18257613-1 2008 Sildenafil citrate (Revatio), an inhibitor of phosphodiesterase type 5 (PDE5), is approved for use in the US, Europe and other countries for the treatment of pulmonary arterial hypertension (PAH). Sildenafil Citrate 20-27 phosphodiesterase 5A Homo sapiens 46-70 18257613-1 2008 Sildenafil citrate (Revatio), an inhibitor of phosphodiesterase type 5 (PDE5), is approved for use in the US, Europe and other countries for the treatment of pulmonary arterial hypertension (PAH). Sildenafil Citrate 20-27 phosphodiesterase 5A Homo sapiens 72-76 17942972-3 2008 Accordingly, PDE5 has been targeted for sexual medicine purposes, and orally administered PDE5 inhibitors such as sildenafil, tadalafil, and vardenafil comprise a foremost intervention for erectile dysfunction (ED). Sildenafil Citrate 114-124 phosphodiesterase 5A Homo sapiens 90-94 17706972-1 2007 The PDE-5 inhibitors sildenafil (Viagra) vardenafil (Levitra) and tadalafil (Cialis) have been taken by millions of men for erectile dysfunction. Sildenafil Citrate 21-31 phosphodiesterase 5A Homo sapiens 4-9 17959709-0 2008 Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. Sildenafil Citrate 146-156 phosphodiesterase 5A Homo sapiens 34-53 17959709-5 2008 In addition, the molecular configuration of vardenafil differs from that of sildenafil when bound to PDE5. Sildenafil Citrate 76-86 phosphodiesterase 5A Homo sapiens 101-105 19544683-6 2008 Recently, preclinical and clinical studies have demonstrated the utility of the selective inhibitor of phosphodiesterase type 5 (PDE5), sildenafil, in decreasing pulmonary hypertension (HP). Sildenafil Citrate 136-146 phosphodiesterase 5A Homo sapiens 103-127 19544683-6 2008 Recently, preclinical and clinical studies have demonstrated the utility of the selective inhibitor of phosphodiesterase type 5 (PDE5), sildenafil, in decreasing pulmonary hypertension (HP). Sildenafil Citrate 136-146 phosphodiesterase 5A Homo sapiens 129-133 19183760-1 2008 Sildenafil is a selective inhibitor of phosphodiesterase type 5 (PDE-5). Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 39-63 19183760-1 2008 Sildenafil is a selective inhibitor of phosphodiesterase type 5 (PDE-5). Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 65-70 18174638-4 2007 To date, sildenafil has been the most extensively studied PDE (phosphodiesterase)-5 inhibitor. Sildenafil Citrate 9-19 phosphodiesterase 5A Homo sapiens 58-83 18040025-2 2007 Inhibitors of PDE5A such as sildenafil are widely used to treat erectile dysfunction, but growing evidence supports important roles for the enzyme in both the vasculature and heart. Sildenafil Citrate 28-38 phosphodiesterase 5A Homo sapiens 14-19 17706972-1 2007 The PDE-5 inhibitors sildenafil (Viagra) vardenafil (Levitra) and tadalafil (Cialis) have been taken by millions of men for erectile dysfunction. Sildenafil Citrate 33-39 phosphodiesterase 5A Homo sapiens 4-9 17646047-2 2007 The recognition of the important role PDE enzymes play and the impact of altering intracellular cyclic nucleotide levels became significant for most urologists and clinicians in the early 1990s with the discovery of sildenafil, a PDE5 inhibitor (PDE5-I). Sildenafil Citrate 216-226 phosphodiesterase 5A Homo sapiens 230-234 17625575-1 2007 The phosphodiesterase type-5 (PDE5) inhibitors sildenafil, vardenafil and tadalafil are widely used first-line therapy for erectile dysfunction (ED). Sildenafil Citrate 47-57 phosphodiesterase 5A Homo sapiens 4-28 17625575-1 2007 The phosphodiesterase type-5 (PDE5) inhibitors sildenafil, vardenafil and tadalafil are widely used first-line therapy for erectile dysfunction (ED). Sildenafil Citrate 47-57 phosphodiesterase 5A Homo sapiens 30-34 17690252-2 2007 In the present study, preincubation with cGMP increased PDE5 catalytic activity for cGMP degradation, and it converted the PDE5 catalytic site to a form that was more potently inhibited by each of the three PDE5 catalytic site-specific inhibitors: sildenafil, vardenafil, and tadalafil. Sildenafil Citrate 248-258 phosphodiesterase 5A Homo sapiens 123-127 18022071-1 2007 BACKGROUND: Sildenafil is a selective inhibitor of phosphodiesterase type 5 (PDE5), and has been shown to improve 6-minute walk distance (SMWD) and World Health Organization (WHO) functional class in patients with idiopathic pulmonary arterial hypertension (iPAH) and PAH associated with connective tissue disease or with repaired congenital systemic-to-pulmonary shunts. Sildenafil Citrate 12-22 phosphodiesterase 5A Homo sapiens 51-75 18022071-1 2007 BACKGROUND: Sildenafil is a selective inhibitor of phosphodiesterase type 5 (PDE5), and has been shown to improve 6-minute walk distance (SMWD) and World Health Organization (WHO) functional class in patients with idiopathic pulmonary arterial hypertension (iPAH) and PAH associated with connective tissue disease or with repaired congenital systemic-to-pulmonary shunts. Sildenafil Citrate 12-22 phosphodiesterase 5A Homo sapiens 77-81 17690252-2 2007 In the present study, preincubation with cGMP increased PDE5 catalytic activity for cGMP degradation, and it converted the PDE5 catalytic site to a form that was more potently inhibited by each of the three PDE5 catalytic site-specific inhibitors: sildenafil, vardenafil, and tadalafil. Sildenafil Citrate 248-258 phosphodiesterase 5A Homo sapiens 123-127 17659276-8 2007 Despite the high PDE5 activity the PDE5 inhibitor sildenafil by itself as well as in combination with brain natriuretic peptide or the nitric oxide-donor DETA-NONOate shows no inhibiting effects. Sildenafil Citrate 50-60 phosphodiesterase 5A Homo sapiens 35-39 17646047-2 2007 The recognition of the important role PDE enzymes play and the impact of altering intracellular cyclic nucleotide levels became significant for most urologists and clinicians in the early 1990s with the discovery of sildenafil, a PDE5 inhibitor (PDE5-I). Sildenafil Citrate 216-226 phosphodiesterase 5A Homo sapiens 246-250 17572443-3 2007 Sildenafil is a phosphodiesterase 5 (PDE5)-inhibitor used for erectile dysfunction (ED). Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 16-35 17806124-7 2007 Thus, positive effects of the PDE 5 inhibitors sildenafil and tadalafil on symptoms and quality of life in men with LUTS, erectile dysfunction, and BPH have also been demonstrated. Sildenafil Citrate 47-57 phosphodiesterase 5A Homo sapiens 30-35 17572443-3 2007 Sildenafil is a phosphodiesterase 5 (PDE5)-inhibitor used for erectile dysfunction (ED). Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 37-41 17604974-4 2007 The aim of the present study was to evaluate the functional effects of the PDE5 inhibitors sildenafil (SIL), vardenafil (VAR), and tadalafil (TAD) on tissue tension and cyclic nucleotide levels of human ureteral smooth muscle segments in vitro. Sildenafil Citrate 91-101 phosphodiesterase 5A Homo sapiens 75-79 29662407-1 2007 Aims: After sildenafil, an inhibitor of type-5 phosphodiesterase (PDE5), was put on the Japanese market in March 1999 and then vardenafil emerged later in June 2004, the diagnosis and therapy of erectile dysfunction (ED) has changed dramatically in Japan. Sildenafil Citrate 13-23 phosphodiesterase 5A Homo sapiens 67-71 17606845-5 2007 PDE5 inhibition (with either MY-5445 or sildenafil) significantly increases contractility, measured in the perfused heart (modified Langendorff preparation) and isolated cardiomyocytes, in RVH but not normal RV. Sildenafil Citrate 40-50 phosphodiesterase 5A Homo sapiens 0-4 19482790-1 2007 Data ascertained in a study of club drug use among 450 gay and bisexual men indicate that at least one class of PDE-5 (phosphodiesterase type 5 inhibitor, sildenafil [Viagra]) is used frequently in combination with club drugs such as methamphetamine, MDMA (3,4 methylenedioxymethamphetamine [ecstasy]), ketamine, cocaine, and GHB (gamma hydroxy butyrate). Sildenafil Citrate 155-165 phosphodiesterase 5A Homo sapiens 112-117 19482790-1 2007 Data ascertained in a study of club drug use among 450 gay and bisexual men indicate that at least one class of PDE-5 (phosphodiesterase type 5 inhibitor, sildenafil [Viagra]) is used frequently in combination with club drugs such as methamphetamine, MDMA (3,4 methylenedioxymethamphetamine [ecstasy]), ketamine, cocaine, and GHB (gamma hydroxy butyrate). Sildenafil Citrate 167-173 phosphodiesterase 5A Homo sapiens 112-117 17258855-1 2007 OBJECTIVES: This pilot study was undertaken to assess the efficacy and safety of the alpha(1)-blocker alfuzosin 10mg once daily (OD), the PDE-5 inhibitor sildenafil 25mg OD, and the combination of both on lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). Sildenafil Citrate 154-164 phosphodiesterase 5A Homo sapiens 138-143 17694282-3 2007 Three PDE5 inhibitors, sildenafil, vardenafil, and tadalafil, have been approved for the treatment of "erectile dysfunction" (ED). Sildenafil Citrate 23-33 phosphodiesterase 5A Homo sapiens 6-10 17553682-0 2007 3D-QSAR studies on sildenafil analogues, selective phosphodiesterase 5 inhibitors. Sildenafil Citrate 19-29 phosphodiesterase 5A Homo sapiens 51-70 17553682-1 2007 Sildenafil, one of selective phosphodiesterase 5 (PDE5) inhibitors, is a widely used oral agent for the treatment of erectile dysfunction. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 29-48 17553682-1 2007 Sildenafil, one of selective phosphodiesterase 5 (PDE5) inhibitors, is a widely used oral agent for the treatment of erectile dysfunction. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 50-54 17553682-2 2007 To develop new PDE5 inhibitors with improved therapeutic efficacy, a series of sildenafil analogues have been prepared and their in vitro PDE5 inhibitory activities were evaluated. Sildenafil Citrate 79-89 phosphodiesterase 5A Homo sapiens 15-19 17534570-6 2007 Furthermore, it summarizes the recommended diagnostic work-up and the current treatment options particularly in PAH, with special emphasis on prostanoids, endothelin receptor antagonists (ERAs), and phosphopdiesterase type 5 (PDE5) inhibitors such as sildenafil. Sildenafil Citrate 251-261 phosphodiesterase 5A Homo sapiens 199-224 17593108-4 2007 Accordingly, the use of sildenafil, a PDE5 inhibitor, has been studied in relation to neurogenic female sexual dysfunction. Sildenafil Citrate 24-34 phosphodiesterase 5A Homo sapiens 38-42 17303994-1 2007 Since the discovery of sildenafil in 1989 as a highly selective inhibitor of the phosphodiesterase type-5 (PDE-5) receptor, 2 additional PDE-5 inhibitors, tadalafil and vardenafil, have emerged as safe and effective treatments of erectile dysfunction (ED). Sildenafil Citrate 23-33 phosphodiesterase 5A Homo sapiens 81-105 17207606-12 2007 The kinetic characteristics of these cGMP peaks were governed by the concerted action of the NO-sensitive guanylyl cyclase (GC) and phosphodiesterase type V (PDE5) as shown by their respective inhibition using 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) and Sildenafil. Sildenafil Citrate 264-274 phosphodiesterase 5A Homo sapiens 158-162 16988721-1 2007 Differences in clinical pharmacology of the currently marketed phosphodiesterase (PDE)5 inhibitors sildenafil, vardenafil and tadalafil are largely determined by their pharmacokinetic (PK) properties and their PDE5 inhibitory activity profile. Sildenafil Citrate 99-109 phosphodiesterase 5A Homo sapiens 82-87 16988721-1 2007 Differences in clinical pharmacology of the currently marketed phosphodiesterase (PDE)5 inhibitors sildenafil, vardenafil and tadalafil are largely determined by their pharmacokinetic (PK) properties and their PDE5 inhibitory activity profile. Sildenafil Citrate 99-109 phosphodiesterase 5A Homo sapiens 210-214 17378846-6 2007 The choice of initial PDE5 inhibitor therapy was a highly significant predictor of switching; men initiated on sildenafil were less likely to switch than those initiated on tadalafil (P < 0.001) or vardenafil (P < 0.003). Sildenafil Citrate 111-121 phosphodiesterase 5A Homo sapiens 22-26 17378846-8 2007 CONCLUSION: Initiating ED therapy with sildenafil was associated with the lowest rate of PDE5 inhibitor switching, which might reflect treatment satisfaction and patient preference. Sildenafil Citrate 39-49 phosphodiesterase 5A Homo sapiens 89-93 17303994-1 2007 Since the discovery of sildenafil in 1989 as a highly selective inhibitor of the phosphodiesterase type-5 (PDE-5) receptor, 2 additional PDE-5 inhibitors, tadalafil and vardenafil, have emerged as safe and effective treatments of erectile dysfunction (ED). Sildenafil Citrate 23-33 phosphodiesterase 5A Homo sapiens 107-125 17303994-1 2007 Since the discovery of sildenafil in 1989 as a highly selective inhibitor of the phosphodiesterase type-5 (PDE-5) receptor, 2 additional PDE-5 inhibitors, tadalafil and vardenafil, have emerged as safe and effective treatments of erectile dysfunction (ED). Sildenafil Citrate 23-33 phosphodiesterase 5A Homo sapiens 107-112 17303994-3 2007 Sildenafil was initially introduced for clinical use as the result of extensive research on chemical agents targeting PDE-5 that might potentially be useful in the treatment of coronary heart disease. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 118-123 17393785-1 2007 OBJECTIVE: To observe and compare the effects and adverse events of the three phosphodiesterase type 5 (PDE-5) inhibitors sildenafil, vardenafil and tadalafil used in the same period for the treatment of erectile dysfunction (ED). Sildenafil Citrate 122-132 phosphodiesterase 5A Homo sapiens 78-102 17138653-2 2007 Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, and vardenafil) decrease lower urinary tract symptoms in patients with erectile dysfunction and BPH. Sildenafil Citrate 44-54 phosphodiesterase 5A Homo sapiens 0-24 17138653-2 2007 Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, and vardenafil) decrease lower urinary tract symptoms in patients with erectile dysfunction and BPH. Sildenafil Citrate 44-54 phosphodiesterase 5A Homo sapiens 26-30 16738695-1 2007 The phosphodiesterase type 5 (PDE5) inhibitors, sildenafil, tadalafil and vardenafil, are a class of medications that are safe and effective in treating erectile dysfunction (ED). Sildenafil Citrate 48-58 phosphodiesterase 5A Homo sapiens 4-28 16738695-1 2007 The phosphodiesterase type 5 (PDE5) inhibitors, sildenafil, tadalafil and vardenafil, are a class of medications that are safe and effective in treating erectile dysfunction (ED). Sildenafil Citrate 48-58 phosphodiesterase 5A Homo sapiens 30-34 17556793-1 2007 Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor and is predominantly used in the treatment of erectile dysfunction. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 16-35 17556793-1 2007 Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor and is predominantly used in the treatment of erectile dysfunction. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 37-41 17393785-1 2007 OBJECTIVE: To observe and compare the effects and adverse events of the three phosphodiesterase type 5 (PDE-5) inhibitors sildenafil, vardenafil and tadalafil used in the same period for the treatment of erectile dysfunction (ED). Sildenafil Citrate 122-132 phosphodiesterase 5A Homo sapiens 104-109 16949200-5 2007 Preservation of corporal smooth muscle with chronic administration of PDE5-Is has been reported and substantial evidence indicates that these drugs have beneficial effects on endothelium and cardiovascular function; sildenafil has been approved for the treatment of idiopathic pulmonary hypertension. Sildenafil Citrate 216-226 phosphodiesterase 5A Homo sapiens 70-74 16801935-9 2007 RESULTS: In clinic trials, PDE5 inhibitors were effective (rigidity enough for penetration) in 85% of the patients on Sildenafil, 74% of the patients on Vardenafil and 72% of the patients on Tadalafil. Sildenafil Citrate 118-128 phosphodiesterase 5A Homo sapiens 27-31 17102958-0 2007 In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach. Sildenafil Citrate 36-46 phosphodiesterase 5A Homo sapiens 20-24 17691956-3 2007 Chemical inhibition of PDE5 by sildenafil, tadalafil or vardenafil recently became a valid therapeutic option aimed at overexpressing the molecular pathway originated from nitric oxide and expressed via increased cell cGMP availability. Sildenafil Citrate 31-41 phosphodiesterase 5A Homo sapiens 23-27 17305582-1 2007 The clinical significance of phosphodiesterase 5 (PDE5) inhibition is increasingly understood following the pioneering work with sildenafil, and the continuing development programmes for both sildenafil and other marketed inhibitors. Sildenafil Citrate 129-139 phosphodiesterase 5A Homo sapiens 29-48 17305582-1 2007 The clinical significance of phosphodiesterase 5 (PDE5) inhibition is increasingly understood following the pioneering work with sildenafil, and the continuing development programmes for both sildenafil and other marketed inhibitors. Sildenafil Citrate 129-139 phosphodiesterase 5A Homo sapiens 50-54 17305582-1 2007 The clinical significance of phosphodiesterase 5 (PDE5) inhibition is increasingly understood following the pioneering work with sildenafil, and the continuing development programmes for both sildenafil and other marketed inhibitors. Sildenafil Citrate 192-202 phosphodiesterase 5A Homo sapiens 29-48 17305582-1 2007 The clinical significance of phosphodiesterase 5 (PDE5) inhibition is increasingly understood following the pioneering work with sildenafil, and the continuing development programmes for both sildenafil and other marketed inhibitors. Sildenafil Citrate 192-202 phosphodiesterase 5A Homo sapiens 50-54 17305584-3 2007 For example, selective PDE5 inhibitors, such as sildenafil (Viagra, Pfizer), tadalafil (Cialis, Lilly-ICOS), and vardenafil (Levitra, Bayer), have been successfully used to treat the condition of human erectile dysfunction. Sildenafil Citrate 48-58 phosphodiesterase 5A Homo sapiens 23-27 17209664-5 2007 Sildenafil citrate is a highly selective inhibitor of PDE5. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 54-58 17127429-0 2007 Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil. Sildenafil Citrate 89-99 phosphodiesterase 5A Homo sapiens 19-38 17127429-1 2007 Phosphodiesterase-5 (PDE5) inhibitors (sildenafil, vardenafil, or tadalafil) or phosphorylation by cyclic nucleotide-dependent protein kinase causes an apparent conformational change in PDE5, as indicated by a shift in migration on non-denaturing PAGE gels and an altered pattern of tryptic digestion. Sildenafil Citrate 39-49 phosphodiesterase 5A Homo sapiens 0-19 17127429-1 2007 Phosphodiesterase-5 (PDE5) inhibitors (sildenafil, vardenafil, or tadalafil) or phosphorylation by cyclic nucleotide-dependent protein kinase causes an apparent conformational change in PDE5, as indicated by a shift in migration on non-denaturing PAGE gels and an altered pattern of tryptic digestion. Sildenafil Citrate 39-49 phosphodiesterase 5A Homo sapiens 21-25 17127429-1 2007 Phosphodiesterase-5 (PDE5) inhibitors (sildenafil, vardenafil, or tadalafil) or phosphorylation by cyclic nucleotide-dependent protein kinase causes an apparent conformational change in PDE5, as indicated by a shift in migration on non-denaturing PAGE gels and an altered pattern of tryptic digestion. Sildenafil Citrate 39-49 phosphodiesterase 5A Homo sapiens 186-190 16888683-2 2007 Although the development of phosphodiesterase type 5 (PDE5) inhibitors (i.e. sildenafil, tadalafil and vardenafil) has revolutionized the treatment of ED, these oral medications require on-demand access and are not as effective in treating ED related to diabetic, post-prostatectomy and severe veno-occlusive disease states. Sildenafil Citrate 77-87 phosphodiesterase 5A Homo sapiens 28-52 16888683-2 2007 Although the development of phosphodiesterase type 5 (PDE5) inhibitors (i.e. sildenafil, tadalafil and vardenafil) has revolutionized the treatment of ED, these oral medications require on-demand access and are not as effective in treating ED related to diabetic, post-prostatectomy and severe veno-occlusive disease states. Sildenafil Citrate 77-87 phosphodiesterase 5A Homo sapiens 54-58 16979814-5 2006 Orally effective PDE5-Is, such as sildenafil, tadalafil, or vardenafil, may be ineffective depending on the demonstration of testosterone regulation of PDE5 expression in human corpus cavernous, and their efficacy may be enhanced by testosterone adjunction whenever necessary. Sildenafil Citrate 34-44 phosphodiesterase 5A Homo sapiens 17-21 26627173-3 2007 In this study, we look at the mechanism and thermodynamics of the binding of selective inhibitors sildenafil (Viagra) and vardenafil (Levitra) to PDE5 using molecular dynamics simulations. Sildenafil Citrate 98-108 phosphodiesterase 5A Homo sapiens 146-150 26627173-3 2007 In this study, we look at the mechanism and thermodynamics of the binding of selective inhibitors sildenafil (Viagra) and vardenafil (Levitra) to PDE5 using molecular dynamics simulations. Sildenafil Citrate 110-116 phosphodiesterase 5A Homo sapiens 146-150 26627173-4 2007 Our simulations of PDE5 with and without sildenafil suggest a binding mechanism in which two loops surrounding the binding pocket of the enzyme (H loop, residues 660-683, and M loop, 787-812) execute sizable conformational changes (~1 nm), clamping the ligand in the pocket. Sildenafil Citrate 41-51 phosphodiesterase 5A Homo sapiens 19-23 17101732-1 2006 Phosphodiesterase-5 (PDE5) inhibitors (sildenafil, tadalafil, and vardenafil) are agents currently in clinical use for nonmalignant conditions. Sildenafil Citrate 39-49 phosphodiesterase 5A Homo sapiens 0-19 17101732-1 2006 Phosphodiesterase-5 (PDE5) inhibitors (sildenafil, tadalafil, and vardenafil) are agents currently in clinical use for nonmalignant conditions. Sildenafil Citrate 39-49 phosphodiesterase 5A Homo sapiens 21-25 16735511-4 2006 In addition, the conformation of sildenafil reported herein differs significantly from those in the previous structures of chimerically hybridized or almost inactive PDE5. Sildenafil Citrate 33-43 phosphodiesterase 5A Homo sapiens 166-170 16926278-0 2006 A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization. Sildenafil Citrate 102-112 phosphodiesterase 5A Homo sapiens 27-46 16926278-0 2006 A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization. Sildenafil Citrate 102-112 phosphodiesterase 5A Homo sapiens 146-165 16926278-7 2006 All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B. Sildenafil Citrate 76-86 phosphodiesterase 5A Homo sapiens 4-8 16716755-1 2006 This study was undertaken to investigate the effect of phosphodiesterase-5 (PDE5) inhibitor, sildenafil, on angiogenic response in human coronary arteriolar endothelial cells (HCAEC). Sildenafil Citrate 93-103 phosphodiesterase 5A Homo sapiens 55-74 16716755-1 2006 This study was undertaken to investigate the effect of phosphodiesterase-5 (PDE5) inhibitor, sildenafil, on angiogenic response in human coronary arteriolar endothelial cells (HCAEC). Sildenafil Citrate 93-103 phosphodiesterase 5A Homo sapiens 76-80 16901064-1 2006 Three different phosphodiesterase 5 (PDE5) inhibitors are currently available for the treatment of erectile dysfunction: sildenafil, vardenafil and tadalafil. Sildenafil Citrate 121-131 phosphodiesterase 5A Homo sapiens 37-41 16884667-3 2006 Phosphodiesterase type 5 (PDE5) inhibitors, sildenafil, vardenafil, and tadalafil, provide effective treatment of erectile dysfunction. Sildenafil Citrate 44-54 phosphodiesterase 5A Homo sapiens 26-30 16735511-1 2006 Phosphodiesterase-5 (PDE5) is the target for sildenafil, vardenafil, and tadalafil, which are drugs for treatment of erectile dysfunction and pulmonary hypertension. Sildenafil Citrate 45-55 phosphodiesterase 5A Homo sapiens 0-19 16735511-1 2006 Phosphodiesterase-5 (PDE5) is the target for sildenafil, vardenafil, and tadalafil, which are drugs for treatment of erectile dysfunction and pulmonary hypertension. Sildenafil Citrate 45-55 phosphodiesterase 5A Homo sapiens 21-25 16716091-0 2006 Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 14-18 16759100-1 2006 Sildenafil (5-[2-ethoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one), a potent and selective phosphodiesterase type 5 (PDE5) inhibitor, provided the first oral treatment for male erectile dysfunction. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 157-181 16759100-1 2006 Sildenafil (5-[2-ethoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one), a potent and selective phosphodiesterase type 5 (PDE5) inhibitor, provided the first oral treatment for male erectile dysfunction. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 183-187 16716091-4 2006 PDE5 is abundantly expressed in the mammalian lung and its inhibition by sildenafil has been demonstrated to improve pulmonary vascular physiology in vitro and in vivo animal models of pulmonary hypertension. Sildenafil Citrate 73-83 phosphodiesterase 5A Homo sapiens 0-4 17017938-2 2006 Best known as the target of the impotence drug sildenafil, PDE5 degrades cGMP in smooth muscle cells so as to maintain the contracted state of contractile organs such as the penis, blood vessels, uterus, and intestines. Sildenafil Citrate 47-57 phosphodiesterase 5A Homo sapiens 59-63 16442298-3 2006 In this study, we evaluate the effect of employing sildenafil (Viagra), a specific inhibitor of PDE-5, to counteract ischemia/reperfusion (I/R) injury in a single lung transplantation model of extended ischemia. Sildenafil Citrate 51-61 phosphodiesterase 5A Homo sapiens 96-101 16442298-3 2006 In this study, we evaluate the effect of employing sildenafil (Viagra), a specific inhibitor of PDE-5, to counteract ischemia/reperfusion (I/R) injury in a single lung transplantation model of extended ischemia. Sildenafil Citrate 63-69 phosphodiesterase 5A Homo sapiens 96-101 16442298-19 2006 Employing the established PDE-5 inhibitor sildenafil during lung perfusion, storage, and implantation, ischemic tolerance may be extended and early graft function improved. Sildenafil Citrate 42-52 phosphodiesterase 5A Homo sapiens 26-31 16498233-2 2006 The main action of sildenafil is the enhancement of the effect of nitric oxide (NO) by inhibiting the cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase-5 (PDE-5), an enzyme responsible for degradation of cGMP. Sildenafil Citrate 19-29 phosphodiesterase 5A Homo sapiens 170-175 16239897-2 2006 This meta-analytic study aims to estimate the likely improvements of erectile dysfunction (ED) measured by the International Index of Erectile Function (IIEF) at the highest fixed dosages of the three available PDE-5-inhibitors: sildenafil, tadalafil, and vardenafil. Sildenafil Citrate 229-239 phosphodiesterase 5A Homo sapiens 211-216 16281046-0 2006 Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil. Sildenafil Citrate 72-82 phosphodiesterase 5A Homo sapiens 16-20 16281046-1 2006 Despite close structural similarity, vardenafil (Levitra) is 32-fold more potent than sildenafil (Viagra) to inhibit cGMP-binding cGMP-specific PDE (PDE5); this is due to differences between their heterocyclic rings. Sildenafil Citrate 86-96 phosphodiesterase 5A Homo sapiens 149-153 16281046-1 2006 Despite close structural similarity, vardenafil (Levitra) is 32-fold more potent than sildenafil (Viagra) to inhibit cGMP-binding cGMP-specific PDE (PDE5); this is due to differences between their heterocyclic rings. Sildenafil Citrate 98-104 phosphodiesterase 5A Homo sapiens 149-153 16281046-2 2006 In co-crystals with PDE5, one of the rings of vardenafil or sildenafil interacts with Tyr(612), a catalytic site AA, via (1) a hydrogen bond with a water molecule and (2) hydrophobic bonds. Sildenafil Citrate 60-70 phosphodiesterase 5A Homo sapiens 20-24 16281046-3 2006 For mutant PDE5(Y612F), which ablates hydrogen-bonding potential, vardenafil or sildenafil inhibition was strengthened (2.2- or 3.0-fold, respectively), implying that the Tyr(612) hydroxyl is a negative determinant for these inhibitors. Sildenafil Citrate 80-90 phosphodiesterase 5A Homo sapiens 11-15 16281046-4 2006 For mutant PDE5(Y612A), which ablates both hydrogen bonding and hydrophobic-bonding potential, vardenafil inhibition was weakened much more than sildenafil inhibition (122- and 26-fold, respectively), suggesting that hydrophobic bonds involving Tyr(612) are stronger for vardenafil than for sildenafil. Sildenafil Citrate 145-155 phosphodiesterase 5A Homo sapiens 11-15 16281046-4 2006 For mutant PDE5(Y612A), which ablates both hydrogen bonding and hydrophobic-bonding potential, vardenafil inhibition was weakened much more than sildenafil inhibition (122- and 26-fold, respectively), suggesting that hydrophobic bonds involving Tyr(612) are stronger for vardenafil than for sildenafil. Sildenafil Citrate 291-301 phosphodiesterase 5A Homo sapiens 11-15 16755146-1 2006 The phosphodiesterase-5 (PDE-5) inhibitor, sildenafil, has been reported to produce sustained pulmonary vasodilatation in patients with pulmonary hypertension (PH). Sildenafil Citrate 43-53 phosphodiesterase 5A Homo sapiens 4-23 16755146-1 2006 The phosphodiesterase-5 (PDE-5) inhibitor, sildenafil, has been reported to produce sustained pulmonary vasodilatation in patients with pulmonary hypertension (PH). Sildenafil Citrate 43-53 phosphodiesterase 5A Homo sapiens 25-30 16263207-4 2006 Of the currently available treatment options for ED, the most commonly prescribed therapies are oral PDE5 inhibitors, which include sildenafil citrate (Viagra, Pfizer Inc), tadalafil (Cialis, Lilly ICOS), and vardenafil (Levitra, Bayer). Sildenafil Citrate 132-150 phosphodiesterase 5A Homo sapiens 101-105 17017938-6 2006 Sildenafil and other selective inhibitors inhibit PDE5 by binding to the catalytic site. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 50-54 17017939-2 2006 Three PDE5 inhibitors (sildenafil, tadalafil, and vardenafil) are clinically available at this time, and extensive drug design efforts are registered for finding agents with a better activity, enhanced selectivity and reduced side effects. Sildenafil Citrate 23-33 phosphodiesterase 5A Homo sapiens 6-10 17017940-6 2006 Finally, the recent approval of PDE5-i sildenafil for the treatment of pulmonary arterial hypertension represents the new challenge for these class of drugs. Sildenafil Citrate 39-49 phosphodiesterase 5A Homo sapiens 32-36 16409214-1 2006 Sildenafil citrate improves erectile function in men with erectile dysfunction (ED) by selectively inhibiting cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), which is present in all vascular tissue. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 183-187 16185664-2 2005 Sildenafil is a phosphodiesterase type 5 (PDE5) inhibitor that potentiates NO action by reducing cGMP breakdown. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 16-40 16817245-2 2006 The Food and Drug Administration (FDA) approved PDE-5 inhibitors include sildenafil citrate, vardenafil hydrochloride and tadalafil. Sildenafil Citrate 73-91 phosphodiesterase 5A Homo sapiens 48-53 16387565-3 2005 Since the introduction of the first PDE5 inhibitor, sildenafil, in 1998, there has been concern about the effects of these agents on the heart and their safety in patients with cardiovascular disease. Sildenafil Citrate 52-62 phosphodiesterase 5A Homo sapiens 36-40 16387566-1 2005 Currently, 3 phosphodiesterase 5 (PDE5) inhibitor agents are available worldwide for the treatment of erectile dysfunction (ED): sildenafil, vardenafil, and tadalafil. Sildenafil Citrate 129-139 phosphodiesterase 5A Homo sapiens 13-32 16387566-1 2005 Currently, 3 phosphodiesterase 5 (PDE5) inhibitor agents are available worldwide for the treatment of erectile dysfunction (ED): sildenafil, vardenafil, and tadalafil. Sildenafil Citrate 129-139 phosphodiesterase 5A Homo sapiens 34-38 16287454-11 2005 CONCLUSIONS: In men with ED who were naive to PDE5 inhibitor therapy, sildenafil and tadalafil were both effective and well tolerated. Sildenafil Citrate 70-80 phosphodiesterase 5A Homo sapiens 46-50 16247643-5 2005 The convincing clinical data on the use of the orally active PDE5 inhibitors sildenafil (VIAGRA), vardenafil (LEVITRA) and tadalafil (CIALIS) in the treatment of erectile dysfunction are accompanied by boosting research activities on intracellular signal transduction and PDE characterisation in female genital tissues with the aid of immunohistochemistry and immunocytochemistry and molecular biology. Sildenafil Citrate 77-87 phosphodiesterase 5A Homo sapiens 61-65 16247643-7 2005 As a consequence, the efficacy and safety of the PDE5 inhibitor sildenafil in the treatment of symptoms of female sexual dysfunction (FSD), including female sexual arousal disorders (FSAD), have been evaluated. Sildenafil Citrate 64-74 phosphodiesterase 5A Homo sapiens 49-53 16273417-6 2005 This review, which is based on the contemporary literature on PDE-5 inhibitors, describes the chemical, pharmacological, and clinical features of sildenafil, vardenafil, and tadalafil. Sildenafil Citrate 146-156 phosphodiesterase 5A Homo sapiens 62-67 16273418-2 2005 Although a complete pharmacological cure for ED is currently unavailable, the phosphodiesterase 5 (PDE5) inhibitors sildenafil, vardenafil, and tadalafil are efficacious oral therapy for ED. Sildenafil Citrate 116-126 phosphodiesterase 5A Homo sapiens 78-97 16273418-2 2005 Although a complete pharmacological cure for ED is currently unavailable, the phosphodiesterase 5 (PDE5) inhibitors sildenafil, vardenafil, and tadalafil are efficacious oral therapy for ED. Sildenafil Citrate 116-126 phosphodiesterase 5A Homo sapiens 99-103 16292559-15 2005 The expression of the cGMP-specific PDE5 and the ability of the PDE5 inhibitor sildenafil to reverse the adrenergic tension of isolated segments of HCA underline the important role of the NO/cGMP pathway in the control of smooth muscle tone of human trabecular smooth musculature and penile cavernous arteries. Sildenafil Citrate 79-89 phosphodiesterase 5A Homo sapiens 64-68 16185664-2 2005 Sildenafil is a phosphodiesterase type 5 (PDE5) inhibitor that potentiates NO action by reducing cGMP breakdown. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 42-46 16182282-1 2005 Sildenafil (Viagra), a selective inhibitor of phosphodiesterase 5 (PDE5), induces headache and migraine. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 46-65 16182282-1 2005 Sildenafil (Viagra), a selective inhibitor of phosphodiesterase 5 (PDE5), induces headache and migraine. Sildenafil Citrate 12-18 phosphodiesterase 5A Homo sapiens 67-71 16182282-11 2005 In conclusion, PDE5 is present in human and guinea pig cerebral arteries, and is inhibited by sildenafil at micromolar levels. Sildenafil Citrate 94-104 phosphodiesterase 5A Homo sapiens 15-19 16246964-1 2005 BACKGROUND: Sildenafil inhibits phosphodiesterase 5 (PDE5A) to elevate intracellular cGMP and to induce vasodilation. Sildenafil Citrate 12-22 phosphodiesterase 5A Homo sapiens 53-58 16246964-11 2005 CONCLUSIONS: PDE5A inhibition by sildenafil blunts systolic responses to beta-adrenergic stimulation. Sildenafil Citrate 33-43 phosphodiesterase 5A Homo sapiens 13-18 16182282-1 2005 Sildenafil (Viagra), a selective inhibitor of phosphodiesterase 5 (PDE5), induces headache and migraine. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 67-71 16182282-1 2005 Sildenafil (Viagra), a selective inhibitor of phosphodiesterase 5 (PDE5), induces headache and migraine. Sildenafil Citrate 12-18 phosphodiesterase 5A Homo sapiens 46-65 16151756-5 2005 Besides psychotherapy, oral pharmacotherapy with oral PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) is the most effective therapy for erectile dysfunction and is superior to centrally acting drugs (yohimbine). Sildenafil Citrate 72-82 phosphodiesterase 5A Homo sapiens 54-59 16236987-2 2005 Interestingly, vascular smooth muscle and platelets are predominant sources of type-5 phosphodiesterase (PDE5) in the body, and this enzyme is specifically inhibited by PDE5 inhibitors (eg, sildenafil citrate). Sildenafil Citrate 190-208 phosphodiesterase 5A Homo sapiens 105-109 16236987-2 2005 Interestingly, vascular smooth muscle and platelets are predominant sources of type-5 phosphodiesterase (PDE5) in the body, and this enzyme is specifically inhibited by PDE5 inhibitors (eg, sildenafil citrate). Sildenafil Citrate 190-208 phosphodiesterase 5A Homo sapiens 169-173 16100293-1 2005 Differences in the clinical pharmacology of the 3 currently available oral phosphodiesterase-5 (PDE5) inhibitors, sildenafil, vardenafil, and tadalafil, are largely determined by their clinical pharmacokinetics as well as their PDE inhibitory activity profile. Sildenafil Citrate 114-124 phosphodiesterase 5A Homo sapiens 75-94 16100293-1 2005 Differences in the clinical pharmacology of the 3 currently available oral phosphodiesterase-5 (PDE5) inhibitors, sildenafil, vardenafil, and tadalafil, are largely determined by their clinical pharmacokinetics as well as their PDE inhibitory activity profile. Sildenafil Citrate 114-124 phosphodiesterase 5A Homo sapiens 96-100 15817798-11 2005 The antiproliferative effects of this signaling pathway may be significant in the chronic treatment of pulmonary hypertension with PDE5 inhibitors such as sildenafil. Sildenafil Citrate 155-165 phosphodiesterase 5A Homo sapiens 131-135 16042713-4 2005 The successful launch and commercialization of the selective PDE5 inhibitor (PDE5I) sildenafil transformed the treatment of ED, not only by providing an effective, well tolerated oral ED therapy, but also by fostering greater candour about the problem among men. Sildenafil Citrate 84-94 phosphodiesterase 5A Homo sapiens 61-65 15941818-9 2005 Sildenafil, vardenafil, and tadalafil are selective PDE5 inhibitors currently available for treatment of ED. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 52-56 15941818-11 2005 CONCLUSIONS: Sildenafil, vardenafil, and tadalafil are safe and effective PDE5 inhibitors for the treatment of ED. Sildenafil Citrate 13-23 phosphodiesterase 5A Homo sapiens 74-78 15750042-2 2005 OBJECTIVE: This study compared adding sildenafil, a PDE5 inhibitor, to conventional treatment with the current practice of adding bosentan, an endothelin receptor antagonist. Sildenafil Citrate 38-48 phosphodiesterase 5A Homo sapiens 52-56 15965806-7 2005 In comparison to the previously mentioned substances, the selective phosphodiesterase-5 (PDE5) inhibitor sildenafil approached approval closest as new therapy for pulmonary arterial hypertension. Sildenafil Citrate 105-115 phosphodiesterase 5A Homo sapiens 68-87 15965806-7 2005 In comparison to the previously mentioned substances, the selective phosphodiesterase-5 (PDE5) inhibitor sildenafil approached approval closest as new therapy for pulmonary arterial hypertension. Sildenafil Citrate 105-115 phosphodiesterase 5A Homo sapiens 89-93 15934858-1 2005 Therapy of erectile dysfunction has been revolutionised in recent years, as specific pharmacological inhibitors of phosphodiesterase 5 (PDE5), such as sildenafil, tadalafil, or vardenafil, were shown to be highly effective in the treatment of erectile dysfunction. Sildenafil Citrate 151-161 phosphodiesterase 5A Homo sapiens 115-134 15934858-1 2005 Therapy of erectile dysfunction has been revolutionised in recent years, as specific pharmacological inhibitors of phosphodiesterase 5 (PDE5), such as sildenafil, tadalafil, or vardenafil, were shown to be highly effective in the treatment of erectile dysfunction. Sildenafil Citrate 151-161 phosphodiesterase 5A Homo sapiens 136-140 16422865-2 2005 We have evaluated the effects of sildenafil, a PDE5 inhibitor that enhances the nitric oxide (NO)/cGMP pathway, calcium dobesilate (DOBE), which potentiates endothelium-derived hyperpolarizing factor (EDHF)-mediated responses and the combination of both on erectile responses elicited by cavernosal nerve electrical stimulation (CNES) in a rat model of ED after 8 weeks of streptozotocin-induced diabetes. Sildenafil Citrate 33-43 phosphodiesterase 5A Homo sapiens 47-51 15888841-3 2005 The goal of this study was to determine the acute pulmonary and systemic hemodynamic effects of the selective PDE5 inhibitor, sildenafil, administered alone or in combination with inhaled NO in patients with congestive heart failure and PH. Sildenafil Citrate 126-136 phosphodiesterase 5A Homo sapiens 110-114 15888841-13 2005 CONCLUSIONS: PDE5 inhibition with sildenafil improves cardiac output by balanced pulmonary and systemic vasodilation, and augments and prolongs the hemodynamic effects of inhaled NO in patients with chronic congestive heart failure and PH. Sildenafil Citrate 34-44 phosphodiesterase 5A Homo sapiens 13-17 15820939-3 2005 Sildenafil citrate is a selective and potent inhibitor of cGMP-specific phosphodiesterase-5 (PDE5) which promotes selective smooth muscle relaxation in lung vasculature and has been utilized successfully in the treatment of PH. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 93-97 15661417-2 2005 Acute and chronic administration of oral sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, improves endothelial function in patients with ED. Sildenafil Citrate 41-51 phosphodiesterase 5A Homo sapiens 55-79 15721505-2 2005 Sildenafil selectively inhibits phosphodiesterase 5 (PDE5), which is abundant in pulmonary and penile tissue. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 32-51 15721505-2 2005 Sildenafil selectively inhibits phosphodiesterase 5 (PDE5), which is abundant in pulmonary and penile tissue. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 53-57 15922255-1 2005 The phosphodiesterase type-5 (PDE5) inhibitor, sildenafil, is the first drug developed for treatment of erectile dysfunction in patients. Sildenafil Citrate 47-57 phosphodiesterase 5A Homo sapiens 4-28 15922255-1 2005 The phosphodiesterase type-5 (PDE5) inhibitor, sildenafil, is the first drug developed for treatment of erectile dysfunction in patients. Sildenafil Citrate 47-57 phosphodiesterase 5A Homo sapiens 30-34 15922255-6 2005 Future demonstration of the cardioprotective effect in patients with the relatively safe and effective FDA-approved PDE5 inhibitors such as sildenafil could have an enormous impact on bringing the long-studied phenomenon of ischemic and pharmacologic preconditioning to the clinical forefront. Sildenafil Citrate 140-150 phosphodiesterase 5A Homo sapiens 116-120 15567064-2 2005 The cGMP-PDE5 inhibitors Sildenafil and Zaprinast have been demonstrated to potentiate the anti-platelet aggregatory effect of NO donors like sodium nitroprusside (SNP) in vitro but the mechanisms of Sildenafil"s action on the secretory function of human platelets have not been analysed in detail. Sildenafil Citrate 25-35 phosphodiesterase 5A Homo sapiens 9-13 15567064-2 2005 The cGMP-PDE5 inhibitors Sildenafil and Zaprinast have been demonstrated to potentiate the anti-platelet aggregatory effect of NO donors like sodium nitroprusside (SNP) in vitro but the mechanisms of Sildenafil"s action on the secretory function of human platelets have not been analysed in detail. Sildenafil Citrate 200-210 phosphodiesterase 5A Homo sapiens 9-13 15766322-1 2005 BACKGROUND: Significant advances in the pharmacologic treatment of erectile dysfunction (ERD) have occurred in recent years, most notably the introduction of sildenafil, the first oral selective phosphodiesterase type 5 (PDE5) inhibitor, in 1998. Sildenafil Citrate 158-168 phosphodiesterase 5A Homo sapiens 195-219 15766322-1 2005 BACKGROUND: Significant advances in the pharmacologic treatment of erectile dysfunction (ERD) have occurred in recent years, most notably the introduction of sildenafil, the first oral selective phosphodiesterase type 5 (PDE5) inhibitor, in 1998. Sildenafil Citrate 158-168 phosphodiesterase 5A Homo sapiens 221-225 15766322-3 2005 Two PDE5 inhibitors, vardenafil and tadalafil, have since joined sildenafil to compete in the ERD market. Sildenafil Citrate 65-75 phosphodiesterase 5A Homo sapiens 4-8 15661417-2 2005 Acute and chronic administration of oral sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, improves endothelial function in patients with ED. Sildenafil Citrate 41-51 phosphodiesterase 5A Homo sapiens 81-85 16156422-4 2005 The PDE5 inhibitors, sildenafil, tadalafil, and vardenafil, have proven to be effective and well tolerated and facilitate erectile function. Sildenafil Citrate 21-31 phosphodiesterase 5A Homo sapiens 4-8 16339700-3 2005 Sildenafil citrate is a selective and potent inhibitor of cGMP-specific phosphodiesterase-5 (PDE5), which promotes selective smooth muscle relaxation in lung vasculature and has been used successfully in the treatment of PH. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 93-97 15988068-2 2005 Phosphodiesterase-5 (PDE5), which is highly specific for guanosine 3"-5"-cyclic-monophosphate (cGMP) at both its catalytic site and its allosteric sites, has generated particular interest because it is potently and specifically inhibited by three drugs: sildenafil (Viagra, Pfizer), tadalafil (Cialis, Lilly-ICOS), and vardenafil (Levitra, Bayer GSK). Sildenafil Citrate 254-264 phosphodiesterase 5A Homo sapiens 0-19 16378510-4 2005 This knowledge has led to the development and current availability of effective oral treatments for erectile dysfunction, the selective phosphodiesterase type 5 (PDE5) inhibitors-sildenafil, vardenafil and tadalafil. Sildenafil Citrate 179-189 phosphodiesterase 5A Homo sapiens 136-160 16378510-4 2005 This knowledge has led to the development and current availability of effective oral treatments for erectile dysfunction, the selective phosphodiesterase type 5 (PDE5) inhibitors-sildenafil, vardenafil and tadalafil. Sildenafil Citrate 179-189 phosphodiesterase 5A Homo sapiens 162-166 15977967-7 2005 The PDE5 sildenafil is also being intensively studied in patients with pulmonary hypertension, and most of the available data look promising, although approval for PAH is still pending. Sildenafil Citrate 9-19 phosphodiesterase 5A Homo sapiens 4-8 16060698-4 2005 Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil) are currently the first-choice of most physicians and patients for the treatment of ED. Sildenafil Citrate 44-54 phosphodiesterase 5A Homo sapiens 0-24 16060698-4 2005 Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil) are currently the first-choice of most physicians and patients for the treatment of ED. Sildenafil Citrate 44-54 phosphodiesterase 5A Homo sapiens 26-30 15538396-0 2005 High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients. Sildenafil Citrate 43-53 phosphodiesterase 5A Homo sapiens 79-100 15538396-0 2005 High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients. Sildenafil Citrate 43-53 phosphodiesterase 5A Homo sapiens 102-106 16042360-4 2005 In facts, inhibition of phosphodiesterase type 5 (PDE5) isoenzyme with sildenafil, tadalafil and vardenafil enhances vasodilatation in the corpus cavernosum and subsequent penile erection. Sildenafil Citrate 71-81 phosphodiesterase 5A Homo sapiens 24-48 16042360-4 2005 In facts, inhibition of phosphodiesterase type 5 (PDE5) isoenzyme with sildenafil, tadalafil and vardenafil enhances vasodilatation in the corpus cavernosum and subsequent penile erection. Sildenafil Citrate 71-81 phosphodiesterase 5A Homo sapiens 50-54 15988068-2 2005 Phosphodiesterase-5 (PDE5), which is highly specific for guanosine 3"-5"-cyclic-monophosphate (cGMP) at both its catalytic site and its allosteric sites, has generated particular interest because it is potently and specifically inhibited by three drugs: sildenafil (Viagra, Pfizer), tadalafil (Cialis, Lilly-ICOS), and vardenafil (Levitra, Bayer GSK). Sildenafil Citrate 254-264 phosphodiesterase 5A Homo sapiens 21-25 15618584-9 2005 CONCLUSIONS: The findings provide proof of principle for sildenafil as a DeltaF508-CFTR trafficking drug and give encouragement for future testing of sildenafil and related PDE5 inhibitors in patients with CF. Sildenafil Citrate 57-67 phosphodiesterase 5A Homo sapiens 173-177 15531735-2 2005 The purpose of this study was to demonstrate the effects of sildenafil, a selective phosphodiesterase-5 (PDE-5) inhibitor on myocardial functional improvement and infarct size reduction during ischemia/reperfusion injury in infant rabbits. Sildenafil Citrate 60-70 phosphodiesterase 5A Homo sapiens 84-103 15531735-2 2005 The purpose of this study was to demonstrate the effects of sildenafil, a selective phosphodiesterase-5 (PDE-5) inhibitor on myocardial functional improvement and infarct size reduction during ischemia/reperfusion injury in infant rabbits. Sildenafil Citrate 60-70 phosphodiesterase 5A Homo sapiens 105-110 16985896-6 2005 In this regard, sildenafil continues to account for almost 70% of PDE-5 inhibitor prescriptions in the United States. Sildenafil Citrate 16-26 phosphodiesterase 5A Homo sapiens 66-71 16095162-7 2005 Several papers documenting hypotensive effect in pulmonary circulation of specific PDE5 inhibitor--sildenafil (Viagra--Pfizer) have been published recently. Sildenafil Citrate 99-109 phosphodiesterase 5A Homo sapiens 83-87 16095162-7 2005 Several papers documenting hypotensive effect in pulmonary circulation of specific PDE5 inhibitor--sildenafil (Viagra--Pfizer) have been published recently. Sildenafil Citrate 111-117 phosphodiesterase 5A Homo sapiens 83-87 16208781-4 2005 Sildenafil citrate, the specific inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE 5) was studied as an antianginal drug during the late 1980s, but is now used for its effect on erectile function in men. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 119-124 15522526-1 2004 A liquid chromatography-electrospray ionisation-mass spectrometry (LC-ESI-MS) method was developed to screen for the presence of synthetic phosphodiesterase type 5 (PDE-5) inhibitors including sildenafil, tadalafil and vardenafil. Sildenafil Citrate 193-203 phosphodiesterase 5A Homo sapiens 139-163 15522526-1 2004 A liquid chromatography-electrospray ionisation-mass spectrometry (LC-ESI-MS) method was developed to screen for the presence of synthetic phosphodiesterase type 5 (PDE-5) inhibitors including sildenafil, tadalafil and vardenafil. Sildenafil Citrate 193-203 phosphodiesterase 5A Homo sapiens 165-170 15312980-0 2004 Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5). Sildenafil Citrate 53-63 phosphodiesterase 5A Homo sapiens 92-111 15475488-3 2004 The aim of this study was to investigate the effect of sildenafil, a selective PDE-5 inhibitor, on fasting and postprandial proximal gastric volume and on gastric emptying rates in humans. Sildenafil Citrate 55-65 phosphodiesterase 5A Homo sapiens 79-84 15881813-1 2004 Newly developed sildenafil citrate (SC), a selective inhibitor of cyclic guanosine monophosphate (c-GMP) specific phosphodiesterase type 5 (PDE 5) in the corpus cavernosum is used for the oral treatment of erectile dysfunction. Sildenafil Citrate 16-34 phosphodiesterase 5A Homo sapiens 114-138 15881813-1 2004 Newly developed sildenafil citrate (SC), a selective inhibitor of cyclic guanosine monophosphate (c-GMP) specific phosphodiesterase type 5 (PDE 5) in the corpus cavernosum is used for the oral treatment of erectile dysfunction. Sildenafil Citrate 16-34 phosphodiesterase 5A Homo sapiens 140-145 15881813-1 2004 Newly developed sildenafil citrate (SC), a selective inhibitor of cyclic guanosine monophosphate (c-GMP) specific phosphodiesterase type 5 (PDE 5) in the corpus cavernosum is used for the oral treatment of erectile dysfunction. Sildenafil Citrate 36-38 phosphodiesterase 5A Homo sapiens 114-138 15881813-1 2004 Newly developed sildenafil citrate (SC), a selective inhibitor of cyclic guanosine monophosphate (c-GMP) specific phosphodiesterase type 5 (PDE 5) in the corpus cavernosum is used for the oral treatment of erectile dysfunction. Sildenafil Citrate 36-38 phosphodiesterase 5A Homo sapiens 140-145 15312980-2 2004 Two commercialized PDE5 inhibitors, sildenafil and vardenafil, are being used to treat erectile dysfunction. Sildenafil Citrate 36-46 phosphodiesterase 5A Homo sapiens 19-23 15312980-5 2004 Although these are the only two structural differences, vardenafil has more than 20-fold greater potency than sildenafil for inhibiting purified PDE5. Sildenafil Citrate 110-120 phosphodiesterase 5A Homo sapiens 145-149 15312980-7 2004 The IC50 of methyl-sildenafil for inhibiting PDE5 indicated that it was 64 times less potent than demethyl-vardenafil, which was similar to the finding that, based on IC50, sildenafil was 40 times less potent than vardenafil. Sildenafil Citrate 19-29 phosphodiesterase 5A Homo sapiens 45-49 15312980-8 2004 Similarly, the EC50 of methyl-sildenafil for inhibiting [3H]vardenafil binding to PDE5 indicated that it was 84 times less potent than demethyl-vardenafil, while the EC50 for sildenafil indicated that it was 31 times less potent than vardenafil. Sildenafil Citrate 30-40 phosphodiesterase 5A Homo sapiens 82-86 15312980-0 2004 Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5). Sildenafil Citrate 53-63 phosphodiesterase 5A Homo sapiens 113-117 15464333-9 2004 CONCLUSIONS: In PAH patients, the three PDE5 inhibitors differ markedly in their kinetics of pulmonary vasorelaxation (most rapid effect by vardenafil), their selectivity for the pulmonary circulation (sildenafil and tadalafil, but not vardenafil), and their impact on arterial oxygenation (improvement with sildenafil only). Sildenafil Citrate 308-318 phosphodiesterase 5A Homo sapiens 40-44 15476742-4 2004 We studied the ability of three compounds that inhibit PDE5--sildenafil, tadalafil, and vardenafil--to block the HERG channel. Sildenafil Citrate 61-71 phosphodiesterase 5A Homo sapiens 55-59 15466636-1 2004 BACKGROUND: The phosphodiesterase type-5 (PDE-5) inhibitor sildenafil has been reported to improve pulmonary arterial hypertension (PAH), but the mechanisms that account for this effect are incompletely understood. Sildenafil Citrate 59-69 phosphodiesterase 5A Homo sapiens 16-40 15466636-1 2004 BACKGROUND: The phosphodiesterase type-5 (PDE-5) inhibitor sildenafil has been reported to improve pulmonary arterial hypertension (PAH), but the mechanisms that account for this effect are incompletely understood. Sildenafil Citrate 59-69 phosphodiesterase 5A Homo sapiens 42-47 15464333-2 2004 BACKGROUND: The PDE5 inhibitor sildenafil has been reported to cause pulmonary vasodilation in patients with PAH. Sildenafil Citrate 31-41 phosphodiesterase 5A Homo sapiens 16-20 15464333-6 2004 RESULTS: All three PDE5 inhibitors caused significant pulmonary vasorelaxation, with maximum effects being obtained after 40 to 45 min (vardenafil), 60 min (sildenafil), and 75 to 90 min (tadalafil). Sildenafil Citrate 157-167 phosphodiesterase 5A Homo sapiens 19-23 15464333-9 2004 CONCLUSIONS: In PAH patients, the three PDE5 inhibitors differ markedly in their kinetics of pulmonary vasorelaxation (most rapid effect by vardenafil), their selectivity for the pulmonary circulation (sildenafil and tadalafil, but not vardenafil), and their impact on arterial oxygenation (improvement with sildenafil only). Sildenafil Citrate 202-212 phosphodiesterase 5A Homo sapiens 40-44 15371988-5 2004 In an animal model of diabetes mellitus, treatment with sildenafil (a PDE-5 inhibitor) restored NO-mediated pyloric relaxation and improved gastric emptying. Sildenafil Citrate 56-66 phosphodiesterase 5A Homo sapiens 70-75 15464535-1 2004 The discovery in 1989 of sildenafil, a highly selective inhibitor of phosphodiesterase-5 (PDE-5), was the result of extensive research on chemical agents targeting PDE-5 that might potentially be useful in the treatment of coronary heart disease. Sildenafil Citrate 25-35 phosphodiesterase 5A Homo sapiens 69-88 15464535-1 2004 The discovery in 1989 of sildenafil, a highly selective inhibitor of phosphodiesterase-5 (PDE-5), was the result of extensive research on chemical agents targeting PDE-5 that might potentially be useful in the treatment of coronary heart disease. Sildenafil Citrate 25-35 phosphodiesterase 5A Homo sapiens 90-95 15464535-1 2004 The discovery in 1989 of sildenafil, a highly selective inhibitor of phosphodiesterase-5 (PDE-5), was the result of extensive research on chemical agents targeting PDE-5 that might potentially be useful in the treatment of coronary heart disease. Sildenafil Citrate 25-35 phosphodiesterase 5A Homo sapiens 164-169 15464535-5 2004 Novel therapeutic indications are emerging for sildenafil with the recent discovery that PDE-5 is expressed in various other tissues such as the arterial vasculature, including pulmonary and coronary arteries, venous vasculature, skeletal muscles, platelets, and visceral and tracheobronchial muscles. Sildenafil Citrate 47-57 phosphodiesterase 5A Homo sapiens 89-94 15175637-3 2004 The PDE5A gene represents a good candidate for the intermediate phenotype EH/ED: genetic variants of the PDE5A may predispose to EH and ED and could affect the local and systemic response to sildenafil administration. Sildenafil Citrate 191-201 phosphodiesterase 5A Homo sapiens 4-9 15175637-3 2004 The PDE5A gene represents a good candidate for the intermediate phenotype EH/ED: genetic variants of the PDE5A may predispose to EH and ED and could affect the local and systemic response to sildenafil administration. Sildenafil Citrate 191-201 phosphodiesterase 5A Homo sapiens 105-110 15295092-3 2004 The PDE5 inhibitor sildenafil produced vasorelaxant responses in isolated pulmonary arteries. Sildenafil Citrate 19-29 phosphodiesterase 5A Homo sapiens 4-8 15333581-6 2004 The NO donor diethylamine NONOate (DEANO), the PKG activator 8-pCPT-cGMP, and the PDE-5 inhibitor sildenafil, cause dose-dependent clitoral relaxation that is inhibited by antagonists of PKG (Rp-8-Br-cGMPS) or BK(Ca) channels (iberiotoxin). Sildenafil Citrate 98-108 phosphodiesterase 5A Homo sapiens 82-87 15497717-1 2004 Vardenafil is a potent and highly selective phosphodiesterase type 5 (PDE5) inhibitor with a potency about 10-fold higher than sildenafil. Sildenafil Citrate 127-137 phosphodiesterase 5A Homo sapiens 70-74 15560162-1 2004 The study has been performed of the efficacy in the treatment of erectile dysfunction (ED) of oral drugs affecting nitric oxide: impase and phosphodiesterase-5 (PDE-5) inhibitors--sildenafil citrate (viagra), tadalafil (sialis)--alone and in combination with impase. Sildenafil Citrate 180-198 phosphodiesterase 5A Homo sapiens 161-166 15197447-4 2004 Because all three PDE 5 inhibitors sildenafil, tadalafil, and vardenafil have a common mode of action, i.e., inhibition of PDE 5, they are not different in terms of their efficacy and safety profile except for color vision disturbances which are more common after sildenafil and back pain/myalgia more often observed after tadalafil. Sildenafil Citrate 35-45 phosphodiesterase 5A Homo sapiens 18-23 15295684-4 2004 She was able to walk only 220 m. All usual methods of treatment failed to give satisfactory results so that sildenafil (phospherodiesterase type-5 PDE-5 inhibitor; Viagra ((R)) was given, even though it is not licensed for this indications ("off-label", as a therapeutic attempt. Sildenafil Citrate 108-118 phosphodiesterase 5A Homo sapiens 148-153 15213306-0 2004 Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Sildenafil Citrate 21-31 phosphodiesterase 5A Homo sapiens 65-84 15213306-1 2004 Sildenafil, tadalafil, and vardenafil each competitively inhibit cGMP hydrolysis by phosphodiesterase-5 (PDE5), thereby fostering cGMP accumulation and relaxation of vascular smooth muscle. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 84-103 15213306-1 2004 Sildenafil, tadalafil, and vardenafil each competitively inhibit cGMP hydrolysis by phosphodiesterase-5 (PDE5), thereby fostering cGMP accumulation and relaxation of vascular smooth muscle. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 105-109 15194181-5 2004 Recently, beneficial effects of the oral PDE-5 inhibitor sildenafil (originally approved for the treatment of erectile dysfunction) were reported for the treatment of PH. Sildenafil Citrate 57-67 phosphodiesterase 5A Homo sapiens 41-46 15183543-1 2004 OBJECTIVE: Sexual medicine has evolved greatly in the past several years, to a large extent because of the introduction of the phosphodiesterase-5 (PDE5) inhibitor, Viagra (sildenafil citrate), as a highly effective oral therapy for erectile dysfunction. Sildenafil Citrate 165-171 phosphodiesterase 5A Homo sapiens 127-146 15183543-1 2004 OBJECTIVE: Sexual medicine has evolved greatly in the past several years, to a large extent because of the introduction of the phosphodiesterase-5 (PDE5) inhibitor, Viagra (sildenafil citrate), as a highly effective oral therapy for erectile dysfunction. Sildenafil Citrate 173-191 phosphodiesterase 5A Homo sapiens 127-146 15183543-1 2004 OBJECTIVE: Sexual medicine has evolved greatly in the past several years, to a large extent because of the introduction of the phosphodiesterase-5 (PDE5) inhibitor, Viagra (sildenafil citrate), as a highly effective oral therapy for erectile dysfunction. Sildenafil Citrate 173-191 phosphodiesterase 5A Homo sapiens 148-152 21224902-5 2004 The introduction of PDE-5 inhibitors like sildenafil, vardenafil and tadalafil has revolutionized the treatment of sexual dysfunctions.This review focuses on the recent pharmacological advances in the treatment of common sexual dysfunctions like ED and PME with special focus on the role of PDE-5 inhibitors. Sildenafil Citrate 42-52 phosphodiesterase 5A Homo sapiens 20-25 15223851-0 2004 Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil. Sildenafil Citrate 108-118 phosphodiesterase 5A Homo sapiens 77-82 15093609-3 2004 PDE5 expression was monitored in different regions of the gastrointestinal tract and nearly 50% of the phosphodiesterase activity in the duodenum, jejunum, ileum and colon was inhibited by sildenafil citrate. Sildenafil Citrate 189-207 phosphodiesterase 5A Homo sapiens 0-4 15093609-5 2004 Inhibition of PDE5 by sildenafil citrate led to fluid accumulation in loops, suggesting a possible explanation for the side effect of diarrhoea observed in individuals administered sildenafil citrate. Sildenafil Citrate 22-40 phosphodiesterase 5A Homo sapiens 14-18 15093609-5 2004 Inhibition of PDE5 by sildenafil citrate led to fluid accumulation in loops, suggesting a possible explanation for the side effect of diarrhoea observed in individuals administered sildenafil citrate. Sildenafil Citrate 181-199 phosphodiesterase 5A Homo sapiens 14-18 15224127-5 2004 The catalytic site of PDE5 normally degrades cGMP, and PDE5 inhibitors such as sildenafil potentiate endogenous increases in cGMP by inhibiting its breakdown at the catalytic site. Sildenafil Citrate 79-89 phosphodiesterase 5A Homo sapiens 55-59 15224129-3 2004 Sildenafil, vardenafil, and tadalafil are selective for PDE5, with vardenafil exhibiting the highest potency and minimal inhibition of other PDEs, with the exception of PDE6. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 56-60 15224132-6 2004 Although active sites of PDEs are apparently structurally similar, PDE4 is specifically inhibited by selective inhibitors such as rolipram, while PDE5 is preferentially blocked by sildenafil. Sildenafil Citrate 180-190 phosphodiesterase 5A Homo sapiens 146-150 15224132-7 2004 Modeling interactions of the PDE5 inhibitor sildenafil with the PDE4 active site may help explain inhibitor selectivity and provide useful information for the design of new inhibitors. Sildenafil Citrate 44-54 phosphodiesterase 5A Homo sapiens 29-33 15281210-6 2004 Oral PDE-5-inhibitors(sildenafil, tadalafil, vardenafil) are superior in effectiveness to centrally acting drugs (apomorphin, yohimbine). Sildenafil Citrate 22-32 phosphodiesterase 5A Homo sapiens 5-10 15080987-1 2004 Synthesis of new sildenafil analogues containing a phosphonate group in the 5(")-sulfonamide moiety of the phenyl ring, 12a-e, 13a-d, and 14a-d, and evaluation of their in vitro PDE5 inhibitory activity are disclosed. Sildenafil Citrate 17-27 phosphodiesterase 5A Homo sapiens 178-182 15080987-3 2004 Docking model of (PDE5: 12d) complex shows that the PDE5-bound conformation of 12d matches completely with that of sildenafil, while 12d is partially overlapped with cGMP with ethyl phosphonate group of 12d superimposed onto the cyclic phosphate group of cGMP. Sildenafil Citrate 115-125 phosphodiesterase 5A Homo sapiens 18-22 15080987-3 2004 Docking model of (PDE5: 12d) complex shows that the PDE5-bound conformation of 12d matches completely with that of sildenafil, while 12d is partially overlapped with cGMP with ethyl phosphonate group of 12d superimposed onto the cyclic phosphate group of cGMP. Sildenafil Citrate 115-125 phosphodiesterase 5A Homo sapiens 52-56 15115191-1 2004 The mechanism of action of the phosphodiesterase type 5 (PDE5) inhibitors (i.e., sildenafil, tadalafil, and vardenafil) involves inhibition of the PDE5 isoenzyme located in penile vascular smooth muscle cells. Sildenafil Citrate 81-91 phosphodiesterase 5A Homo sapiens 31-55 15155143-3 2004 Sildenafil citrate, an inhibitor of the enzyme phosphodiesterase type 5 (PDE5), is the most widely prescribed oral agent and has a very satisfactory efficacy-safety profile in all patient categories. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 47-71 15155143-3 2004 Sildenafil citrate, an inhibitor of the enzyme phosphodiesterase type 5 (PDE5), is the most widely prescribed oral agent and has a very satisfactory efficacy-safety profile in all patient categories. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 73-77 15115191-1 2004 The mechanism of action of the phosphodiesterase type 5 (PDE5) inhibitors (i.e., sildenafil, tadalafil, and vardenafil) involves inhibition of the PDE5 isoenzyme located in penile vascular smooth muscle cells. Sildenafil Citrate 81-91 phosphodiesterase 5A Homo sapiens 57-61 15115191-1 2004 The mechanism of action of the phosphodiesterase type 5 (PDE5) inhibitors (i.e., sildenafil, tadalafil, and vardenafil) involves inhibition of the PDE5 isoenzyme located in penile vascular smooth muscle cells. Sildenafil Citrate 81-91 phosphodiesterase 5A Homo sapiens 147-151 15115191-7 2004 Differences in pharmacokinetic properties among the PDE5 inhibitors include the fact that sildenafil and vardenafil have a shorter duration of action (approximately 4 h) compared with the longer period of responsiveness observed with tadalafil (up to 36 h). Sildenafil Citrate 90-100 phosphodiesterase 5A Homo sapiens 52-56 15148932-1 2004 Since the introduction of the phosphodiesterase type 5 (PDE-5) inhibitor sildenafil in 1998, there has been a fundamental change in the treatment of erectile dysfunction (ED). Sildenafil Citrate 73-83 phosphodiesterase 5A Homo sapiens 30-54 15075013-6 2004 Three PDE5 inhibitors are currently available, sildenafil, vardenafil and tadalafil. Sildenafil Citrate 47-57 phosphodiesterase 5A Homo sapiens 6-10 15148932-1 2004 Since the introduction of the phosphodiesterase type 5 (PDE-5) inhibitor sildenafil in 1998, there has been a fundamental change in the treatment of erectile dysfunction (ED). Sildenafil Citrate 73-83 phosphodiesterase 5A Homo sapiens 56-61 14871543-1 2004 Phosphodiesterase type-5 (PDE-5) inhibitors including sildenafil, vardenafil and tadalafil are a new class of vasoactive drugs that have been developed for treatment of erectile dysfunction in patients. Sildenafil Citrate 54-64 phosphodiesterase 5A Homo sapiens 0-24 15083994-1 2004 Clinical evidence in men with erectile dysfunction (ED) shows that the phosphodiesterase type 5 (PDE5) inhibitors sildenafil citrate, tadalafil, and vardenafil hydrochloride have favorable safety and efficacy profiles. Sildenafil Citrate 114-132 phosphodiesterase 5A Homo sapiens 71-95 15083994-1 2004 Clinical evidence in men with erectile dysfunction (ED) shows that the phosphodiesterase type 5 (PDE5) inhibitors sildenafil citrate, tadalafil, and vardenafil hydrochloride have favorable safety and efficacy profiles. Sildenafil Citrate 114-132 phosphodiesterase 5A Homo sapiens 97-101 14871543-1 2004 Phosphodiesterase type-5 (PDE-5) inhibitors including sildenafil, vardenafil and tadalafil are a new class of vasoactive drugs that have been developed for treatment of erectile dysfunction in patients. Sildenafil Citrate 54-64 phosphodiesterase 5A Homo sapiens 26-31 14871543-5 2004 Future demonstration of the cardioprotective effect in patients with the relatively safe and effective FDA-approved PDE-5 inhibitors, such as sildenafil, could have an enormous impact on bringing the long-studied phenomena of ischemic and pharmacologic preconditioning to the clinical forefront. Sildenafil Citrate 142-152 phosphodiesterase 5A Homo sapiens 116-121 15322323-2 2004 In this monocentric, prospective, double-blind, placebo-controlled, randomized cross-over study we investigated the acute effect of 50 mg sildenafil, a selective PDE-5 inhibitor, on resting and post-ischemic capillary circulation in twenty patients with angiographically confirmed coronary artery disease not taking nitrates or NO-donors. Sildenafil Citrate 138-148 phosphodiesterase 5A Homo sapiens 162-167 14562139-3 2003 Sildenafil purified according to this protocol has been characterized with respect to its IC50 for PDE5, its ultraviolet absorption profile, and by collision-induced dissociation fingerprinting, positive ion nanospray, and MALDI mass spectrometry. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 99-103 15260511-10 2004 New PDE5 inhibitors such as vardenafil should be tried first as therapy for sildenafil nonresponders before exploring any combination therapy options. Sildenafil Citrate 76-86 phosphodiesterase 5A Homo sapiens 4-8 15537369-14 2004 Sildenafil was the first PDE5 inhibitor to undergo evaluation and has been studied extensively. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 25-29 14652001-5 2003 The PDE5 inhibitor, sildenafil (10nM), reversed diabetes-induced endothelial dysfunction in HCC, but not in HPRA. Sildenafil Citrate 20-30 phosphodiesterase 5A Homo sapiens 4-8 14622499-2 2003 Three potent and selective PDE-5 inhibitors (sildenafil, tadalafil, and vardenafil) have been approved for clinical use. Sildenafil Citrate 45-55 phosphodiesterase 5A Homo sapiens 27-32 14622500-3 2003 Oral therapy for ED, such as sildenafil, inhibits phosphodiesterase-5 (PDE-5) and the breakdown of cyclic guanosine monophosphate. Sildenafil Citrate 29-39 phosphodiesterase 5A Homo sapiens 50-69 14622500-3 2003 Oral therapy for ED, such as sildenafil, inhibits phosphodiesterase-5 (PDE-5) and the breakdown of cyclic guanosine monophosphate. Sildenafil Citrate 29-39 phosphodiesterase 5A Homo sapiens 71-76 14609619-7 2003 The prototype of this new therapeutic class of PDE5 inhibitors is sildenafil, which was approved for treatment of erectile dysfunction in 1998. Sildenafil Citrate 66-76 phosphodiesterase 5A Homo sapiens 47-51 14609621-3 2003 Most of the published data linking PDE5 inhibitor effects and cardiovascular disease relate to sildenafil, although >or=2 new agents are in various stages of development and clinical trials. Sildenafil Citrate 95-105 phosphodiesterase 5A Homo sapiens 35-39 14551572-3 2003 This article examines the correlation between the available biochemical and clinical data for the PDE 5 inhibitors sildenafil (Viagra), tadalafil (Cialis) and vardenafil (Levitra). Sildenafil Citrate 115-125 phosphodiesterase 5A Homo sapiens 98-103 14562136-15 2003 However, higher PDE5 activity was measured in the sildenafil group and lower activity of PDE5 was recorded in the cohort receiving vitamin E with sildenafil. Sildenafil Citrate 146-156 phosphodiesterase 5A Homo sapiens 89-93 14618646-7 2003 Sildenafil, a specific PDE5 inhibitor, appears the most promising of such agents. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 23-27 14618646-9 2003 The reasons why caution is warranted before specific PDE5 inhibitors like sildenafil are labelled as potential magic bullets for PPHN will be discussed. Sildenafil Citrate 74-84 phosphodiesterase 5A Homo sapiens 53-57 14693300-1 2003 BACKGROUND: Three inhibitors of phosphodiesterase 5 (PDE5) are now available for the treatment of erectile dysfunction (ED): sildenafil citrate, vardenafil, and tadalafil. Sildenafil Citrate 125-143 phosphodiesterase 5A Homo sapiens 32-51 14693300-1 2003 BACKGROUND: Three inhibitors of phosphodiesterase 5 (PDE5) are now available for the treatment of erectile dysfunction (ED): sildenafil citrate, vardenafil, and tadalafil. Sildenafil Citrate 125-143 phosphodiesterase 5A Homo sapiens 53-57 12842049-6 2003 Docking of the PDE5 inhibitor sildenafil into the PDE4 catalytic pocket further helps understand inhibitor selectivity. Sildenafil Citrate 30-40 phosphodiesterase 5A Homo sapiens 15-19 12955149-6 2003 Here we present the three-dimensional structures of the catalytic domain (residues 537-860) of human PDE5 complexed with the three drug molecules sildenafil, tadalafil (Cialis) and vardenafil (Levitra). Sildenafil Citrate 146-156 phosphodiesterase 5A Homo sapiens 101-105 12934045-5 2003 PDE5 inhibitors such as sildenafil promote the cGMP pathway, while alprostadil affects the cAMP pathway. Sildenafil Citrate 24-34 phosphodiesterase 5A Homo sapiens 0-4 12934045-10 2003 First-line therapy for other patients is typically oral PDE5 inhibitors, such as sildenafil, tadalafil, or vardenafil. Sildenafil Citrate 81-91 phosphodiesterase 5A Homo sapiens 56-60 14569380-2 2003 The introduction of the PDE-5 inhibitor Sildenafil, as the first highly potent oral therapy for ED, caused dramatic changes in the diagnostic and therapeutic strategies in this area. Sildenafil Citrate 40-50 phosphodiesterase 5A Homo sapiens 24-29 14569380-3 2003 The later PDE-5 inhibitors Tadalafil and Vardenafil show, as far as it is currently possible to judge, a similar profile to Sildenafil. Sildenafil Citrate 124-134 phosphodiesterase 5A Homo sapiens 10-15 12853767-1 2003 PURPOSE: We identify whether tachyphylaxis and priapism effects of sildenafil are related to regulation of phosphodiesterase-5 (PDE-5) expression. Sildenafil Citrate 67-77 phosphodiesterase 5A Homo sapiens 128-133 12853767-7 2003 RESULTS: Up-regulation of PDE-5 was noted in CSMCs treated with 25 microM sildenafil for 7 days. Sildenafil Citrate 74-84 phosphodiesterase 5A Homo sapiens 26-31 12853767-8 2003 PDE-5 messenger RNA and protein levels were significantly increased in the 7-day sildenafil treated cultures. Sildenafil Citrate 81-91 phosphodiesterase 5A Homo sapiens 0-5 12825147-10 2003 The phosphodiesterase type 5 (PDE-5) inhibitors sildenafil, vardenafil, and taldalafil are peripheral conditioners. Sildenafil Citrate 48-58 phosphodiesterase 5A Homo sapiens 4-28 12825143-15 2003 Sildenafil acts as a selective inhibitor of cyclic guanosine monophosphate-(cGMP-)specific phosphodiesterase type 5 (PDE 5), resulting in smooth muscle relaxation, vasodilation, and enhanced penile erection. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 117-122 12825143-19 2003 The risk of precipitating a cardiotoxic, hypotensive, or hemorrhagic event secondary to combining sildenafil (a PDE 5 inhibitor) with specific PDE 3 inhibitors such as milrinone and enoximone or with nonspecific PDE inhibitors such as theophylline and pentoxifylline is unlikely. Sildenafil Citrate 98-108 phosphodiesterase 5A Homo sapiens 112-117 12825147-10 2003 The phosphodiesterase type 5 (PDE-5) inhibitors sildenafil, vardenafil, and taldalafil are peripheral conditioners. Sildenafil Citrate 48-58 phosphodiesterase 5A Homo sapiens 30-35 12694895-1 2003 Sildenafil (Viagra) is a selective inhibitor of the cyclic guanosine monophosphate (cGMP) specific phosphodiesterase 5 (PDE5) used for the oral treatment of male erectile dysfunction due to vasodilation. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 99-118 12695418-0 2003 PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers. Sildenafil Citrate 15-33 phosphodiesterase 5A Homo sapiens 0-4 12695418-2 2003 The purpose of this study was to determine the effect of sildenafil, an inhibitor of phosphodiesterase type 5 (PDE5), on endothelial function in smokers. Sildenafil Citrate 57-67 phosphodiesterase 5A Homo sapiens 85-109 12695418-2 2003 The purpose of this study was to determine the effect of sildenafil, an inhibitor of phosphodiesterase type 5 (PDE5), on endothelial function in smokers. Sildenafil Citrate 57-67 phosphodiesterase 5A Homo sapiens 111-115 12695418-9 2003 The findings suggest that endothelial function is impaired in smokers compared with that in nonsmokers, that inhibition of PDE5 by sildenafil significantly increases nitric oxide-mediated vasodilation, and that the activities of PDE5 in smokers and nonsmokers may be similar. Sildenafil Citrate 131-141 phosphodiesterase 5A Homo sapiens 123-127 12761347-0 2003 [3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP. Sildenafil Citrate 4-14 phosphodiesterase 5A Homo sapiens 26-45 12761347-1 2003 Sildenafil (Viagra) potentiates penile erection by acting as a nonhydrolyzable analog of cGMP and competing with this nucleotide for catalysis by phosphodiesterase-5 (PDE5), but the characteristics of direct binding of radiolabeled sildenafil to PDE5 have not been determined. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 146-165 12761347-1 2003 Sildenafil (Viagra) potentiates penile erection by acting as a nonhydrolyzable analog of cGMP and competing with this nucleotide for catalysis by phosphodiesterase-5 (PDE5), but the characteristics of direct binding of radiolabeled sildenafil to PDE5 have not been determined. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 167-171 12761347-1 2003 Sildenafil (Viagra) potentiates penile erection by acting as a nonhydrolyzable analog of cGMP and competing with this nucleotide for catalysis by phosphodiesterase-5 (PDE5), but the characteristics of direct binding of radiolabeled sildenafil to PDE5 have not been determined. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 246-250 12761347-1 2003 Sildenafil (Viagra) potentiates penile erection by acting as a nonhydrolyzable analog of cGMP and competing with this nucleotide for catalysis by phosphodiesterase-5 (PDE5), but the characteristics of direct binding of radiolabeled sildenafil to PDE5 have not been determined. Sildenafil Citrate 12-18 phosphodiesterase 5A Homo sapiens 146-165 12761347-1 2003 Sildenafil (Viagra) potentiates penile erection by acting as a nonhydrolyzable analog of cGMP and competing with this nucleotide for catalysis by phosphodiesterase-5 (PDE5), but the characteristics of direct binding of radiolabeled sildenafil to PDE5 have not been determined. Sildenafil Citrate 12-18 phosphodiesterase 5A Homo sapiens 167-171 12761347-1 2003 Sildenafil (Viagra) potentiates penile erection by acting as a nonhydrolyzable analog of cGMP and competing with this nucleotide for catalysis by phosphodiesterase-5 (PDE5), but the characteristics of direct binding of radiolabeled sildenafil to PDE5 have not been determined. Sildenafil Citrate 12-18 phosphodiesterase 5A Homo sapiens 246-250 12761347-2 2003 [3H]Sildenafil binding to PDE5 was retained when filtered through nitrocellulose or glass-fiber membranes. Sildenafil Citrate 4-14 phosphodiesterase 5A Homo sapiens 26-30 12761347-4 2003 PDE5 was the only [3H]sildenafil binding protein detected in human lung extract. Sildenafil Citrate 22-32 phosphodiesterase 5A Homo sapiens 0-4 12761347-5 2003 Using purified recombinant PDE5, [3H]sildenafil exchange dissociation yielded two components with t1/2 values of 1 and 14 min and corresponding calculated KD values of 12 and 0.83 nM, respectively. Sildenafil Citrate 37-47 phosphodiesterase 5A Homo sapiens 27-31 12761347-7 2003 [3H]Sildenafil binding isotherm of PDE5 indicated KD was 8.3 to 13.3 nM, and low cGMP decreased the KD to 4.8 nM but only slightly increased Bmax to a maximum of 0.61 mol/mol-subunit. Sildenafil Citrate 4-14 phosphodiesterase 5A Homo sapiens 35-39 12761347-9 2003 Results imply that by inhibiting PDE5 and thereby increasing cGMP, sildenafil accentuates its own binding affinity for PDE5, which further elevates cGMP. Sildenafil Citrate 67-77 phosphodiesterase 5A Homo sapiens 33-37 12761347-9 2003 Results imply that by inhibiting PDE5 and thereby increasing cGMP, sildenafil accentuates its own binding affinity for PDE5, which further elevates cGMP. Sildenafil Citrate 67-77 phosphodiesterase 5A Homo sapiens 119-123 12694895-1 2003 Sildenafil (Viagra) is a selective inhibitor of the cyclic guanosine monophosphate (cGMP) specific phosphodiesterase 5 (PDE5) used for the oral treatment of male erectile dysfunction due to vasodilation. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 120-124 12694895-1 2003 Sildenafil (Viagra) is a selective inhibitor of the cyclic guanosine monophosphate (cGMP) specific phosphodiesterase 5 (PDE5) used for the oral treatment of male erectile dysfunction due to vasodilation. Sildenafil Citrate 12-18 phosphodiesterase 5A Homo sapiens 99-118 12694895-1 2003 Sildenafil (Viagra) is a selective inhibitor of the cyclic guanosine monophosphate (cGMP) specific phosphodiesterase 5 (PDE5) used for the oral treatment of male erectile dysfunction due to vasodilation. Sildenafil Citrate 12-18 phosphodiesterase 5A Homo sapiens 120-124 12614192-4 2003 Sildenafil is inhibitory of PDE5 at a rate tenfold higher than for the next PDE (PDE6), which produces visual changes through the retinal rods. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 28-32 12614192-10 2003 With the use of sildenafil, it has been clearly, clinically demonstrated that the selective inhibition of PDE5 is an appropriate, effective, safe method for the treatment of ED of all aetiologies and severities. Sildenafil Citrate 16-26 phosphodiesterase 5A Homo sapiens 106-110 12572636-2 2002 The introduction of sildenafil citrate, the first oral phosphodiesterase type 5 (PDE5) isoenzyme inhibitor, has helped to restore erectile function and improve overall health and quality of life. Sildenafil Citrate 20-38 phosphodiesterase 5A Homo sapiens 55-79 12477710-3 2003 We examined whether sildenafil (Viagra), a selective inhibitor of cGMP-hydrolysing phosphodiesterase 5 (PDE5), which acts exclusively by increasing cGMP, can induce migraine and dilatation of cerebral arteries. Sildenafil Citrate 20-30 phosphodiesterase 5A Homo sapiens 104-108 12477710-3 2003 We examined whether sildenafil (Viagra), a selective inhibitor of cGMP-hydrolysing phosphodiesterase 5 (PDE5), which acts exclusively by increasing cGMP, can induce migraine and dilatation of cerebral arteries. Sildenafil Citrate 32-38 phosphodiesterase 5A Homo sapiens 104-108 14687446-1 2003 OBJECTIVE: This study evaluated whether sildenafil citrate, an oral treatment for erectile dysfunction and a selective inhibitor of phosphodiesterase type 5 (PDE5) with modest vasodilating properties, affects cardiac contractility in vitro. Sildenafil Citrate 40-58 phosphodiesterase 5A Homo sapiens 132-156 14687446-1 2003 OBJECTIVE: This study evaluated whether sildenafil citrate, an oral treatment for erectile dysfunction and a selective inhibitor of phosphodiesterase type 5 (PDE5) with modest vasodilating properties, affects cardiac contractility in vitro. Sildenafil Citrate 40-58 phosphodiesterase 5A Homo sapiens 158-162 12494279-1 2002 Sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, has become a first-line therapy for diabetic patients with erectile dysfunction (ED). Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 14-33 12494279-1 2002 Sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, has become a first-line therapy for diabetic patients with erectile dysfunction (ED). Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 35-39 12554648-6 2003 Activated PDE5 showed higher sensitivity towards sildenafil than non-activated PDE5. Sildenafil Citrate 49-59 phosphodiesterase 5A Homo sapiens 10-14 12625845-4 2003 Sildenafil, tadalafil, and vardenafil are all potent inhibitors of PDE5 and show the same mechanism of action, although they have some pharmacological differences that may translate into varying clinical effects. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 67-71 12625847-5 2003 As such, sildenafil (and, likely, other new phosphodiesterase type 5 [PDE5] inhibitors) is contraindicated in men who use nitrate medications. Sildenafil Citrate 9-19 phosphodiesterase 5A Homo sapiens 44-68 12625847-5 2003 As such, sildenafil (and, likely, other new phosphodiesterase type 5 [PDE5] inhibitors) is contraindicated in men who use nitrate medications. Sildenafil Citrate 9-19 phosphodiesterase 5A Homo sapiens 70-74 12841917-1 2003 Sildenafil citrate (Viagra) is a potent orally active cGMP-specific phosphodiesterase type 5 (PDE5) inhibitor that is effective as a peripheral conditioner in the treatment of male erectile dysfunction (ED) of organic, psychogenic or mixed aetiology. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 94-98 12841917-1 2003 Sildenafil citrate (Viagra) is a potent orally active cGMP-specific phosphodiesterase type 5 (PDE5) inhibitor that is effective as a peripheral conditioner in the treatment of male erectile dysfunction (ED) of organic, psychogenic or mixed aetiology. Sildenafil Citrate 20-26 phosphodiesterase 5A Homo sapiens 94-98 12572636-2 2002 The introduction of sildenafil citrate, the first oral phosphodiesterase type 5 (PDE5) isoenzyme inhibitor, has helped to restore erectile function and improve overall health and quality of life. Sildenafil Citrate 20-38 phosphodiesterase 5A Homo sapiens 81-85 12437503-2 2002 Treatment options have widened since the launch of the phosphodiesterase type 5 (PDE5) inhibitor, sildenafil citrate (Viagra trade mark ). Sildenafil Citrate 98-116 phosphodiesterase 5A Homo sapiens 55-79 12437503-2 2002 Treatment options have widened since the launch of the phosphodiesterase type 5 (PDE5) inhibitor, sildenafil citrate (Viagra trade mark ). Sildenafil Citrate 98-116 phosphodiesterase 5A Homo sapiens 81-85 15570464-3 2002 PDE5 inhibitors were initially developed for a possible role in cardiovascular disease; their role in the treatment of erectile dysfunction was brought to the forefront by the development of sildenafil. Sildenafil Citrate 191-201 phosphodiesterase 5A Homo sapiens 0-4 12442206-8 2002 Recent data are indicative for a strong pulmonary vasodilative potency of the selective phosphodiesterase-5 (PDE5) inhibitor sildenafil. Sildenafil Citrate 125-135 phosphodiesterase 5A Homo sapiens 88-107 12442206-8 2002 Recent data are indicative for a strong pulmonary vasodilative potency of the selective phosphodiesterase-5 (PDE5) inhibitor sildenafil. Sildenafil Citrate 125-135 phosphodiesterase 5A Homo sapiens 109-113 12435622-0 2002 Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature. Sildenafil Citrate 86-96 phosphodiesterase 5A Homo sapiens 69-74 12435622-1 2002 Since introduction of the PDE-5 inhibitor sildenafil 4 years ago, there has been a fundamental change in the treatment of erectile dysfunction (ED). Sildenafil Citrate 42-52 phosphodiesterase 5A Homo sapiens 26-31 12192104-1 2002 Sildenafil is a potent and selective inhibitor of the cyclic GMP-specific phosphodiesterase (PDE5) that is very effective in the treatment of male impotence. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 93-97 12207947-1 2002 Viagra (sildenafil citrate) improves penile erections in men with erectile dysfunction (ED) by selectively inhibiting cGMP-specific phosphodiesterase type 5 (PDE5), which is present in all vascular tissue. Sildenafil Citrate 0-6 phosphodiesterase 5A Homo sapiens 158-162 12207947-1 2002 Viagra (sildenafil citrate) improves penile erections in men with erectile dysfunction (ED) by selectively inhibiting cGMP-specific phosphodiesterase type 5 (PDE5), which is present in all vascular tissue. Sildenafil Citrate 8-26 phosphodiesterase 5A Homo sapiens 158-162 12207947-13 2002 Based on this experience, intermittent, short-term, partial inhibition of PDE5 or PDE6 by sildenafil is unlikely to induce any long-term visual change. Sildenafil Citrate 90-100 phosphodiesterase 5A Homo sapiens 74-78 12414329-2 2002 Published literature on the nitric oxide-cyclic guanosine monophosphate (cGMP) pathway for penile erection and on PDE5 inhibition using sildenafil as the model for pharmacologic PDE5 inhibition are assessed. Sildenafil Citrate 136-146 phosphodiesterase 5A Homo sapiens 114-118 12414329-6 2002 This approach is validated by the clinical efficacy and safety of sildenafil, the pioneering drug for selective PDE5 inhibitor therapy for ED. Sildenafil Citrate 66-76 phosphodiesterase 5A Homo sapiens 112-116 12414329-7 2002 Sildenafil exhibits inhibitory potency against PDE5 and a 10-fold lower dose-related inhibitory potency against rod outer segment PDE6, the predominant PDE in the phototransduction cascade in rods. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 47-51 12414329-12 2002 Selective inhibition of PDE5 is a rational therapeutic approach in ED, as proved by the clinical success of sildenafil. Sildenafil Citrate 108-118 phosphodiesterase 5A Homo sapiens 24-28 12145231-2 2002 Sildenafil (Viagra) is an inhibitor of phosphodiesterase 5 (PDE-5), which is used for management of erectile dysfunction in a broad range of patients, including those with type 2 diabetes. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 39-58 12145231-2 2002 Sildenafil (Viagra) is an inhibitor of phosphodiesterase 5 (PDE-5), which is used for management of erectile dysfunction in a broad range of patients, including those with type 2 diabetes. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 60-65 12145231-2 2002 Sildenafil (Viagra) is an inhibitor of phosphodiesterase 5 (PDE-5), which is used for management of erectile dysfunction in a broad range of patients, including those with type 2 diabetes. Sildenafil Citrate 12-18 phosphodiesterase 5A Homo sapiens 39-58 12145231-2 2002 Sildenafil (Viagra) is an inhibitor of phosphodiesterase 5 (PDE-5), which is used for management of erectile dysfunction in a broad range of patients, including those with type 2 diabetes. Sildenafil Citrate 12-18 phosphodiesterase 5A Homo sapiens 60-65 12161769-2 2002 The most commonly reported adverse events of all causalities associated with sildenafil treatment were headache (19%), flushing (14%), dyspepsia (6%), and nasal congestion (4%), reflecting the inhibitory effects of sildenafil on cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) in the peripheral vasculature, gastroesophageal sphincter, and nasal mucosa. Sildenafil Citrate 77-87 phosphodiesterase 5A Homo sapiens 302-306 12086542-10 2002 Whether sildenafil causes these effects by inhibiting PDE-5 in the brain, accumulating cyclic-GMP, decreasing NO, and affecting cell-cell signaling and modulation of aggressive behavior requires further investigation. Sildenafil Citrate 8-18 phosphodiesterase 5A Homo sapiens 54-59 12002434-1 2002 Vardenafil and sildenafil are potent and specific phosphodiesterase type 5 (PDE 5) inhibitors. Sildenafil Citrate 15-25 phosphodiesterase 5A Homo sapiens 50-74 12002434-1 2002 Vardenafil and sildenafil are potent and specific phosphodiesterase type 5 (PDE 5) inhibitors. Sildenafil Citrate 15-25 phosphodiesterase 5A Homo sapiens 76-81 12358156-5 2002 Sildenafil, phosphodiesterase-(PDE)-5-selective inhibitor has been the drug of choice for patients with ED since it has been launched in March 1998. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 12-37 12209148-2 2002 Phosphodiesterase 5 (PDE5) inhibition is now a widely accepted and efficacious therapeutic option for the treatment of erectile dysfunction in men, as a result of extensive clinical experience with sildenafil and other new PDE5 inhibitors. Sildenafil Citrate 198-208 phosphodiesterase 5A Homo sapiens 0-19 12209148-2 2002 Phosphodiesterase 5 (PDE5) inhibition is now a widely accepted and efficacious therapeutic option for the treatment of erectile dysfunction in men, as a result of extensive clinical experience with sildenafil and other new PDE5 inhibitors. Sildenafil Citrate 198-208 phosphodiesterase 5A Homo sapiens 21-25 11815339-1 2002 BACKGROUND: The cardiovascular effects of sildenafil (Viagra), a selective inhibitor of phosphodiesterase type 5 (PDE5), have been extensively studied. Sildenafil Citrate 42-52 phosphodiesterase 5A Homo sapiens 88-112 11815339-1 2002 BACKGROUND: The cardiovascular effects of sildenafil (Viagra), a selective inhibitor of phosphodiesterase type 5 (PDE5), have been extensively studied. Sildenafil Citrate 42-52 phosphodiesterase 5A Homo sapiens 114-118 11815339-1 2002 BACKGROUND: The cardiovascular effects of sildenafil (Viagra), a selective inhibitor of phosphodiesterase type 5 (PDE5), have been extensively studied. Sildenafil Citrate 54-60 phosphodiesterase 5A Homo sapiens 88-112 11815339-1 2002 BACKGROUND: The cardiovascular effects of sildenafil (Viagra), a selective inhibitor of phosphodiesterase type 5 (PDE5), have been extensively studied. Sildenafil Citrate 54-60 phosphodiesterase 5A Homo sapiens 114-118 11890515-15 2001 Vardenafil was more potent and selective than sildenafil on its inhibitory activity on PDE5. Sildenafil Citrate 46-56 phosphodiesterase 5A Homo sapiens 87-91 11896473-1 2002 Sildenafil improves erectile function by inhibiting the cGMP-catalytic activity of phosphodiesterase type V (PDE5). Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 109-113 11696815-3 2001 With the introduction of the phosphodiesterase (PDE) 5 inhibitor sildenafil the concept of PDE inhibition has gained tremendous interest in the field of urology. Sildenafil Citrate 65-75 phosphodiesterase 5A Homo sapiens 48-54 11770869-2 2001 This study sought to evaluate whether PDE5 inhibition with sildenafil exerts any effect on exercise-induced myocardial ischemia in patients on beta-blockers. Sildenafil Citrate 59-69 phosphodiesterase 5A Homo sapiens 38-42 12836729-3 2002 Sildenafil citrate (Viagra) is a potent and selective PDE-5 inhibitor, which is the first drug in this class to be approved for treatment of ED. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 54-59 12836729-3 2002 Sildenafil citrate (Viagra) is a potent and selective PDE-5 inhibitor, which is the first drug in this class to be approved for treatment of ED. Sildenafil Citrate 20-26 phosphodiesterase 5A Homo sapiens 54-59 11760783-7 2001 The PDE 5 specific inhibitor sildenafil (Viagra) has revolutionized the treatment of patients with erectile dysfunction. Sildenafil Citrate 29-39 phosphodiesterase 5A Homo sapiens 4-9 11408180-4 2001 On the other hand, sildenafil showed the least co-planarity with the torsional angle of 23 degrees compared with the target compounds, 6a--d and 7a--d. In the enzyme assay, however, the in vitro PDE 5 inhibitory activity was found out to be inversely related to the degree of co-planarity. Sildenafil Citrate 19-29 phosphodiesterase 5A Homo sapiens 195-200 11669467-3 2001 In this study, we compared the inhibition of cGMP hydrolysis by vardenafil and sildenafil; two inhibitors selective for phosphodiesterase type 5 (PDE5). Sildenafil Citrate 79-89 phosphodiesterase 5A Homo sapiens 120-144 11557915-1 2001 BACKGROUND: Sildenafil, a treatment for erectile dysfunction, is a specific phosphodiesterase type 5 (PDE 5) inhibitor that enhances nitric oxide (NO)-mediated vasodilation in the corpus cavernosum by inhibiting cyclic guanosine monophosphate breakdown. Sildenafil Citrate 12-22 phosphodiesterase 5A Homo sapiens 76-100 11557915-1 2001 BACKGROUND: Sildenafil, a treatment for erectile dysfunction, is a specific phosphodiesterase type 5 (PDE 5) inhibitor that enhances nitric oxide (NO)-mediated vasodilation in the corpus cavernosum by inhibiting cyclic guanosine monophosphate breakdown. Sildenafil Citrate 12-22 phosphodiesterase 5A Homo sapiens 102-107 11306686-3 2001 Organic nitrates [glycerol trinitrate (GTN), isosorbide 5"-mononitrate (ISMN), pentaerythrityl-tetranitrate (PETN)] and the PDE5 inhibitor sildenafil reduced PDGF-induced DNA synthesis, measured by ((3)H]thymidine incorporation. Sildenafil Citrate 139-149 phosphodiesterase 5A Homo sapiens 124-128 11289569-0 2001 Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor: urologic and cardiovascular implications. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 32-56 11351772-1 2001 As a potent and selective inhibitor of cyclic guanosine monophosphate-specific phosphodiesterase 5 (PDE5), sildenafil citrate (Viagra) is safe and effective in men with erectile dysfunction (ED) of diverse aetiologies, including patients with common cardiovascular diseases who are not receiving organic nitrates or nitrate donor drugs. Sildenafil Citrate 107-125 phosphodiesterase 5A Homo sapiens 100-104 11289565-2 2001 The first promising clinical data on the use of the orally active PDE5 inhibitor Sildenafil in the treatment of erectile dysfunction were accompanied by boosting research activities on cavernous intracellular signal transduction and phosphodiesterase characterization with the aid of molecular biology and protein chemistry. Sildenafil Citrate 81-91 phosphodiesterase 5A Homo sapiens 66-70 11162575-1 2001 PDE5A gene encodes type 5 phosphodiesterase (PDE5), the principal cGMP-catalyzing enzyme in the penis and the primary target of sildenafil (Viagra). Sildenafil Citrate 128-138 phosphodiesterase 5A Homo sapiens 0-5 11162575-1 2001 PDE5A gene encodes type 5 phosphodiesterase (PDE5), the principal cGMP-catalyzing enzyme in the penis and the primary target of sildenafil (Viagra). Sildenafil Citrate 128-138 phosphodiesterase 5A Homo sapiens 0-4 11162575-1 2001 PDE5A gene encodes type 5 phosphodiesterase (PDE5), the principal cGMP-catalyzing enzyme in the penis and the primary target of sildenafil (Viagra). Sildenafil Citrate 140-146 phosphodiesterase 5A Homo sapiens 0-5 11162575-1 2001 PDE5A gene encodes type 5 phosphodiesterase (PDE5), the principal cGMP-catalyzing enzyme in the penis and the primary target of sildenafil (Viagra). Sildenafil Citrate 140-146 phosphodiesterase 5A Homo sapiens 0-4 11162576-1 2001 PDE5A gene encodes type 5 phosphodiesterase (PDE5), the principal cGMP-catalyzing enzyme in the penis and the primary target of sildenafil (Viagra). Sildenafil Citrate 128-138 phosphodiesterase 5A Homo sapiens 0-5 11162576-1 2001 PDE5A gene encodes type 5 phosphodiesterase (PDE5), the principal cGMP-catalyzing enzyme in the penis and the primary target of sildenafil (Viagra). Sildenafil Citrate 128-138 phosphodiesterase 5A Homo sapiens 0-4 11162576-1 2001 PDE5A gene encodes type 5 phosphodiesterase (PDE5), the principal cGMP-catalyzing enzyme in the penis and the primary target of sildenafil (Viagra). Sildenafil Citrate 140-146 phosphodiesterase 5A Homo sapiens 0-5 11162576-1 2001 PDE5A gene encodes type 5 phosphodiesterase (PDE5), the principal cGMP-catalyzing enzyme in the penis and the primary target of sildenafil (Viagra). Sildenafil Citrate 140-146 phosphodiesterase 5A Homo sapiens 0-4 10893544-0 2000 New PDE5 inhibitors: more selective than Viagra? Sildenafil Citrate 41-47 phosphodiesterase 5A Homo sapiens 4-8 11053205-1 2000 Sildenafil (0.1 - 30 microM), a cyclic GMP phosphodiesterase 5 (PDE 5) inhibitor, induced inhibition of electrically evoked contractions of ring segments of human vas deferens from 34 vasectomies. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 64-69 10913932-7 2000 Papaverine is a non-specific inhibitor of these enzymes; sildenafil is an orally active, potent and selective inhibitor of GMP-specific PDE5, the predominant isoenzyme metabolizing cGMP in the cells of the corpus cavernosum. Sildenafil Citrate 57-67 phosphodiesterase 5A Homo sapiens 136-140 11137498-3 2000 Sildenafil is a potent and selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP). Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 50-74 11137498-3 2000 Sildenafil is a potent and selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP). Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 76-80 11137498-7 2000 Because PDE5 is also present in small amounts in the systemic vasculature, sildenafil can cause a synergistic and major decrease in pressure when combined with organic nitrates. Sildenafil Citrate 75-85 phosphodiesterase 5A Homo sapiens 8-12 10953172-3 2000 It had been shown that milrinone, a PDE3 inhibitor, was as potent as sildenafil, a PDE5 inhibitor, in relaxing human corpus cavernosum. Sildenafil Citrate 69-79 phosphodiesterase 5A Homo sapiens 83-87 11152621-2 2000 Incubation of primary cultures of HCC smooth muscle cells with either the NO donor sodium nitroprusside (SNP, 10 microM) or the phosphodiesterase type 5 (PDE 5) inhibitor sildenafil (50 nM) produced little or no changes in the intracellular cGMP levels. Sildenafil Citrate 171-181 phosphodiesterase 5A Homo sapiens 128-152 10899281-3 2000 Sildenafil inhibits phosphodiesterase-5 (PDE-5) which is found in the corpus cavernosum and in the systemic vasculature. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 20-39 10899281-3 2000 Sildenafil inhibits phosphodiesterase-5 (PDE-5) which is found in the corpus cavernosum and in the systemic vasculature. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 41-46 11152621-2 2000 Incubation of primary cultures of HCC smooth muscle cells with either the NO donor sodium nitroprusside (SNP, 10 microM) or the phosphodiesterase type 5 (PDE 5) inhibitor sildenafil (50 nM) produced little or no changes in the intracellular cGMP levels. Sildenafil Citrate 171-181 phosphodiesterase 5A Homo sapiens 154-159 10584234-2 1999 Sildenafil (VIAGRA) selectively inhibited phosphodiesterase type 5 (PDE5) activity in the human corpus cavernosum and increased cGMP concentrations in the rabbit cavernosum in the presence of NO. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 68-72 10693332-1 2000 Sildenafil is a selective and by oral administration potent type-5 phosphodiesterase (PDE 5) inhibitor, which increases the erection by corpus cavernosum smooth muscle relaxation. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 86-91 10574925-6 1999 The catalytic fragment and full-length PDE5 have similar IC(50) values for the inhibitors 3-isobutyl-1-methylxanthine (20 microM) and sildenafil (Viagra(TM))(4 nM). Sildenafil Citrate 134-144 phosphodiesterase 5A Homo sapiens 39-43 10574925-6 1999 The catalytic fragment and full-length PDE5 have similar IC(50) values for the inhibitors 3-isobutyl-1-methylxanthine (20 microM) and sildenafil (Viagra(TM))(4 nM). Sildenafil Citrate 146-152 phosphodiesterase 5A Homo sapiens 39-43 12567500-2 1999 Sildenafil is a selective inhibitor of cGMP-specific phosphodiesterase (PDE-5). Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 72-77 10753463-1 2000 Phosphodiesterase type 5 (PDE5) inhibitors with improved PDE isozyme selectivity relative to sildenafil may result in agents for the treatment of male erectile dysfunction (MED) with a lower incidence of PDE-associated adverse effects. Sildenafil Citrate 93-103 phosphodiesterase 5A Homo sapiens 26-30 10753463-2 2000 This paper describes the discovery of 14, a PDE5 inhibitor with improved potency and selectivity in vitro compared to sildenafil. Sildenafil Citrate 118-128 phosphodiesterase 5A Homo sapiens 44-48 16107932-13 2000 The widespread use of Viagra (sildenafil; Pfizer Inc) over the last year has reinforced the perception that PDE5 inhibitors are safe and effective agents for the treatment of MED. Sildenafil Citrate 22-28 phosphodiesterase 5A Homo sapiens 108-112 16107932-13 2000 The widespread use of Viagra (sildenafil; Pfizer Inc) over the last year has reinforced the perception that PDE5 inhibitors are safe and effective agents for the treatment of MED. Sildenafil Citrate 30-40 phosphodiesterase 5A Homo sapiens 108-112 10654914-1 2000 OBJECTIVES: To further investigate the mechanism of action of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase 5 (PDE5), that has been proved to be effective in the treatment of male erectile dysfunction. Sildenafil Citrate 62-72 phosphodiesterase 5A Homo sapiens 167-171 10584234-2 1999 Sildenafil (VIAGRA) selectively inhibited phosphodiesterase type 5 (PDE5) activity in the human corpus cavernosum and increased cGMP concentrations in the rabbit cavernosum in the presence of NO. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 42-66 10541153-1 1999 Sildenafil citrate (Viagra) is a new oral medication that inhibits phosphodiesterase-5 (PDE5) in the corpus cavernosum to facilitate penile erection for the treatment of male impotence. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 67-86 10541153-1 1999 Sildenafil citrate (Viagra) is a new oral medication that inhibits phosphodiesterase-5 (PDE5) in the corpus cavernosum to facilitate penile erection for the treatment of male impotence. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 88-92 10541153-1 1999 Sildenafil citrate (Viagra) is a new oral medication that inhibits phosphodiesterase-5 (PDE5) in the corpus cavernosum to facilitate penile erection for the treatment of male impotence. Sildenafil Citrate 20-26 phosphodiesterase 5A Homo sapiens 67-86 10541153-1 1999 Sildenafil citrate (Viagra) is a new oral medication that inhibits phosphodiesterase-5 (PDE5) in the corpus cavernosum to facilitate penile erection for the treatment of male impotence. Sildenafil Citrate 20-26 phosphodiesterase 5A Homo sapiens 88-92 10584234-2 1999 Sildenafil (VIAGRA) selectively inhibited phosphodiesterase type 5 (PDE5) activity in the human corpus cavernosum and increased cGMP concentrations in the rabbit cavernosum in the presence of NO. Sildenafil Citrate 12-18 phosphodiesterase 5A Homo sapiens 42-66 10584234-2 1999 Sildenafil (VIAGRA) selectively inhibited phosphodiesterase type 5 (PDE5) activity in the human corpus cavernosum and increased cGMP concentrations in the rabbit cavernosum in the presence of NO. Sildenafil Citrate 12-18 phosphodiesterase 5A Homo sapiens 68-72 10584234-8 1999 It should be noted, however, that sildenafil enhanced the hypotensive effect of glyceryl trinitrate, as a result of inhibition of PDE5 in vascular smooth muscle. Sildenafil Citrate 34-44 phosphodiesterase 5A Homo sapiens 130-134 10385692-2 1999 Sildenafil (Viagra), a specific PDE5 inhibitor, promotes penile erection by blocking the activity of PDE5, which causes cGMP to accumulate in the corpus cavernosum. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 32-36 10385692-2 1999 Sildenafil (Viagra), a specific PDE5 inhibitor, promotes penile erection by blocking the activity of PDE5, which causes cGMP to accumulate in the corpus cavernosum. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 101-105 10385692-2 1999 Sildenafil (Viagra), a specific PDE5 inhibitor, promotes penile erection by blocking the activity of PDE5, which causes cGMP to accumulate in the corpus cavernosum. Sildenafil Citrate 12-18 phosphodiesterase 5A Homo sapiens 32-36 10385692-2 1999 Sildenafil (Viagra), a specific PDE5 inhibitor, promotes penile erection by blocking the activity of PDE5, which causes cGMP to accumulate in the corpus cavernosum. Sildenafil Citrate 12-18 phosphodiesterase 5A Homo sapiens 101-105 10385692-3 1999 In the present study, sildenafil, like other PDE5 inhibitors, stimulates cGMP binding to the allosteric sites of PDE5 by interacting at the catalytic site of this enzyme, but the drug does not compete with cGMP for binding at the allosteric sites. Sildenafil Citrate 22-32 phosphodiesterase 5A Homo sapiens 45-49 10385692-3 1999 In the present study, sildenafil, like other PDE5 inhibitors, stimulates cGMP binding to the allosteric sites of PDE5 by interacting at the catalytic site of this enzyme, but the drug does not compete with cGMP for binding at the allosteric sites. Sildenafil Citrate 22-32 phosphodiesterase 5A Homo sapiens 113-117 10385692-4 1999 Both sildenafil and zaprinast are competitive inhibitors of PDE5, and double-inhibition analysis shows that these two inhibitors added together interact with the catalytic site of PDE5 in a mutually exclusive manner. Sildenafil Citrate 5-15 phosphodiesterase 5A Homo sapiens 60-64 10385692-4 1999 Both sildenafil and zaprinast are competitive inhibitors of PDE5, and double-inhibition analysis shows that these two inhibitors added together interact with the catalytic site of PDE5 in a mutually exclusive manner. Sildenafil Citrate 5-15 phosphodiesterase 5A Homo sapiens 180-184 10385692-5 1999 After site-directed mutagenesis of each of 23 conserved amino acid residues in the catalytic domain of PDE5, the pattern of changes in the IC50 values for sildenafil or UK-122764 is similar to that found for zaprinast. Sildenafil Citrate 155-165 phosphodiesterase 5A Homo sapiens 103-107 10385692-7 1999 This may explain in part the stronger inhibitory potency of sildenafil for wild-type PDE5 compared with the other inhibitors [sildenafil (Ki = 1 nM) > UK-122764 (Ki = 5 nM) > zaprinast (Ki = 130 nM)]. Sildenafil Citrate 60-70 phosphodiesterase 5A Homo sapiens 85-89 10385692-9 1999 It is concluded that residues such as Tyr602, His607, His643, and Asp754 may form important interactions for sildenafil in PDE5, but because these amino acids are conserved in all mammalian PDEs, the selectivity and potency of sildenafil is likely to be provided by a nonconserved residue or residues in the PDE5 catalytic domain. Sildenafil Citrate 109-119 phosphodiesterase 5A Homo sapiens 123-127 10385692-9 1999 It is concluded that residues such as Tyr602, His607, His643, and Asp754 may form important interactions for sildenafil in PDE5, but because these amino acids are conserved in all mammalian PDEs, the selectivity and potency of sildenafil is likely to be provided by a nonconserved residue or residues in the PDE5 catalytic domain. Sildenafil Citrate 109-119 phosphodiesterase 5A Homo sapiens 308-312 8858389-6 1996 Sildenafil is a selective inhibitor of PDE5 with a mean IC50 of 0.0039 microM. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 39-43 10078537-7 1999 The distribution of PDE5 in the cardiovascular system is consistent with the observed pharmacodynamic and clinical effects of sildenafil. Sildenafil Citrate 126-136 phosphodiesterase 5A Homo sapiens 20-24 10078537-9 1999 Sildenafil selectively increased cGMP levels in coronary vascular smooth muscle tissue but produced no change in cyclic adenosine monophosphate (cAMP) levels, which is consistent with the drug"s selectivity for PDE5. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 211-215 10078537-11 1999 Human platelets were found to contain PDE5, which was inhibited by 50% (IC50) by sildenafil at a concentration of 6.3 nM, consistent with the IC50 value in the corpus cavernosum. Sildenafil Citrate 81-91 phosphodiesterase 5A Homo sapiens 38-42 10078537-13 1999 The pharmacodynamic and adverse event profiles observed in clinical trials with sildenafil are consistent with the in vitro profile of the tissue distribution of PDE5 and its known mechanism of action as a selective inhibitor of PDE5. Sildenafil Citrate 80-90 phosphodiesterase 5A Homo sapiens 162-166 10078537-13 1999 The pharmacodynamic and adverse event profiles observed in clinical trials with sildenafil are consistent with the in vitro profile of the tissue distribution of PDE5 and its known mechanism of action as a selective inhibitor of PDE5. Sildenafil Citrate 80-90 phosphodiesterase 5A Homo sapiens 229-233 10078538-2 1999 Sildenafil, which selectively inhibits phosphodiesterase type 5 (PDE5) found predominantly in the corpora cavernosa of the penis, effectively blocks the degradation of cGMP and enhances erectile function in men with erectile dysfunction. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 39-63 10078538-2 1999 Sildenafil, which selectively inhibits phosphodiesterase type 5 (PDE5) found predominantly in the corpora cavernosa of the penis, effectively blocks the degradation of cGMP and enhances erectile function in men with erectile dysfunction. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 65-69 10078539-1 1999 Sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), is a well-tolerated and highly effective treatment for erectile dysfunction. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 110-114 10078540-2 1999 Sildenafil citrate, an orally active, selective inhibitor of phosphodiesterase type 5 (PDE5), has demonstrated excellent efficacy and safety profiles in men with erectile dysfunction of various etiologies. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 61-85 10078540-2 1999 Sildenafil citrate, an orally active, selective inhibitor of phosphodiesterase type 5 (PDE5), has demonstrated excellent efficacy and safety profiles in men with erectile dysfunction of various etiologies. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 87-91 10078541-1 1999 Sildenafil, a selective inhibitor of phosphodiesterase type 5 (PDE5), is the first in a new class of orally effective treatments for erectile dysfunction. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 37-61 10078541-1 1999 Sildenafil, a selective inhibitor of phosphodiesterase type 5 (PDE5), is the first in a new class of orally effective treatments for erectile dysfunction. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 63-67 10078541-3 1999 Sildenafil facilitates the erectile process during sexual stimulation by inhibiting PDE5 and thus blocking the breakdown of cGMP. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 84-88 12973386-5 1999 Sildenafil causes an erection by inhibiting PDE5, which in turn causes an increase in the intracellular levels of cGMP. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 44-48 10078537-1 1999 Sildenafil is a selective inhibitor of phosphodiesterase type 5 (PDE5), which has been shown to be a clinically effective treatment for erectile dysfunction. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 39-63 10078537-1 1999 Sildenafil is a selective inhibitor of phosphodiesterase type 5 (PDE5), which has been shown to be a clinically effective treatment for erectile dysfunction. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 65-69 9916601-1 1998 Sildenafil citrate, an oral therapy for erectile dysfunction, is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), the predominant isozyme metabolizing cGMP in the corpus cavernosum. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 163-167 9916601-3 1998 Sildenafil has no direct relaxant effect on human corpus cavernosum but enhances the relaxant effect of nitric oxide (NO) on the corpus cavernosum by inhibiting PDE5, which is responsible for degradation of cGMP in this tissue. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 161-165 9916601-4 1998 When sexual stimulation causes local release of NO, inhibition of PDE5 by sildenafil increases concentrations of cGMP in the corpus cavernosum, causing smooth muscle relaxation and blood flow into the penis, resulting in an erection. Sildenafil Citrate 74-84 phosphodiesterase 5A Homo sapiens 66-70 9598563-1 1998 PURPOSE: Sildenafil, an inhibitor of cGMP-specific phosphodiesterase 5 (PDE5), is currently undergoing evaluation as an oral therapy for penile erectile dysfunction. Sildenafil Citrate 9-19 phosphodiesterase 5A Homo sapiens 72-76 9598563-7 1998 Compared with zaprinast, an early PDE5 inhibitor, sildenafil was approximately 240-fold more potent, inhibiting PDE5 from HCC with a geometric mean IC50 of 3.5 nM. Sildenafil Citrate 50-60 phosphodiesterase 5A Homo sapiens 34-38 9598563-7 1998 Compared with zaprinast, an early PDE5 inhibitor, sildenafil was approximately 240-fold more potent, inhibiting PDE5 from HCC with a geometric mean IC50 of 3.5 nM. Sildenafil Citrate 50-60 phosphodiesterase 5A Homo sapiens 112-116 9598563-10 1998 Sildenafil is a potent inhibitor of PDE5 from HCC, with high selectivity for PDE5 relative to other PDE isozymes. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 36-40 9598563-10 1998 Sildenafil is a potent inhibitor of PDE5 from HCC, with high selectivity for PDE5 relative to other PDE isozymes. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 77-81 8858389-8 1996 Moreover, in a clinical study of 12 patients with erectile dysfunction without an established organic cause, we have shown sildenafil to enhance the erectile response (duration and rigidity of erection) to visual sexual stimulation, thus highlighting the important role of PDE5 in human penile erection. Sildenafil Citrate 123-133 phosphodiesterase 5A Homo sapiens 273-277 33809319-1 2021 Phosphodiesterase type 5 (PDE5) inhibitors such as Viagra (sildenafil citrate) have demonstrated efficacy in the treatment of erectile dysfunction (ED) by inducing cyclic guanosine monophosphate (cGMP) elevation followed by vasodilation and increased blood flow. Sildenafil Citrate 51-57 phosphodiesterase 5A Homo sapiens 0-24 33809319-1 2021 Phosphodiesterase type 5 (PDE5) inhibitors such as Viagra (sildenafil citrate) have demonstrated efficacy in the treatment of erectile dysfunction (ED) by inducing cyclic guanosine monophosphate (cGMP) elevation followed by vasodilation and increased blood flow. Sildenafil Citrate 51-57 phosphodiesterase 5A Homo sapiens 26-30 33809319-1 2021 Phosphodiesterase type 5 (PDE5) inhibitors such as Viagra (sildenafil citrate) have demonstrated efficacy in the treatment of erectile dysfunction (ED) by inducing cyclic guanosine monophosphate (cGMP) elevation followed by vasodilation and increased blood flow. Sildenafil Citrate 60-78 phosphodiesterase 5A Homo sapiens 0-24 33809319-1 2021 Phosphodiesterase type 5 (PDE5) inhibitors such as Viagra (sildenafil citrate) have demonstrated efficacy in the treatment of erectile dysfunction (ED) by inducing cyclic guanosine monophosphate (cGMP) elevation followed by vasodilation and increased blood flow. Sildenafil Citrate 60-78 phosphodiesterase 5A Homo sapiens 26-30 26253809-1 2015 Sildenafil is a selective inhibitor of cGMP-specific type 5 phosphodiesterase (PDE5) used for the treatment of masculine erectile dysfunction and Pulmonary Arterial Hypertension (PAH). Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 79-83 34861900-3 2021 The STRIDER Consortium conducted four randomised trials to investigate the use of a PDE-5 inhibitor, sildenafil, for the treatment of early onset fetal growth restriction. Sildenafil Citrate 101-111 phosphodiesterase 5A Homo sapiens 84-89 15924597-5 2005 Viagra (sildenafil citrate), the first-in-class phosphodiesterase type 5 (PDE5) inhibitor, was introduced in 1998 for the treatment of ED. Sildenafil Citrate 0-6 phosphodiesterase 5A Homo sapiens 48-72 15924597-5 2005 Viagra (sildenafil citrate), the first-in-class phosphodiesterase type 5 (PDE5) inhibitor, was introduced in 1998 for the treatment of ED. Sildenafil Citrate 0-6 phosphodiesterase 5A Homo sapiens 74-78 15924597-5 2005 Viagra (sildenafil citrate), the first-in-class phosphodiesterase type 5 (PDE5) inhibitor, was introduced in 1998 for the treatment of ED. Sildenafil Citrate 8-26 phosphodiesterase 5A Homo sapiens 48-72 15924597-5 2005 Viagra (sildenafil citrate), the first-in-class phosphodiesterase type 5 (PDE5) inhibitor, was introduced in 1998 for the treatment of ED. Sildenafil Citrate 8-26 phosphodiesterase 5A Homo sapiens 74-78 34768607-0 2021 Sildenafil Citrate Downregulates PDE5A mRNA Expression in Women with Recurrent Pregnancy Loss without Altering Angiogenic Factors-A Preliminary Study. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 33-38 34768119-9 2021 CONCLUSION: PDE-5 inhibitors administration, especially sildenafil, may improve uteroplacental, but not fetal cerebral blood perfusion in pregnancies complicated by FGR. Sildenafil Citrate 56-66 phosphodiesterase 5A Homo sapiens 12-17 34453753-1 2021 INTRODUCTION: For phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil, the only approved indication in women is for pulmonary arterial hypertension. Sildenafil Citrate 70-80 phosphodiesterase 5A Homo sapiens 18-42 34453753-1 2021 INTRODUCTION: For phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil, the only approved indication in women is for pulmonary arterial hypertension. Sildenafil Citrate 70-80 phosphodiesterase 5A Homo sapiens 44-48 34453753-9 2021 Sildenafil was the most used PDE5 inhibitor. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 29-33 34768607-1 2021 In our previous study, we showed that sildenafil citrate (SC), a selective PDE5A blocker, modulated NK cell activity in patients with recurrent pregnancy loss, which correlated with positive pregnancy outcomes. Sildenafil Citrate 38-56 phosphodiesterase 5A Homo sapiens 75-80 34768607-1 2021 In our previous study, we showed that sildenafil citrate (SC), a selective PDE5A blocker, modulated NK cell activity in patients with recurrent pregnancy loss, which correlated with positive pregnancy outcomes. Sildenafil Citrate 58-60 phosphodiesterase 5A Homo sapiens 75-80 34175342-1 2022 Sildenafil citrate is a selective oral phosphodiesterase 5 (PDE5) inhibitor, a widely used drug for erectile dysfunction that acts by elevating cGMP levels and causing smooth muscle relaxation. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 39-58 34986542-3 2021 In recent years, a series of researches suggest that PDE inhibitors such as several PDE4 inhibitors, PDE5 inhibitors (sildenafil, tadalafil and vardenafil), PDE3 inhibitors (cilostazol), PDE9 inhibitor (PF-04447943) and PDE3/PDE4 double inhibitor (pumafentrine) have ameliorating effect on experimental colitis in animals. Sildenafil Citrate 118-128 phosphodiesterase 5A Homo sapiens 101-105 34685745-3 2021 Sildenafil is a selective inhibitor of the enzyme phosphodiesterase 5 (PDE5) that is able to cross the blood-brain barrier. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 50-69 34685745-3 2021 Sildenafil is a selective inhibitor of the enzyme phosphodiesterase 5 (PDE5) that is able to cross the blood-brain barrier. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 71-75 34820318-1 2021 Sildenafil is a specific inhibitor of the phosphodiesterase type 5 (PDE-5) enzyme that protects cyclic guanosine monophosphate from breakdown by PDE-5. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 42-66 34820318-1 2021 Sildenafil is a specific inhibitor of the phosphodiesterase type 5 (PDE-5) enzyme that protects cyclic guanosine monophosphate from breakdown by PDE-5. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 68-73 34820318-1 2021 Sildenafil is a specific inhibitor of the phosphodiesterase type 5 (PDE-5) enzyme that protects cyclic guanosine monophosphate from breakdown by PDE-5. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 145-150 34557099-9 2021 Moreover, comparing among different PDE5 inhibitors, sildenafil 50 mg or sildenafil 100 mg were considered the most effective compounds in the general population. Sildenafil Citrate 53-63 phosphodiesterase 5A Homo sapiens 36-40 34746425-2 2021 Vasodilating phosphodiesterase inhibitors may improve cardiovascular pulsatility and reactivity, and potentially reduce progression of SVD.Hypothesis: Sildenafil, a PDE5 inhibitor, will reduce cerebrovascular pulsatility and increase cerebrovascular reactivity compared to placebo, and is non-inferior to cilostazol, a PDE3 inhibitor. Sildenafil Citrate 151-161 phosphodiesterase 5A Homo sapiens 165-169 34300281-1 2021 Sildenafil citrate (SC), a PDE5 inhibitor, a drug for erectile dysfunction (ED) and pulmonary hypertension (PAH), was found to exert a positive effect on pregnancy outcomes when administered intravaginally before conception. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 27-31 34300281-1 2021 Sildenafil citrate (SC), a PDE5 inhibitor, a drug for erectile dysfunction (ED) and pulmonary hypertension (PAH), was found to exert a positive effect on pregnancy outcomes when administered intravaginally before conception. Sildenafil Citrate 20-22 phosphodiesterase 5A Homo sapiens 27-31 34205602-3 2021 Sildenafil is a potent inhibitor of phosphodiesterase 5 (PDE-5) used for the treatment of erectile dysfunction (ED) through the relaxation of smooth muscles and the modulation of vascular endothelial permeability. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 36-55 34205602-3 2021 Sildenafil is a potent inhibitor of phosphodiesterase 5 (PDE-5) used for the treatment of erectile dysfunction (ED) through the relaxation of smooth muscles and the modulation of vascular endothelial permeability. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 57-62 34175342-1 2022 Sildenafil citrate is a selective oral phosphodiesterase 5 (PDE5) inhibitor, a widely used drug for erectile dysfunction that acts by elevating cGMP levels and causing smooth muscle relaxation. Sildenafil Citrate 0-18 phosphodiesterase 5A Homo sapiens 60-64 35286987-4 2022 Nevertheless, many of these products are adulterated with PDE5 inhibitors like sildenafil or alpha-blockers. Sildenafil Citrate 79-89 phosphodiesterase 5A Homo sapiens 58-62 34012848-4 2021 Sildenafil, a representative PDE-5 inhibitor, has an important role as a single mode of therapy. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 29-34 35596935-2 2022 Sildenafil, a phosphodiesterase-5 (PDE-5) inhibitor, might have beneficial effects on pulmonary haemodynamics, cardiac function and exercise capacity in HFrEF and PHT. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 14-33 35596935-2 2022 Sildenafil, a phosphodiesterase-5 (PDE-5) inhibitor, might have beneficial effects on pulmonary haemodynamics, cardiac function and exercise capacity in HFrEF and PHT. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 35-40 35396013-1 2022 Lodenafil is a class of drugs called an inhibitor of PDE5 which also include a wide range of other erectile medicines, such as sildenafil, tadalafil and vardenafil. Sildenafil Citrate 0-9 phosphodiesterase 5A Homo sapiens 53-57 33952455-0 2021 Over-expression of PDE5 in Oral Squamous Cell Carcinoma - Effect of Sildenafil Citrate. Sildenafil Citrate 68-86 phosphodiesterase 5A Homo sapiens 19-23 33226665-1 2021 Sildenafil, approved two decades ago, is the inhibitor of Phosphodiesterase 5 (PDE5). Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 58-77 33226665-1 2021 Sildenafil, approved two decades ago, is the inhibitor of Phosphodiesterase 5 (PDE5). Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 79-83 35119252-6 2022 Different drugs inhibiting PDE5 (PDE5i) exist, the main of which commercially available are sildenafil, vardenafil, tadalafil, and avanafil. Sildenafil Citrate 92-102 phosphodiesterase 5A Homo sapiens 27-31 35119252-6 2022 Different drugs inhibiting PDE5 (PDE5i) exist, the main of which commercially available are sildenafil, vardenafil, tadalafil, and avanafil. Sildenafil Citrate 92-102 phosphodiesterase 5A Homo sapiens 33-38 34984916-3 2022 PDE5 inhibitors have been used for treating erectile dysfunction, such as drug Viagra (sildenafil). Sildenafil Citrate 87-97 phosphodiesterase 5A Homo sapiens 0-4 34984916-4 2022 However, a few clinical cases have reported the association of Viagra usage with aortic dissection, and reduced PDE5A expression was found in human aortic aneurysm tissues. Sildenafil Citrate 63-69 phosphodiesterase 5A Homo sapiens 112-117 33662516-3 2021 Medically, ED is treated with potent inhibitors of the phosphodiesterase-5 (PDE-5) enzyme, as in the case of sildenafil. Sildenafil Citrate 109-119 phosphodiesterase 5A Homo sapiens 55-74 33662516-3 2021 Medically, ED is treated with potent inhibitors of the phosphodiesterase-5 (PDE-5) enzyme, as in the case of sildenafil. Sildenafil Citrate 109-119 phosphodiesterase 5A Homo sapiens 76-81 33662516-7 2021 Further investigations are needed to confirm if the observed effects are due to inherent plant constituents or merely the result of added synthetic PDE-5 enzyme inhibitors, especially because doses above 100 mg sildenafil equivalents per day may result in severe health risks. Sildenafil Citrate 211-221 phosphodiesterase 5A Homo sapiens 148-153 34006491-2 2021 Tadalafil and sildenafil are the two most common phosphodiesterase-5 inhibitors (PDE5is) used to treat ED. Sildenafil Citrate 14-24 phosphodiesterase 5A Homo sapiens 81-85 33947926-5 2021 The PDE-5i concentration in total reached 62 +- 12 (STP#1) and 88 +- 37 ng L-1 (STP#2) in the sewage influent; about 70% of it was Sildenafil in both STPs. Sildenafil Citrate 131-141 phosphodiesterase 5A Homo sapiens 4-9 33741394-6 2021 We found that phosphodiesterase 5 (PDE5) inhibitors, including sildenafil (Viagra; Pfizer), appeared to be nontoxic and effective inhibitors of romidepsin-induced EBV reactivation. Sildenafil Citrate 63-73 phosphodiesterase 5A Homo sapiens 35-39 33741394-8 2021 We also investigated the molecular consequences downstream of sildenafil-induced PDE5 inhibition in NKTL cells. Sildenafil Citrate 62-72 phosphodiesterase 5A Homo sapiens 81-85 33741394-11 2021 Co-treatment with romidepsin and sildenafil (inhibiting HDAC and PDE5, respectively) showed a synergistic inhibitory effect on NKTL cells, highlighting PDE5 as an attractive target for future therapy in NKTL. Sildenafil Citrate 33-43 phosphodiesterase 5A Homo sapiens 65-69 33741394-11 2021 Co-treatment with romidepsin and sildenafil (inhibiting HDAC and PDE5, respectively) showed a synergistic inhibitory effect on NKTL cells, highlighting PDE5 as an attractive target for future therapy in NKTL. Sildenafil Citrate 33-43 phosphodiesterase 5A Homo sapiens 152-156 33920975-1 2021 Sildenafil is a potent selective, reversible inhibitor of phosphodiesterase type 5 (PDE5) approved for the treatment of erectile dysfunction and pulmonary arterial hypertension. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 58-82 33920975-1 2021 Sildenafil is a potent selective, reversible inhibitor of phosphodiesterase type 5 (PDE5) approved for the treatment of erectile dysfunction and pulmonary arterial hypertension. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 84-88 33105385-3 2021 Sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, increases blood flow and improves O2 consumption, although the exact mechanisms in CF have yet to be elucidated. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 14-38 33105385-3 2021 Sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, increases blood flow and improves O2 consumption, although the exact mechanisms in CF have yet to be elucidated. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 40-44 32964819-0 2021 Repurposing of the PDE5 inhibitor sildenafil for treatment of persistent pulmonary hypertension in neonates. Sildenafil Citrate 34-44 phosphodiesterase 5A Homo sapiens 19-23 33718200-0 2021 New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil. Sildenafil Citrate 79-89 phosphodiesterase 5A Homo sapiens 64-68 33718200-4 2021 This is the case of sildenafil (Viagra), a phosphodiesterase-5 (PDE5) inhibitor, which was originally designed to treat systemic hypertension and angina but is currently commercialized as erectile dysfunction treatment. Sildenafil Citrate 20-30 phosphodiesterase 5A Homo sapiens 43-62 33718200-4 2021 This is the case of sildenafil (Viagra), a phosphodiesterase-5 (PDE5) inhibitor, which was originally designed to treat systemic hypertension and angina but is currently commercialized as erectile dysfunction treatment. Sildenafil Citrate 20-30 phosphodiesterase 5A Homo sapiens 64-68 33718200-4 2021 This is the case of sildenafil (Viagra), a phosphodiesterase-5 (PDE5) inhibitor, which was originally designed to treat systemic hypertension and angina but is currently commercialized as erectile dysfunction treatment. Sildenafil Citrate 32-38 phosphodiesterase 5A Homo sapiens 43-62 33718200-4 2021 This is the case of sildenafil (Viagra), a phosphodiesterase-5 (PDE5) inhibitor, which was originally designed to treat systemic hypertension and angina but is currently commercialized as erectile dysfunction treatment. Sildenafil Citrate 32-38 phosphodiesterase 5A Homo sapiens 64-68 33718200-5 2021 Sildenafil, tadalafil, and vardenafil are PDE5 inhibitors and potent vasodilators, that extend the physiological effects of nitric oxide and cyclic guanosine monophosphate (cGMP) signaling. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 42-46 33693035-9 2021 Recent own experiments demonstrated that Sildenafil, a phosphodiesterase 5A inhibitor drug that has been widely used for the treatment of erectile dysfunction is able to decrease NHE1 phosphorylation, and hence reduce its hyperactivity. Sildenafil Citrate 41-51 phosphodiesterase 5A Homo sapiens 55-75 33670094-8 2021 These unique features of the potential activity of PDE5 protein and its inhibitors, sildenafil and sulfoaildenafil, may play a key consideration for understanding the mode of actions and predicting the biological activities of PDE5 inhibitors. Sildenafil Citrate 84-94 phosphodiesterase 5A Homo sapiens 51-55 33670094-8 2021 These unique features of the potential activity of PDE5 protein and its inhibitors, sildenafil and sulfoaildenafil, may play a key consideration for understanding the mode of actions and predicting the biological activities of PDE5 inhibitors. Sildenafil Citrate 84-94 phosphodiesterase 5A Homo sapiens 227-231 32744956-6 2021 The pro-apoptotic effect of Sildenafil through nitric oxide (NO)/ phosphodiesterase type 5 (PDE5)-dependent manner seems to be one of the most common mechanisms. Sildenafil Citrate 28-38 phosphodiesterase 5A Homo sapiens 66-90 32744956-6 2021 The pro-apoptotic effect of Sildenafil through nitric oxide (NO)/ phosphodiesterase type 5 (PDE5)-dependent manner seems to be one of the most common mechanisms. Sildenafil Citrate 28-38 phosphodiesterase 5A Homo sapiens 92-96 32964819-4 2021 Small molecule PDE5 inhibitors (PDE5is) such as sildenafil prolong the availability of cGMP and so enhance NO-mediated signalling. Sildenafil Citrate 48-58 phosphodiesterase 5A Homo sapiens 15-19 32964819-4 2021 Small molecule PDE5 inhibitors (PDE5is) such as sildenafil prolong the availability of cGMP and so enhance NO-mediated signalling. Sildenafil Citrate 48-58 phosphodiesterase 5A Homo sapiens 32-36 33136535-3 2020 The IC50 value of the inhibitory activity for PDE5A1 (one of the PDE5 isoforms) was 2.0 nM (sildenafil IC50 value was 4.5 nM). Sildenafil Citrate 92-102 phosphodiesterase 5A Homo sapiens 46-50 33087445-6 2020 We found that sildenafil, a phosphodiesterase 5 (PDE5) inhibitor induced mitochondrial biogenesis as measured by increased uncoupled oxygen consumption, mitochondrial DNA content and voltage-dependent anion channel protein expression. Sildenafil Citrate 14-24 phosphodiesterase 5A Homo sapiens 28-47 33087445-6 2020 We found that sildenafil, a phosphodiesterase 5 (PDE5) inhibitor induced mitochondrial biogenesis as measured by increased uncoupled oxygen consumption, mitochondrial DNA content and voltage-dependent anion channel protein expression. Sildenafil Citrate 14-24 phosphodiesterase 5A Homo sapiens 49-53 32543093-4 2020 Here we are reporting a case of sildenafil induced hypersensitivity syndrome that is possibly the first one and reviewing the medical literature on type of adverse cutaneous drug eruption due to sildenafil and other PDE5 inhibitors. Sildenafil Citrate 32-42 phosphodiesterase 5A Homo sapiens 216-220 33342806-6 2020 In this study, the antitumor activity of the sildenafil as a PDE-5 inhibitor alone and in combination with cisplatin on human mammary adenocarcinomas and MCF-7 and MDA-MB-468 was assessed. Sildenafil Citrate 45-55 phosphodiesterase 5A Homo sapiens 61-66 33342806-7 2020 Materials and Methods: Sildenafil as PDE type 5 (PDE5) inhibitor is the drugs that we combined with the cisplatin (chemotherapeutic agent), in vitro. Sildenafil Citrate 23-33 phosphodiesterase 5A Homo sapiens 37-47 33342806-7 2020 Materials and Methods: Sildenafil as PDE type 5 (PDE5) inhibitor is the drugs that we combined with the cisplatin (chemotherapeutic agent), in vitro. Sildenafil Citrate 23-33 phosphodiesterase 5A Homo sapiens 49-53 33342806-17 2020 And also sildenafil as a PDE-5 inhibitor could be used as additive treatment in combination with cisplatin to make a reduction in cisplatin dosage and its side effects. Sildenafil Citrate 9-19 phosphodiesterase 5A Homo sapiens 25-30 31311394-1 2019 Background In murine heart failure models and in humans with diabetic-related heart hypertrophy, inhibition of phosphodiesterase 5 (PDE5) by sildenafil improves cardiac outcomes. Sildenafil Citrate 141-151 phosphodiesterase 5A Homo sapiens 111-130 32912157-0 2020 Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study. Sildenafil Citrate 30-40 phosphodiesterase 5A Homo sapiens 0-19 32850387-2 2020 Sildenafil, a specific phosphodiesterase type 5 (PDE5) inhibitor, has been suggested to display both cardioprotective and neuroprotective activities that provide a rationale for the combination with vincristine on the treatment against castration-resistant prostate cancer (CRPC). Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 23-47 32850387-2 2020 Sildenafil, a specific phosphodiesterase type 5 (PDE5) inhibitor, has been suggested to display both cardioprotective and neuroprotective activities that provide a rationale for the combination with vincristine on the treatment against castration-resistant prostate cancer (CRPC). Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 49-53 32850387-7 2020 Sildenafil-mediated synergistic effects were mimicked by other PDE5 inhibitors including vardenafil and tadalafil, and also by PDE5A knockdown in cells, suggesting PDE5-involved mechanism. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 63-67 32850387-7 2020 Sildenafil-mediated synergistic effects were mimicked by other PDE5 inhibitors including vardenafil and tadalafil, and also by PDE5A knockdown in cells, suggesting PDE5-involved mechanism. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 127-132 32850387-7 2020 Sildenafil-mediated synergistic effects were mimicked by other PDE5 inhibitors including vardenafil and tadalafil, and also by PDE5A knockdown in cells, suggesting PDE5-involved mechanism. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 127-131 32850387-11 2020 In conclusion, the data suggest that sildenafil, in a PDE5-dependent manner, potentiates vincristine-induced mitotic arrest signaling, and sensitizes mitochondria damage-involved apoptosis in CRPC. Sildenafil Citrate 37-47 phosphodiesterase 5A Homo sapiens 54-58 32467879-2 2020 Sildenafil inhibits PDE5 and increases cGMP levels. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 20-24 32231130-11 2020 Sildenafil, a inhibitor of the PDE5A-cGMP-PKG pathway, preserved the mitochondrial structure, respiratory chain efficiency and energy status in cardiac tissue. Sildenafil Citrate 0-10 phosphodiesterase 5A Homo sapiens 31-36 32336717-1 2020 Some illegal dietary supplements contain phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil, for exerting "therapeutic" effects in erectile dysfunction. Sildenafil Citrate 93-103 phosphodiesterase 5A Homo sapiens 41-65 32336717-1 2020 Some illegal dietary supplements contain phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil, for exerting "therapeutic" effects in erectile dysfunction. Sildenafil Citrate 93-103 phosphodiesterase 5A Homo sapiens 67-71 31409013-11 2019 In isolated pulmonary small arteries, sensitivity to NO donor SNP was similar in PVB vs. sham groups irrespective of HP/LF and HP/HF, while sensitivity to the PDE5 inhibitor sildenafil was lower in PVB HP/HF and sensitivity to bradykinin was lower in PVB HP/LF. Sildenafil Citrate 174-184 phosphodiesterase 5A Homo sapiens 159-163 32794708-4 2020 This movement directly blocks the binding of substrate/inhibitors to the PDE5 active site, which is different from all traditional PDE5 inhibitors such as sildenafil, tadalafil, and vardenafil. Sildenafil Citrate 155-165 phosphodiesterase 5A Homo sapiens 73-77 32794708-4 2020 This movement directly blocks the binding of substrate/inhibitors to the PDE5 active site, which is different from all traditional PDE5 inhibitors such as sildenafil, tadalafil, and vardenafil. Sildenafil Citrate 155-165 phosphodiesterase 5A Homo sapiens 131-135 32315926-3 2020 In recent years, phosphodiesterase type 5 (PDE5) inhibitor drugs like sildenafil, which cause peripheral vasodilation, are used commonly in cases of erectile dysfunction, pulmonary hypertension and cardiac insufficiency. Sildenafil Citrate 70-80 phosphodiesterase 5A Homo sapiens 17-41 32315926-3 2020 In recent years, phosphodiesterase type 5 (PDE5) inhibitor drugs like sildenafil, which cause peripheral vasodilation, are used commonly in cases of erectile dysfunction, pulmonary hypertension and cardiac insufficiency. Sildenafil Citrate 70-80 phosphodiesterase 5A Homo sapiens 43-47 32675225-7 2021 Consequently, we tested the endothelium-protective PDE5 inhibitor sildenafil, which reduced apoptosis and improved metabolic activity of endothelial cells in vitro. Sildenafil Citrate 66-76 phosphodiesterase 5A Homo sapiens 51-55 31654676-8 2020 Intriguingly, we found that the oocyte maturation could be stimulated by treatment of either two different PDE5a inhibitors, sildenafil or tadalafil, and such effects could be completely blocked by a PKG inhibitor KT5823 and two gap junction blockers, respectively. Sildenafil Citrate 125-135 phosphodiesterase 5A Homo sapiens 107-112 31350821-5 2019 RESULTS: The main reasons for patient dissatisfaction when using PDE5is on demand are the relatively long Tonset after taking vardenafil and sildenafil, including formulations such as film-coated tablets, fine granules, orally disintegrating tablets (ODTs), and oral thin films (ODFs). Sildenafil Citrate 141-151 phosphodiesterase 5A Homo sapiens 65-69 31311394-1 2019 Background In murine heart failure models and in humans with diabetic-related heart hypertrophy, inhibition of phosphodiesterase 5 (PDE5) by sildenafil improves cardiac outcomes. Sildenafil Citrate 141-151 phosphodiesterase 5A Homo sapiens 132-136 30946047-6 2019 Phosphodiesterase-5 (PDE-5) inhibitors, such as sildenafil, were approved for treatment of pulmonary arterial hypertension (PAH) by the Food and Drug Administration (FDA) in 2005, which holds promise in improving quality of life and therefore making this class of medications effective palliative therapy agents. Sildenafil Citrate 48-58 phosphodiesterase 5A Homo sapiens 21-26 31463257-2 2019 Because no human study has surveyed the effect of PDEs on pulmonary function, except some case reports and animal researches, we decided to perform a pilot study for evaluating the effect of sildenafil (PDE5) on pulmonary function in patients with severe asthma. Sildenafil Citrate 191-201 phosphodiesterase 5A Homo sapiens 203-207 30189250-9 2019 PDE5-specific inhibitors, such as sildenafil, show considerable anti-tumorigenic potential against CRC by amplifying the GUCY2C/cGMP signaling pathway, but cannot achieve complete anti-tumorigenic effects. Sildenafil Citrate 34-44 phosphodiesterase 5A Homo sapiens 0-4 30946047-6 2019 Phosphodiesterase-5 (PDE-5) inhibitors, such as sildenafil, were approved for treatment of pulmonary arterial hypertension (PAH) by the Food and Drug Administration (FDA) in 2005, which holds promise in improving quality of life and therefore making this class of medications effective palliative therapy agents. Sildenafil Citrate 48-58 phosphodiesterase 5A Homo sapiens 0-19 31204276-1 2019 BACKGROUND: The phosphodiesterase-5 inhibitor (PDE5) sildenafil has emerged as a promising treatment for preeclampsia (PE). Sildenafil Citrate 53-63 phosphodiesterase 5A Homo sapiens 47-51 31248114-3 2019 We previously found the PDE5 inhibitor sildenafil to synergize with leucine and leucine-metformin combinations in preclinical studies of NASH and obesity. Sildenafil Citrate 39-49 phosphodiesterase 5A Homo sapiens 24-28 31248114-10 2019 However, further increases in cGMP from higher sildenafil concentrations activate PDE2 and consequently decrease cAMP, which demonstrates crosstalk between cAMP and cGMP via PDE2, PDE3, and PDE5. Sildenafil Citrate 47-57 phosphodiesterase 5A Homo sapiens 190-194